

MEDICIS PHARMACEUTICAL CORP  
Form 10-Q  
November 09, 2012  
Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

**FORM 10-Q**

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  
For the quarterly period ended September 30, 2012

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  
For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number: 001-14471

**MEDICIS PHARMACEUTICAL CORPORATION**

(Exact name of Registrant as specified in its charter)

Delaware  
(State or other jurisdiction of  
incorporation or organization)

52-1574808  
(I.R.S. Employer Identification No.)

7720 North Dobson Road

Scottsdale, Arizona 85256-2740

(Address of principal executive offices and zip code)

(602) 808-8800

(Registrant's telephone number,

including area code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the

## Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 10-Q

registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer  (do not check if a smaller reporting company)

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes  No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class

Class A Common Stock \$.014 Par Value

Outstanding at November 5, 2012

58,393,411 (a)

(a) includes 1,975,334 shares of unvested restricted stock awards

**Table of Contents**

**MEDICIS PHARMACEUTICAL CORPORATION**

**Table of Contents**

	Page
<b>PART I. <u>FINANCIAL INFORMATION</u></b>	
Item 1 <u>Financial Statements</u>	
<u>Condensed Consolidated Balance Sheets as of September 30, 2012 and December 31, 2011</u>	1
<u>Condensed Consolidated Statements of Income for the Three and Nine Months Ended September 30, 2012 and 2011</u>	3
<u>Condensed Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended September 30, 2012 and 2011</u>	4
<u>Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2012 and 2011</u>	5
<u>Notes to the Condensed Consolidated Financial Statements</u>	6
Item 2 <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	38
Item 3 <u>Quantitative and Qualitative Disclosures About Market Risk</u>	68
Item 4 <u>Controls and Procedures</u>	68
<b>PART II. <u>OTHER INFORMATION</u></b>	
Item 1 <u>Legal Proceedings</u>	69
Item 1A <u>Risk Factors</u>	73
Item 2 <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	74
Item 6 <u>Exhibits</u>	75
<b><u>SIGNATURES</u></b>	76

Table of Contents**Part I. Financial Information****Item 1. Financial Statements****MEDICIS PHARMACEUTICAL CORPORATION****CONDENSED CONSOLIDATED BALANCE SHEETS****(in thousands)**

	September 30, 2012	December 31, 2011
<b>Assets</b>	(unaudited)	
Current assets:		
Cash and cash equivalents	\$ 130,115	\$ 42,823
Short-term investments	629,808	245,497
Accounts receivable, net	145,824	193,009
Inventories, net	34,881	34,519
Deferred tax assets, net	73,476	12,720
Prepaid income taxes	31,618	1,314
Other current assets	22,885	21,272
Total current assets	1,068,607	551,154
Property and equipment, net	32,495	25,081
Intangible assets, net	452,615	502,492
Goodwill	202,703	202,627
Deferred tax assets, net	58,963	114,555
Long-term investments	12,778	40,270
Other assets	35,622	15,780
	\$ 1,863,783	\$ 1,451,959

See accompanying notes to condensed consolidated financial statements.

**Table of Contents**

**MEDICIS PHARMACEUTICAL CORPORATION**  
**CONDENSED CONSOLIDATED BALANCE SHEETS, Continued**

(in thousands, except share amounts)

	September 30, 2012	December 31, 2011
<b>Liabilities</b>	(unaudited)	
Current liabilities:		
Accounts payable	\$ 77,398	\$ 54,094
Current portion of long-term debt	181	169,145
Reserve for sales returns	52,318	60,024
Accrued consumer rebates and loyalty programs	63,621	139,948
Managed care and Medicaid reserves	83,043	72,801
Other current liabilities	114,437	78,785
<b>Total current liabilities</b>	<b>390,998</b>	<b>574,797</b>
Long-term liabilities:		
Long-term debt	594,739	181
Other liabilities	50,212	44,998
<b>Stockholders Equity</b>		
Preferred stock, \$0.01 par value; shares authorized: 5,000,000; issued and outstanding: none	-	-
Class A common stock, \$0.014 par value; shares authorized: 150,000,000; issued and outstanding: 76,137,275 and 74,740,324 at September 30, 2012 and December 31, 2011, respectively	1,066	1,028
Class B common stock, \$0.014 par value; shares authorized: 1,000,000; issued and outstanding: none	-	-
Additional paid-in capital	851,334	796,979
Accumulated other comprehensive loss	(17,003)	(21,315)
Accumulated earnings	571,113	567,581
Less: Treasury stock, 19,737,309 and 17,745,039 shares at cost at September 30, 2012 and December 31, 2011, respectively	(578,676)	(512,290)
<b>Total stockholders equity</b>	<b>827,834</b>	<b>831,983</b>
	<b>\$ 1,863,783</b>	<b>\$ 1,451,959</b>

See accompanying notes to condensed consolidated financial statements.

**Table of Contents**

**MEDICIS PHARMACEUTICAL CORPORATION**  
**CONDENSED CONSOLIDATED STATEMENTS OF INCOME**

**(unaudited)**

**(in thousands, except per share data)**

	Three Months Ended		Nine Months Ended	
	September 30, 2012	September 30, 2011	September 30, 2012	September 30, 2011
Net product revenues	\$ 179,126	\$ 183,456	\$ 574,263	\$ 537,171
Net contract revenues	1,069	1,212	4,228	3,237
Net revenues	180,195	184,668	578,491	540,408
Cost of product revenues (1)	19,601	17,169	62,303	49,737
Gross profit	160,594	167,499	516,188	490,671
Operating expenses:				
Selling, general and administrative (2)	111,489	93,228	316,859	268,251
Research and development (3)	12,263	28,733	87,406	58,202
Depreciation and amortization	18,322	7,254	54,480	21,688
Impairment of intangible assets	2,745	2,259	2,745	2,259
Operating income	15,775	36,025	54,698	140,271
Interest and investment income	(950)	(1,283)	(2,123)	(3,796)
Interest expense	7,158	1,267	12,240	3,467
Other expense (income), net	7,743	-	7,643	-
Income from continuing operations before income tax expense	1,824	36,041	36,938	140,600
Income tax expense	887	13,091	15,725	56,454
Net income from continuing operations	937	22,950	21,213	84,146
Loss from discontinued operations, net of income tax benefit	-	3,498	-	16,551
Net income	\$ 937	\$ 19,452	\$ 21,213	\$ 67,595
Basic net income per share - continuing operations	\$ 0.02	\$ 0.36	\$ 0.36	\$ 1.35
Basic net loss per share - discontinued operations	\$ -	\$ (0.06)	\$ -	\$ (0.27)
Basic net income per share	\$ 0.02	\$ 0.31	\$ 0.36	\$ 1.09
Diluted net income per share - continuing operations	\$ 0.02	\$ 0.34	\$ 0.36	\$ 1.25
Diluted net loss per share - discontinued operations	\$ -	\$ (0.06)	\$ -	\$ (0.27)
Diluted net income per share	\$ 0.02	\$ 0.29	\$ 0.36	\$ 1.01
Cash dividend declared per common share	\$ 0.10	\$ 0.08	\$ 0.30	\$ 0.24

## Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 10-Q

Common shares used in calculating:

Basic net income per share	57,222	61,336	57,296	60,264
Diluted net income per share	58,326	67,914	63,672	66,960

(1) amounts exclude amortization of intangible assets related to acquired products	\$ 15,605	\$ 5,266	\$ 46,957	\$ 15,984
(2) amounts include share-based compensation expense	\$ 12,627	\$ 4,343	\$ 24,185	\$ 19,331
(3) amounts include share-based compensation expense	\$ 930	\$ 95	\$ 1,563	\$ 1,114

See accompanying notes to condensed consolidated financial statements.

Table of Contents

**MEDICIS PHARMACEUTICAL CORPORATION**  
**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**

**(unaudited)**

**(in thousands)**

	Three Months Ended		Nine Months Ended	
	September 30, 2012	September 30, 2011	September 30, 2012	September 30, 2011
Net income	\$ 937	\$ 19,452	\$ 21,213	\$ 67,595
Other comprehensive income, net of income taxes:				
Amortization of prior service costs related to supplemental executive retirement plan	775	768	2,325	1,025
Establishment of prior service costs for new participants under supplemental executive retirement plan	-	-	(531)	(21,647)
Net unrealized gain (loss) on available-for-sale securities	1,767	(602)	2,098	(427)
Foreign currency translation adjustment	369	(435)	420	(369)
Total other comprehensive income (loss) , net of income taxes	2,911	(269)	4,312	(21,418)
Comprehensive income	\$ 3,848	\$ 19,183	\$ 25,525	\$ 46,177

See accompanying notes to condensed consolidated financial statements.



**Table of Contents**

**MEDICIS PHARMACEUTICAL CORPORATION**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

(unaudited)

(in thousands)

	Nine Months Ended	
	September 30, 2012	September 30, 2011
<b>Operating Activities:</b>		
Net income	\$ 21,213	\$ 67,595
Loss from discontinued operations, net of income tax benefit	-	16,551
Net income from continuing operations	21,213	84,146
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities from continuing operations:		
Depreciation and amortization	54,480	21,688
Impairment of intangible assets	2,745	2,259
Amortization of prior service costs, supplemental executive retirement plan	3,629	1,599
Amortization of discount on long-term debt	5,327	-
Amortization of debt issuance costs	891	-
Gain on sale of product rights	(3,000)	-
Loss on Counterparty Settlement Agreement	7,743	-
Charge reducing value of investment in a third party entity	2,900	-
Net gain on sale of available-for-sale investments and supplemental executive retirement plan investments, net	(1,374)	(152)
Share-based compensation expense	25,748	20,445
Deferred income tax (benefit)	(194)	(1,821)
Tax benefit from exercise of stock options and vesting of restricted stock awards	1,481	2,265
Excess tax benefits from share-based payment arrangements	(5,899)	(3,403)
(Decrease) increase in provision for sales discounts and chargebacks	(407)	996
Net amortization (accretion) of premium (discount) on investments	2,154	3,774
Changes in operating assets and liabilities:		
Accounts receivable	47,592	(23,407)
Inventories	(362)	4,410
Prepaid income taxes	(30,304)	(3,518)
Other current assets	(1,612)	(1,501)
Accounts payable	21,315	6,303
Reserve for sales returns	(7,706)	11,988
Accrued consumer rebates and loyalty programs	(76,327)	30,754
Managed care and Medicaid reserves	10,242	10,046
Income taxes payable	-	(4,628)
Other current liabilities	(7,762)	(13,929)
Other liabilities	4,385	710
Net cash provided by operating activities from continuing operations	76,898	149,024
Net cash used in operating activities from discontinued operations	-	(12,287)
Net cash provided by operating activities	76,898	136,737
<b>Investing Activities:</b>		
Purchase of property and equipment	(12,757)	(4,225)
Payments for purchase of product rights	(92)	(12,880)
Proceeds from sale of product rights	6,000	-

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 10-Q

Purchase of investments for supplemental executive retirement plan	(12,884)	(9,840)
Purchase of available-for-sale investments	(608,367)	(602,765)
Sale of available-for-sale investments	147,849	199,574
Maturity of available-for-sale investments	107,336	269,830
Net cash used in investing activities	(372,915)	(160,306)
<b>Financing Activities:</b>		
Payment of dividends	(16,555)	(13,568)
Proceeds from issuance of long-term debt	500,000	-
Purchase of hedge related to long-term debt	(80,000)	-
Proceeds from sale of warrants related to long-term debt	35,150	-
Payment of debt issuance costs	(14,143)	-
Payment of principal of long-term debt	(3)	-
Purchase of treasury stock	(49,914)	(1,775)
Cash paid in advance under structured share repurchase arrangements	-	(50,000)
Withholding of common shares for tax obligations on vested restricted stock awards	(16,472)	(6,508)
Excess tax benefits from share-based payment arrangements	5,899	3,403
Proceeds from the exercise of stock options	18,927	58,071
Net cash provided by (used in) financing activities	382,889	(10,377)
Effect of exchange rate on cash and cash equivalents	420	(369)
Net increase (decrease) in cash and cash equivalents	87,292	(34,315)
Cash and cash equivalents at beginning of period	42,823	218,362
Cash and cash equivalents at end of period	\$ 130,115	\$ 184,047

See accompanying notes to condensed consolidated financial statements.

**Table of Contents**

**MEDICIS PHARMACEUTICAL CORPORATION**  
**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**September 30, 2012**

**(unaudited)**

**1. NATURE OF BUSINESS**

Medicis Pharmaceutical Corporation ( Medicis or the Company ) is a leading specialty pharmaceutical company focusing primarily on helping patients attain a healthy and youthful appearance and self-image through the development and marketing in the United States ( U.S. ) and Canada of products for the treatment of dermatological and aesthetic conditions.

The Company offers a broad range of products addressing various conditions or aesthetic improvements including facial wrinkles, glabellar lines, acne, fungal infections, hyperpigmentation, photoaging, psoriasis, actinic keratosis, bronchospasms, external genital and perianal warts/condyloma acuminata, seborrheic dermatitis and cosmesis (improvement in the texture and appearance of skin). Medicis currently offers 28 branded products. Its primary brands are DYSPORT<sup>®</sup>, PERLANE<sup>®</sup>, RESTYLANE<sup>®</sup>, SOLODYN<sup>®</sup>, VANOS<sup>®</sup>, ZIANA<sup>®</sup> and ZYCLARA<sup>®</sup>.

On September 2, 2012, the Company entered into an Agreement and Plan of Merger with Valeant Pharmaceuticals International ( Valeant ), whereby the Company will become a wholly owned subsidiary of Valeant upon the closing of the transaction. See Note 2 for further discussion.

The condensed consolidated financial statements include the accounts of Medicis and its wholly owned subsidiaries. The Company does not have any subsidiaries in which it does not own 100% of the outstanding stock. All of the Company's subsidiaries are included in the condensed consolidated financial statements. All significant intercompany accounts and transactions have been eliminated in consolidation.

The accompanying interim condensed consolidated financial statements of Medicis have been prepared in conformity with U.S. generally accepted accounting principles ( GAAP ), consistent in all material respects with those applied in the Company's Annual Report on Form 10-K for the year ended December 31, 2011. The financial information is unaudited, but reflects all adjustments, consisting only of normal recurring adjustments and accruals, which are, in the opinion of the Company's management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year. Certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been omitted. Therefore, the information included in this Form 10-Q should be read in conjunction with the Company's Annual Report on Form 10-K for the year ended December 31, 2011.

**2. AGREEMENT AND PLAN OF MERGER WITH VALEANT**

On September 2, 2012, the Company, Valeant, Valeant Pharmaceuticals International, Inc., and Merlin Merger Sub, Inc., a wholly-owned subsidiary of Valeant ( Merger Sub ), entered into an Agreement and Plan of Merger (the Merger Agreement ). Pursuant to the terms of the Merger Agreement, upon consummation of the Merger (as defined below) each share of the Company's Class A common stock, par value \$0.014 per share (the Shares ), issued and outstanding immediately prior to the Merger will convert into a right to receive \$44.00 per Share (the Per Share Merger Consideration ), without interest, and Merger Sub will merge with and into the Company (the Merger ) with the Company continuing as the surviving corporation and a wholly owned subsidiary of Valeant.

Upon consummation of the Merger, each option to acquire Shares (whether vested or unvested) that is outstanding immediately prior to the Merger will be cancelled in exchange for the right to receive the Per Share Merger Consideration less the exercise price per Share of each respective award. Each stock appreciation right relating to Shares (whether vested or unvested) that is outstanding immediately prior to the Merger will be canceled in exchange for the right to receive the Per Share Merger Consideration less the exercise price per share of the stock appreciation right. Each Share that is subject to vesting restrictions will also convert into a right to receive the Per Share Merger Consideration.

Also upon consummation of the Merger, the principal amount of the Company's 1.375% Convertible Senior Notes Due 2017 will become immediately due and payable. The long-term debt has not been reclassified to current liabilities as of September 30, 2012, however, as the acceleration of payment is contingent upon the consummation of the Merger.



## **Table of Contents**

The completion of the Merger is subject to customary conditions, including the approval of the Company's stockholders, the absence of any material adverse effect on the Company's business and receiving antitrust approvals (including under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended).

The Merger Agreement contains customary representations, warranties and covenants by the Company and Valeant. The Company has agreed, among other things, not to solicit alternative transactions. The Company has also agreed, subject to certain exceptions, not to enter into discussions concerning, or provide confidential information in connection with, any alternative transaction. In addition, each of the parties has agreed to use their reasonable best efforts to cause the Merger to be consummated. Subject to certain exceptions, the Merger Agreement also requires the Company to call and hold a stockholders' meeting and for the Company's board of directors (the Board) to recommend that the Company's stockholders adopt the Merger Agreement.

The Merger Agreement may be terminated under certain circumstances, including by Valeant if the Board (i) makes a change to its recommendation in support of the Merger, (ii) fails to reaffirm its recommendation in support of the Merger within specified periods of time, or (iii) fails to recommend against a competing tender offer or exchange offer for outstanding Shares within certain periods of time. The Company may terminate the Merger Agreement prior to its adoption by the Company's stockholders in the event that the Company receives an unsolicited proposal that the Board concludes, after following certain procedures, is a Superior Proposal (as defined in the Merger Agreement). In each of these cases, the Company may be required to pay Valeant a fee of \$85 million and reimburse Valeant for up to \$7.5 million in expenses (the Termination Fee). In addition, if either party terminates the Merger Agreement (i) under certain circumstances specified in the Merger Agreement and the Company has received an Acquisition Proposal (as defined in the Merger Agreement) or an Acquisition Proposal has been publicly announced and has not been publicly withdrawn prior to a specified time and (ii) the Company enters into an agreement to consummate, or actually consummates, certain alternative transactions within twelve (12) months after such termination, the Company also may be required to pay Valeant the Termination Fee.

The Merger Agreement has been approved by the boards of directors of both Valeant and the Company. The Board has also determined that the Merger is fair to, and in the best interests of, the Company and its stockholders, approved and declared advisable the Merger Agreement and the Merger and the other transactions contemplated by the Merger Agreement and recommended that stockholders of the Company adopt the Merger Agreement.

On October 17, 2012, the Company announced that its stockholders of record at the close of business on October 29, 2012, will be entitled to notice of, and vote at a special meeting of stockholders upon, among other things, the proposal to adopt the Merger Agreement. The meeting will be held on December 7, 2012.

### **3. DISCONTINUED OPERATIONS**

On February 25, 2011, the Company announced that as a result of the Company's strategic planning process and the existing regulatory and commercial capital equipment environment, the Company would explore strategic alternatives for its LipoSonix business including, but not limited to, the sale of the stand-alone business. As a result of this decision, the Company classified the LipoSonix business as a discontinued operation for consolidated financial statement reporting purposes. On November 1, 2011, the Company sold LipoSonix to Solta Medical, Inc.

**Table of Contents**

The following is a summary of loss from discontinued operations, net of income tax benefit, for the three and nine months ended September 30, 2011 (in thousands):

	Three Months Ended September 30, 2011	Nine Months Ended September 30, 2011
Net revenues	\$ 157	\$ 513
Cost of revenues	87	2,543
Gross profit	70	(2,030)
Operating expenses:		
Selling, general and administrative	3,478	15,072
Research and development	1,788	8,436
Loss from discontinued operations before income tax benefit	(5,196)	(25,538)
Income tax benefit	(1,698)	(8,987)
Loss from discontinued operations, net of income tax benefit	\$ (3,498)	\$ (16,551)

The Company included only revenues and costs directly attributable to the discontinued operations, and not those attributable to the ongoing entity. Accordingly, no interest expense or general corporate overhead costs were allocated to the LipoSonix discontinued operations. Included in cost of revenues for the nine months ended September 30, 2011 was a \$1.9 million charge related to an increase in the valuation reserve for LipoSonix inventory that was not expected to be sold.

The following is a summary of net cash used in operating activities from discontinued operations for the nine months ended September 30, 2011 (in thousands):

	<u>Nine Months Ended</u> September 30, 2011
Loss from discontinued operations, net of income tax benefit	\$ (16,551)
Share-based compensation expense	(129)
Decrease in assets held for sale from discontinued operations	5,024
Decrease in liabilities held for sale from discontinued operations	(631)
Net cash used in operating activities from discontinued operations	\$ (12,287)

**4. CHANGE IN ESTIMATE**

During the three months ended September 30, 2012, the Company reduced its estimate for the amount of expected future returns of SOLODYN<sup>®</sup>, based on recent historical experience and the reduced amount of units that flow through the traditional wholesale and retail chain drugstore channel that has resulted from the Company's alternate fulfillment initiatives. As a result, the Company decreased the reserve for sales returns for SOLODYN<sup>®</sup> by \$11.5 million, and correspondingly increased managed care and Medicaid reserves for SOLODYN<sup>®</sup> by \$3.4 million and increased the reserve for consumer rebates for SOLODYN<sup>®</sup> by \$1.3 million. The net \$6.8 million reduction in these reserves increased net income for the three and nine months ended September 30, 2012 by \$4.4 million, or \$0.07 per common share.



**Table of Contents****5. SHARE-BASED COMPENSATION**

At September 30, 2012, the Company had seven active share-based employee compensation plans. Of these seven share-based compensation plans, only the 2006 Incentive Award Plan is eligible for the granting of future awards.

Upon consummation of the pending Merger with Valeant (see Note 2), each stock option award (whether vested or unvested) that is outstanding immediately prior to the Merger will be cancelled in exchange for the right to receive the Per Share Merger Consideration less the exercise price per Share of each respective award. Each stock appreciation right (whether vested or unvested) that is outstanding immediately prior to the Merger will be canceled in exchange for the right to receive the Per Share Merger Consideration less the exercise price per share of the stock appreciation right. Each unvested restricted stock award will also convert into a right to receive the Per Share Merger Consideration. Unrecognized compensation costs and related weighted average periods over which they are expected to be recognized for share-based compensation awards described below do not contemplate the impact of the pending Merger on the awards.

**Stock Option Awards**

Stock option awards are granted at the fair market value on the date of grant. The option awards vest over a period determined at the time the options are granted, ranging from one to five years, and generally have a maximum term of ten years. Certain options provide for accelerated vesting if there is a change in control of the Company (as defined in the plans). When options are exercised, new shares of the Company's Class A common stock are issued.

The total value of the stock option awards is expensed ratably over the service period of the employees receiving the awards. As of September 30, 2012, total unrecognized compensation cost related to stock option awards, to be recognized as expense subsequent to September 30, 2012, was approximately \$1.3 million and the related weighted average period over which it is expected to be recognized is approximately 2.4 years.

A summary of stock option activity within the Company's stock-based compensation plans and changes for the nine months ended September 30, 2012, is as follows:

	Number of Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Balance at December 31, 2011	4,101,505	\$ 31.31		
Granted	88,818	\$ 36.72		
Exercised	(798,841)	\$ 23.69		
Terminated/expired	(70,526)	\$ 37.28		
Balance at September 30, 2012	3,320,956	\$ 33.15	2.2	\$ 33,594,606

The intrinsic value of options exercised during the nine months ended September 30, 2012 was approximately \$10.6 million. Options exercisable under the Company's share-based compensation plans at September 30, 2012 were 3,154,275 with a weighted average exercise price of \$33.34, a weighted average remaining contractual term of 1.9 years, and an aggregate intrinsic value of approximately \$31.3 million.



**Table of Contents**

A summary of outstanding and exercisable stock options that are fully vested and are expected to vest, based on historical forfeiture rates, as of September 30, 2012, is as follows:

	Number of Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding, net of expected forfeitures	3,162,353	\$ 33.22	2.1	\$ 31,777,261
Exercisable, net of expected forfeitures	3,036,138	\$ 33.30	1.9	\$ 30,279,871

The fair value of each stock option award is estimated on the date of the grant using the Black-Scholes option pricing model with the following assumptions:

	Nine Months Ended	
	September 30, 2012	September 30, 2011
Expected dividend yield	1.06% to 1.14%	0.77% to 0.88%
Expected stock price volatility	31% to 32%	33%
Risk-free interest rate	1.13% to 1.19%	2.47% to 2.81%
Expected life of options in years	6.0 to 7.0	7.0

The expected dividend yield is based on expected annual dividends to be paid by the Company as a percentage of the market value of the Company's stock as of the date of grant. The Company determined that a blend of implied volatility and historical volatility is more reflective of market conditions and a better indicator of expected volatility than using purely historical volatility. The risk-free interest rate is based on the U.S. treasury security rate in effect as of the date of grant whose term is consistent with the expected life of the related grant. The expected lives of the options are based on the Company's historical exercise data.

The weighted average fair value of stock options granted during the nine months ended September 30, 2012 and 2011, was \$10.77 and \$12.25, respectively.

**Restricted Stock Awards**

The Company also grants restricted stock awards to certain employees. Restricted stock awards are valued at the closing market value of the Company's Class A common stock on the date of grant, and the total value of the award is expensed ratably over the service period of the employees receiving the grants. As of September 30, 2012, the total amount of unrecognized compensation cost related to nonvested restricted stock awards, to be recognized as expense subsequent to September 30, 2012, was approximately \$43.3 million, and the related weighted average period over which it is expected to be recognized is approximately 3.4 years.

**Table of Contents**

A summary of restricted stock activity within the Company's share-based compensation plans and changes for the nine months ended September 30, 2012, is as follows:

	<b>Nonvested Shares</b>	<b>Shares</b>	<b>Weighted Average Grant-Date Fair Value</b>
Nonvested at December 31, 2011		1,919,462	\$ 22.61
Granted		715,593	\$ 35.02
Vested		(590,678)	\$ 20.49
Forfeited		(57,659)	\$ 31.80
Nonvested at September 30, 2012		1,986,718	\$ 27.44

The total fair value of restricted shares vested during the nine months ended September 30, 2012 and 2011 was approximately \$12.1 million and \$9.3 million, respectively.

**Stock Appreciation Rights**

During 2009, the Company began granting cash-settled stock appreciation rights (SARs) to many of its employees. SARs generally vest over a graduated five-year period and expire seven years from the date of grant, unless such expiration occurs sooner due to the employee's termination of employment, as provided in the applicable SAR award agreement. SARs allow the holder to receive cash (less applicable tax withholding) upon the holder's exercise, equal to the excess, if any, of the market price of the Company's Class A common stock on the exercise date over the exercise price, multiplied by the number of shares relating to the SAR with respect to which the SAR is exercised. The exercise price of the SAR is the fair market value of a share of the Company's Class A common stock relating to the SAR on the date of grant. The total value of the SAR is expensed over the service period of the employee receiving the grant, and a liability is recognized in the Company's condensed consolidated balance sheets until settled. The fair value of SARs is required to be remeasured at the end of each reporting period until the award is settled, and changes in fair value must be recognized as compensation expense to the extent of vesting during each reporting period based on the new fair value. As of September 30, 2012, the total measured amount of unrecognized compensation cost related to outstanding SARs, to be recognized as expense subsequent to September 30, 2012, based on the remeasurement at September 30, 2012, was approximately \$22.8 million, and the related weighted average period over which it is expected to be recognized is approximately 2.0 years.

The fair value of each SAR was estimated on the date of the grant, and was remeasured at quarter-end, using the Black-Scholes option pricing model with the following assumptions:

	<b>Remeasurement as of September 30, 2012</b>	<b>SARs Granted During the Nine Months Ended September 30, 2011</b>
Expected dividend yield	0.92%	0.87%
Expected stock price volatility	29%	32%
Risk-free interest rate	0.23% to 0.62%	3.12%
Expected life of SARs in years	2.4 to 4.4	7.0

The expected dividend yield is based on expected annual dividends to be paid by the Company as a percentage of the market value of the Company's stock as of the date of grant. The Company determined that a blend of implied volatility and historical volatility is more reflective of market conditions and a better indicator of expected volatility than using purely historical volatility. The risk-free interest rate is based on the U.S. treasury security rate in effect as of the date of grant whose term is consistent with the expected life of the related grant. The expected lives of the SARs are based on the Company's historical exercise data.



**Table of Contents**

No SARs were granted during the nine months ended September 30, 2012. The weighted average fair value of SARs granted during the nine months ended September 30, 2011, as of the grant date, was \$9.90. The weighted average fair value of all SARs outstanding as of the remeasurement date of September 30, 2012 was \$25.00.

A summary of SARs activity for the nine months ended September 30, 2012 is as follows:

	Number of SARs	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Balance at December 31, 2011	2,323,060	\$ 17.52		
Granted	-	\$ -		
Exercised	(316,067)	\$ 14.64		
Terminated/expired	(138,303)	\$ 18.65		
Balance at September 30, 2012	1,868,690	\$ 17.92	4.0	\$ 47,364,073

The intrinsic value of SARs exercised during the nine months ended September 30, 2012 was approximately \$6.7 million.

As of September 30, 2012, 162,074 SARs were exercisable, with a weighted average exercise price of \$17.42, a weighted average remaining contractual term of 4.0 years, and an aggregate intrinsic value of approximately \$4.2 million.

Total share-based compensation expense related to continuing operations recognized during the three and nine months ended September 30, 2012 and 2011 was as follows (in thousands):

	Three Months Ended		Nine Months Ended	
	September 30, 2012	September 30, 2011	September 30, 2012	September 30, 2011
Stock options	\$ 208	\$ 187	\$ 612	\$ 670
Restricted stock awards	3,791	2,794	10,774	8,593
Stock appreciation rights	9,558	1,457	14,362	11,182
Total share-based compensation expense	\$ 13,557	\$ 4,438	\$ 25,748	\$ 20,445

**6. SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN**

On June 24, 2011, the Company's Compensation Committee adopted the Medicis Pharmaceutical Corporation Supplemental Executive Retirement Plan, as amended on October 3, 2011 (the "SERP"), a non-qualified, noncontributory, defined benefit pension plan that provides supplemental retirement income for a select group of officers, including the Company's named executive officers. The SERP became effective as of June 1, 2011. Retirement benefits are calculated based on a percentage of a SERP participant's average earnings, beginning with the 2009 calendar year. The SERP retirement benefit is intended to be paid to participants who reach the normal retirement date, which is age 65, or age 59 1/2 with twenty years of service, subject to certain exceptions.

## Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 10-Q

A SERP participant vests in 1/6th of his or her retirement benefit per plan year, (which runs from June 1 to May 31), effective as of the first day of the plan year, and becomes fully vested in his or her accrued retirement benefit upon (1) the participant's normal retirement date, provided that the participant has at least fifteen years of service with the Company and is employed by the Company on such date, (2) the participant's separation from

**Table of Contents**

service due to a discharge without cause or resignation for good reason (as such terms are defined in the participant's employment agreement, or in the absence of such employment agreement or definitions, in the Company's Executive Retention Plan), or (3) a change in control of the Company. The completion of the pending merger with Valeant (see Note 2) will constitute a change in control of the Company under the SERP, upon which each participant's accrued retirement benefit will become fully vested and distributable on the 30th day following the merger.

Participants in the SERP received credit for prior service with the Company. The prior service accrued benefit of approximately \$33.8 million was recorded during the three months ended June 30, 2011 as other comprehensive income within stockholders' equity, and is amortized as compensation expense over the remaining service years of each participant. The Company also established a deferred tax asset of approximately \$12.0 million, the benefit of which was also recorded in other comprehensive income. During the three months ended March 31, 2012, an additional participant was added to the plan, and a prior service accrued benefit of approximately \$0.8 million was recorded as other comprehensive income within stockholders' equity, and is being amortized over the remaining service years of the participant. Total amortization of prior service costs recognized as compensation expense during the three and nine months ended September 30, 2012, was approximately \$1.2 million and \$3.6 million, respectively. Amortization of prior service costs recognized as compensation expense during the three and nine months ended September 30, 2011, was approximately \$1.2 million and \$1.6 million, respectively.

Compensation expense recognized during the three and nine months ended September 30, 2012 related to current service costs was approximately \$0.3 million and \$0.7 million, respectively. Compensation expense recognized during the three and nine months ended September 30, 2011 was \$0.3 million. Interest cost accrued related to prior and current service costs during the three and nine months ended September 30, 2012 was approximately \$0.4 million and \$1.2 million, respectively. Interest cost accrued related to prior and current service costs during the three and nine months ended September 30, 2011 was approximately \$0.4 million. The total present value of accrued benefits for the SERP as of September 30, 2012 was approximately \$37.8 million, which is included in other long-term liabilities in the Company's condensed consolidated balance sheets as of September 30, 2012.

The Company maintains a rabbi trust to fund the SERP benefit. During the three months ended September 30, 2011 and three months ended June 30, 2012, the Company purchased life insurance policy investments of approximately \$9.8 million and \$12.1 million, respectively, to fund the SERP. The life insurance policies cover the SERP participants. The Company intends to make similar annual purchases during each of the next three years. During the three months ended March 31, 2012 and September 30, 2012, the Company made additional life insurance policy investment purchases of approximately \$0.4 million and \$0.4 million, respectively, related to the new participant added to the SERP during the three months ended March 31, 2012. Net gains on the investments aggregating approximately \$1.2 million were recognized during the three and nine months ended September 30, 2012. The Company's expected return on the plan assets is 4%. The total investment related to the SERP of \$24.0 million is included in other assets in the Company's condensed consolidated balance sheets as of September 30, 2012, and is the cash surrender value of the life insurance policies, representing the fair value of the plan assets.

**7. SHORT-TERM AND LONG-TERM INVESTMENTS**

The Company's policy for its short-term and long-term investments is to establish a high-quality portfolio that preserves principal, meets liquidity needs, avoids inappropriate concentrations and delivers an appropriate yield in relationship to the Company's investment guidelines and market conditions. Short-term and long-term investments consist of corporate and various government agency and municipal debt securities. The Company's investments in auction rate floating securities consist of investments in student loans. Management classifies the Company's short-term and long-term investments as available-for-sale. Available-for-sale securities are carried at fair value with unrealized gains and losses reported in stockholders' equity. Realized gains and losses and declines in value judged to be other than temporary, if any, are included in other expense in the condensed consolidated statement of operations. A decline in the market value of any available-for-sale security below cost that is deemed to be other than temporary, results in impairment of the fair value of the investment. Except for impairments related to the illiquidity of the Company's auction rate floating securities, other-than-temporary impairments are charged to earnings and a new cost basis for the security is established. Premiums and discounts are amortized or accreted over the life of the related available-for-sale security. Dividends and interest income are recognized when earned. The cost of securities sold is calculated using the specific identification method. At September 30, 2012, the Company has recorded the estimated fair value of available-for-sale securities in short-term and long-term investments of approximately \$629.8 million and \$12.8 million, respectively.

**Table of Contents**

Available-for-sale securities consist of the following at September 30, 2012 (in thousands):

	<b>September 30, 2012</b>				
	<b>Cost</b>	<b>Gross Unrealized Gains</b>	<b>Gross Unrealized Losses</b>	<b>Other- Than- Temporary Impairment Losses</b>	<b>Fair Value</b>
Corporate notes and bonds	\$ 323,691	\$ 2,674	\$(8)	\$ -	\$ 326,357
Federal agency notes and bonds	254,072	324	(15)	-	254,381
Auction rate floating securities	17,350	-	(4,572)	-	12,778
Asset-backed securities	49,008	63	(1)	-	49,070
<b>Total securities</b>	<b>\$ 644,121</b>	<b>\$ 3,061</b>	<b>\$ (4,596)</b>	<b>\$ -</b>	<b>\$ 642,586</b>

	<b>December 31, 2011</b>				
	<b>Cost</b>	<b>Gross Unrealized Gains</b>	<b>Gross Unrealized Losses</b>	<b>Other- Than- Temporary Impairment Losses</b>	<b>Fair Value</b>
Corporate notes and bonds	\$ 138,554	\$ 161	\$ (549)	\$ -	\$ 138,166
Federal agency notes and bonds	125,092	221	(24)	-	125,289
Auction rate floating securities	17,400	-	(4,607)	-	12,793
Asset-backed securities	9,527	-	(8)	-	9,519
<b>Total securities</b>	<b>\$ 290,573</b>	<b>\$ 382</b>	<b>\$ (5,188)</b>	<b>\$ -</b>	<b>\$ 285,767</b>

During the three and nine months ended September 30, 2012, gross realized gains on sales of available-for-sale securities totaled approximately \$0.1 million. During the three and nine months ended September 30, 2012, there were no significant gross realized losses on sales of available-for-sale securities. During the three and nine months ended September 30, 2011, gross realized gains on sales of available-for-sale securities totaled approximately \$0.1 million. During the three and nine months ended September 30, 2011, there were no significant gross realized losses on sales of available-for-sale securities. Gross unrealized gains and losses are determined based on the specific identification method. The net adjustment to unrealized gains during the nine months ended September 30, 2012, on available-for-sale securities included in stockholders' equity totaled approximately \$2.1 million. The amortized cost and estimated fair value of the available-for-sale securities at September 30, 2012, by maturity, are shown below (in thousands):

**September 30, 2012**

<b>Cost</b>	<b>Estimated Fair Value</b>
-------------	---------------------------------

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 10-Q

<b>Available-for-sale</b>		
Due in one year or less	\$ 309,421	\$ 311,520
Due after one year through five years	317,350	318,288
Due after 10 years	17,350	12,778
	\$ 644,121	\$ 642,586

Expected maturities will differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties, and the Company views its available-for-sale securities



**Table of Contents**

as available for current operations. At September 30, 2012, approximately \$12.8 million in estimated fair value expected to mature greater than one year has been classified as long-term investments since these investments are in an unrealized loss position, and management has both the ability and intent to hold these investments until recovery of fair value, which may be maturity.

As of September 30, 2012, the Company's investments included auction rate floating securities with a fair value of \$12.8 million. The Company's auction rate floating securities are debt instruments with a long-term maturity and with an interest rate that is reset in short intervals through auctions. The negative conditions in the credit markets from 2008 through the first nine months of 2012 have prevented some investors from liquidating their holdings, including their holdings of auction rate floating securities. During the three months ended March 31, 2008, the Company was informed that there was insufficient demand at auction for the auction rate floating securities. As a result, these affected auction rate floating securities are now considered illiquid, and the Company could be required to hold them until they are redeemed by the holder at maturity. The Company may not be able to liquidate the securities until a future auction on these investments is successful.

The following table shows the gross unrealized losses and the fair value of the Company's investments, with unrealized losses that are not deemed to be other-than-temporarily impaired aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position at September 30, 2012 (in thousands):

	Less Than 12 Months		Greater Than 12 Months	
	Fair Value	Gross Unrealized Loss	Fair Value	Gross Unrealized Loss
Corporate notes and bonds	\$ 24,412	\$ (8)	\$ -	\$-
Federal agency notes and bonds	28,965	(15)	-	-
Auction rate floating securities	-	-	12,778	(4,572)
Asset-backed securities	12,019	(1)	-	-
Total securities	\$ 65,396	\$ (24)	\$ 12,778	\$(4,572)

As of September 30, 2012, the Company has concluded that the unrealized losses on its investment securities are temporary in nature and are caused by changes in credit spreads and liquidity issues in the marketplace. Available-for-sale securities are reviewed quarterly for possible other-than-temporary impairment. This review includes an analysis of the facts and circumstances of each individual investment such as the severity of loss, the expectation for that security's performance and the creditworthiness of the issuer. Additionally, the Company does not intend to sell and it is not more-likely-than-not that the Company will be required to sell any of the securities before the recovery of their amortized cost basis.

**8. FAIR VALUE MEASUREMENTS**

As of September 30, 2012, the Company held certain assets and liabilities that are required to be measured at fair value on a recurring basis. These included the Company's short-term and long-term investments, including investments in auction rate floating securities, and the liability associated with the Counterparty Settlement Agreement (see Note 15).

The Company has invested in auction rate floating securities, which are classified as available-for-sale securities and reflected at fair value. Due to events in credit markets, the auction events for some of these instruments held by the Company failed during the three months ended March 31, 2008 (See Note 7). Therefore, the fair values of these auction rate floating securities, which are primarily rated AAA, are estimated utilizing a discounted cash flow analysis as of September 30, 2012. These analyses consider, among other items, the collateralization underlying the security investments, the creditworthiness of the counterparty, the timing of expected future cash flows, and the expectation of the next time the security is expected to have a successful auction. These investments were also compared, when possible, to other observable market data with similar characteristics to the securities held by the Company. Changes to these assumptions in future periods could result in additional declines in fair value of the auction rate floating securities.



**Table of Contents**

The Company's assets and liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820, *Fair Value Measurements and Disclosures*, at September 30, 2012 and December 31, 2011, were as follows (in thousands):

	<b>Fair Value Measurement at Reporting Date Using</b>			
	<b>Sept. 30, 2012</b>	<b>Quoted Prices in Active Markets (Level 1)</b>	<b>Significant Other Observable Inputs (Level 2)</b>	<b>Significant Unobservable Inputs (Level 3)</b>
Corporate notes and bonds	\$ 326,357	\$ 4,155	\$ 322,202	\$ -
Federal agency notes and bonds	254,381	-	254,381	-
Auction rate floating securities	12,778	-	-	12,778
Asset-backed securities	49,070	-	49,070	-
<b>Total assets measured at fair value</b>	<b>\$ 642,586</b>	<b>\$ 4,155</b>	<b>\$ 625,653</b>	<b>\$ 12,778</b>
Counterparty Settlement Agreement liability	\$ 24,925	\$ -	\$ -	\$ 24,925
<b>Total liabilities measured at fair value</b>	<b>\$ 24,925</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 24,925</b>

	<b>Fair Value Measurement at Reporting Date Using</b>			
	<b>Dec. 31, 2011</b>	<b>Quoted Prices in Active Markets (Level 1)</b>	<b>Significant Other Observable Inputs (Level 2)</b>	<b>Significant Unobservable Inputs (Level 3)</b>
Corporate notes and bonds	\$ 138,166	\$ -	\$ 138,166	\$ -
Federal agency notes and bonds	125,289	-	125,289	-
Auction rate floating securities	12,793	-	-	12,793
Asset-backed securities	9,519	-	9,519	-
<b>Total assets measured at fair value</b>	<b>\$ 285,767</b>	<b>\$ -</b>	<b>\$ 272,974</b>	<b>\$ 12,793</b>

**Table of Contents**

The following tables present the Company's assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three and nine months ended September 30, 2012 (in thousands):

	<b>Fair Value</b>	
	<b>Measurements Using</b>	
	<b>Significant</b>	
	<b>Unobservable Inputs</b>	
	<b>(Level 3)</b>	
	<b>Auction Rate Floating Securities</b>	<b>Counterparty Settlement Agreement Liability</b>
Balance at June 30, 2012	\$ 12,766	\$ -
Transfers to (from) Level 3	-	17,182
Total losses (gains) included in other expense (income), net	-	7,743
Total gains included in other comprehensive income	12	-
Purchases	-	-
Settlements	-	-
Balance at September 30, 2012	\$ 12,778	\$ 24,925

	<b>Fair Value</b>	
	<b>Measurements Using</b>	
	<b>Significant</b>	
	<b>Unobservable Inputs</b>	
	<b>(Level 3)</b>	
	<b>Auction Rate Floating Securities</b>	<b>Counterparty Settlement Agreement Liability</b>
Balance at December 31, 2011	\$ 12,793	\$ -
Transfers to (from) Level 3	-	17,182
Total losses (gains) included in other expense (income), net	-	7,743
	35	-

## Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 10-Q

Total gains included in other comprehensive income

Purchases	-	-
Settlements	(50)	-
Balance at September 30, 2012	\$ 12,778	\$ 24,925

The following is a description of the valuation techniques used for the assets and liabilities measured at fair value classified within Level 2 or Level 3 of the fair value hierarchy:

Available-for-sale securities classified within Level 2 of the fair value hierarchy are valued utilizing reports from third-party asset managers that hold the Company's investments, showing closing prices on the last business day of the period presented. These asset managers utilize an independent pricing source to obtain quotes for most fixed income securities, and utilize internal procedures to validate the prices obtained. In addition, the Company uses an independent third-party to perform price testing, comparing a sample of quoted prices listed in the asset managers reports to quotes listed through a public quotation service.

## **Table of Contents**

Available-for-sale securities classified within Level 3 of the fair value hierarchy (auction rate floating securities) are valued utilizing a discounted cash flow model. Key variables that are included in the Company's calculation of the fair value of its auction rate floating securities utilizing a discounted cash flow model are weighted average cost of capital ( WACC ), liquidity horizon and estimated coupon rate. The liquidity horizon is an estimation of how long the liquidity issue of the auction rate floating securities will continue to exist. As part of its calculation of the fair value of its auction rate floating securities as of September 30, 2012, the Company used a WACC of 5.0%, a liquidity horizon of nine years, and an estimated coupon rate of a 12-month historical average for the indexes. The 12-month historical averages for 1-Month LIBOR and 90-Day T-Bills were 0.25% and 0.06%, respectively. As part of its assessment of these variables used in calculating the fair value of its auction rate floating securities, the Company performs a sensitivity analysis to understand the potential impact of using different amounts for these variables. As of September 30, 2012, the sensitivity analysis did not produce calculated fair values that were significantly different from those calculated using the variables described above.

The fair value of the Note Hedge and Warrant Transactions before the execution of the Counterparty Settlement Agreement was calculated utilizing potential settlement outcomes with the Counterparty under the original terms of the Note Hedge and Warrant Transactions considering merger and non-merger events as probability weighted and discounted using a credit adjusted risk free rate. This valuation model utilizes inputs including market based settlement terms upon a merger or non-merger event for the respective Note Hedge and Warrant Transactions, a credit adjusted discount rate, and probability weighting (Level 3 inputs). The probability-weighting was based on a market participant's expectation as to the outcome of a merger event. The fair value of the Note Hedge and Warrant Transactions after the execution of the Counterparty Settlement Agreement was calculated using potential settlement outcomes considering merger and non-merger events as probability weighted and discounted using a credit adjusted risk free rate. This valuation model utilizes inputs including a fixed settlement amount based on the terms of the Counterparty Settlement Agreement, the assumed payment to be made under the Consulting Agreement as discounted for counterparty credit risk, a counterparty credit risk adjusted discount rate, and probability weighting (Level 3 inputs).

## **9. RESEARCH AND DEVELOPMENT**

All research and development costs, including payments related to products under development and research consulting agreements, are expensed as incurred. The Company may continue to make non-refundable payments to third parties for new technologies and for research and development work that has been completed. These payments may be expensed or capitalized at the time of payment depending on the nature of the payment made and the related stage of the research and development project.

The Company's policy on accounting for costs of strategic collaborations determines the timing of the recognition of certain development costs. In addition, this policy determines whether the cost is classified as development expense or capitalized as an asset. Management is required to form judgments with respect to the commercial status of such products in determining whether development costs meet the criteria for immediate expense or capitalization. For example, when the Company acquires certain products for which there already is an Abbreviated New Drug Application ( ANDA ) or a New Drug Application ( NDA ) approval related directly to the product, and there is net realizable value based on projected sales for these products, the Company capitalizes the amount paid as an intangible asset.

**Table of Contents**

Research and development expense for the three and nine months ended September 30, 2012 and 2011 are as follows (in thousands):

	Three Months Ended		Nine Months Ended	
	September 30, 2012	September 30, 2011	September 30, 2012	September 30, 2011
Ongoing research and development costs	\$ 11,833	\$ 7,638	\$ 39,337	\$ 21,588
Payments related to strategic collaborations	(500)	21,000	46,506	35,500
Share-based compensation expense	930	95	1,563	1,114
Total research and development	\$ 12,263	\$ 28,733	\$ 87,406	\$ 58,202

**10. STRATEGIC COLLABORATIONS***Development and License Agreement with a specialty pharmaceutical company*

On March 30, 2012, the Company entered into a Development and License Agreement with a specialty pharmaceutical company pursuant to which the Company obtained exclusive worldwide rights for the development and commercialization of an investigational drug targeted at certain topical skin applications. Under the terms of the agreement, the Company agreed to pay an up-front payment of \$25.0 million in connection with the execution of the agreement, and will pay up to an additional \$80.0 million upon the achievement of certain research, development and regulatory milestones and up to an additional \$120.0 million upon the achievement of certain commercial milestones, as well as royalties on future sales. The initial \$25.0 million up-front payment, which was paid in April 2012, was recognized as research and development expense during the three months ended March 31, 2012.

*License Agreement with 3M*

On February 24, 2012, the Company entered into a License Agreement with 3M Company and 3M Innovative Properties Company (collectively, 3M ) for worldwide rights to a number of leading molecules in 3M's platform of immune response modifiers, for all topical dermatology indications and options for all human uses associated with the licensed molecules, excluding vaccine adjuvant. Under the terms of the agreement, the Company made an up-front payment of \$7.5 million to 3M in connection with the execution of the agreement, and will pay up to an additional \$25.6 million of contingent license and option fees. The Company may also pay up to an additional \$25.0 million upon the achievement of certain research, development and regulatory milestones, as well as royalties on future sales. The initial \$7.5 million payment was recognized as research and development expense during the three months ended March 31, 2012.

*Joint Development Agreement with Lupin*

On July 21, 2011, the Company entered into a Joint Development Agreement (the Original Agreement ) with Lupin Limited, on behalf of itself and its affiliates (hereinafter collectively referred to as Lupin ), whereby the Company and Lupin will collaborate to develop multiple novel proprietary therapeutic products. Pursuant to the Original Agreement, subject to the terms and conditions contained therein, the Company made an up-front \$20.0 million payment to Lupin and was to make additional payments to Lupin upon the achievement of certain research, development, regulatory and other milestones, as well as royalty payments on sales of the products covered under the Original Agreement. In addition, the Company was to receive an exclusive, worldwide (excluding India) license on the sale of the products covered under the Original Agreement.

On March 30, 2012, the Company entered into an Amended and Restated Joint Development Agreement, with Lupin (the Amended and Restated Joint Development Agreement ), which modified the list of products being developed. The Company made a \$2.5 million payment to Lupin in April 2012 in connection with the execution of the Amended and Restated Joint Development Agreement, and will make additional payments to Lupin of up to \$35.5 million upon the achievement of certain research, development, regulatory and other milestones, as well as royalty payments on sales of the products covered under the Amended and Restated Joint Development Agreement, which supersedes the

## Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 10-Q

additional payments the Company would have made under the Original Agreement. In addition, the Company will receive an exclusive, worldwide (excluding India) license on the sale of the products covered under the Amended and Restated Joint Development Agreement.



**Table of Contents**

The \$20.0 million up-front payment related to the Original Agreement was recognized as research and development expense during the three months ended September 30, 2011. The \$2.5 million payment related to the Amended and Restated Joint Development Agreement was recognized as research and development expense during the three months ended March 31, 2012.

*Amended and Restated Collaboration Agreement and Asset Purchase Agreement with Hyperion*

On March 22, 2012, Ucyclid Pharma, Inc. ( Ucyclid ), a wholly-owned subsidiary of the Company, and Hyperion Therapeutics, Inc. ( Hyperion ) entered into an Amended and Restated Collaboration Agreement (the Amended Collaboration Agreement ), which amended and restated their existing Collaboration Agreement, dated August 23, 2007, as previously amended on or about November 24, 2008, June 29, 2009 and October 12, 2009 (the Prior Collaboration Agreement ).

Pursuant to the terms of the Prior Collaboration Agreement, Ucyclid granted rights to Hyperion, exercisable in the future, to purchase certain worldwide rights to Ucyclid s existing on-market products AMMONUL<sup>®</sup> and BUPHENYL<sup>®</sup> under certain conditions, as well as to develop and commercialize Ravicti , a compound referred to as HPN-100 (and also previously referred to as GT4P in the Prior Collaboration Agreement), for the treatment of urea cycle disorder, hepatic encephalopathies and other indications. The parties agreed to supersede the Prior Collaboration Agreement with the Amended Collaboration Agreement, under which Hyperion will continue to have the right, exercisable no earlier than January 1, 2013, to purchase certain worldwide rights to AMMONUL<sup>®</sup> and BUPHENYL<sup>®</sup>, subject to Ucyclid s right to elect to retain such rights to AMMONUL<sup>®</sup>, and an Asset Purchase Agreement of even date (the APA ), under which Hyperion agreed to purchase Ucyclid s rights to Ravicti on the terms set forth therein. The parties completed the sale of Ravicti under the APA on March 22, 2012, for which Hyperion paid Ucyclid \$6.0 million. If Ravicti is not approved by the FDA by January 1, 2013, Ucyclid will pay Hyperion \$0.5 million per month until June 30, 2013, or until Ravicti is approved, whichever comes first, subject to a maximum of \$3.0 million in aggregate payments. Pursuant to the APA, Hyperion will pay Ucyclid certain royalties and regulatory and sales milestones relating to Ravicti and, pursuant to the terms of the Amended Collaboration Agreement, following exercise of its purchase rights, Hyperion will pay Ucyclid certain royalties and regulatory and sales milestones relating to AMMONUL<sup>®</sup> (but only if Ucyclid does not elect to retain rights to AMMONUL<sup>®</sup>) and BUPHENYL<sup>®</sup>. Ucyclid will continue to be entitled to all revenue from the sales of AMMONUL<sup>®</sup> and BUPHENYL<sup>®</sup> until the exercise of the purchase rights by Hyperion. If Hyperion elects to purchase AMMONUL<sup>®</sup> and BUPHENYL<sup>®</sup>, but Ucyclid elects to retain AMMONUL<sup>®</sup>, then AMMONUL<sup>®</sup> will remain an asset of Ucyclid and Ucyclid will continue to be entitled to all revenue from the sales of AMMONUL<sup>®</sup>. A net gain of \$3.0 million on the sale of Ravicti to Hyperion was recognized in other income during the three months ended March 31, 2012. This consisted of the \$6.0 million payment Ucyclid received from Hyperion, partially offset by the \$3.0 million in total potential contingent payments that Ucyclid could pay to Hyperion during the first six months of 2013, based upon the timing of the approval of Ravicti by the FDA. The \$3.0 million contingent liability is included in other current liabilities in the Company s condensed consolidated balance sheets as of September 30, 2012.

*Collaboration with a privately-held U.S. biotechnology company*

On September 10, 2010, the Company and a privately-held U.S. biotechnology company entered into a sublicense and development agreement to develop an agent for specific dermatological conditions in the Americas and Europe and a purchase option to acquire the privately-held U.S. biotechnology company.

Under the terms of the agreements, the Company paid the privately-held U.S. biotechnology company \$5.0 million in connection with the execution of the agreement, and will pay additional potential milestone payments totaling approximately \$100.5 million upon successful completion of certain clinical, regulatory and commercial milestones.

During the three months ended December 31, 2010 and June 30, 2011, development milestones were achieved, and the Company made a \$10.0 million and a \$5.5 million payment, respectively, pursuant to the agreements. The initial \$5.0 million payment and the \$10.0 million milestone payment were recognized as research and development expense during 2010, and the \$5.5 million milestone payment was recognized as research and development expense during the three months ended June 30, 2011. As of September 30, 2012, \$75.0 million of potential milestone payments remain upon successful completion of certain clinical, regulatory and commercial milestones.

**Table of Contents***Research and Development Agreement with Anacor*

On February 9, 2011, the Company entered into a research and development agreement with Anacor Pharmaceuticals, Inc. ( Anacor ) for the discovery and development of boron-based small molecule compounds directed against a target for the potential treatment of acne. Under the terms of the agreement, the Company paid Anacor \$7.0 million in connection with the execution of the agreement, and will pay up to \$153.0 million upon the achievement of certain research, development, regulatory and commercial milestones, as well as royalties on sales by the Company. Anacor will be responsible for discovering and conducting the early development of product candidates which utilize Anacor s proprietary boron chemistry platform, while the Company will have an option to obtain an exclusive license for products covered by the agreement. The initial \$7.0 million payment was recognized as research and development expense during the three months ended March 31, 2011.

**11. IMPAIRMENT OF INTANGIBLE ASSETS**

The Company assesses the potential impairment of long-lived assets when events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant under-performance of a product line in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the Company s use of the assets. Recoverability of assets that will continue to be used in the Company s operations is measured by comparing the carrying amount of the asset grouping to the Company s estimate of the related total future net cash flows. If an asset carrying value is not recoverable through the related cash flows, the asset is considered to be impaired. The impairment is measured by the difference between the asset grouping s carrying amount and its fair value, based on the best information available, including market prices or discounted cash flow analysis. If the assets determined to be impaired are to be held and used, the Company recognizes an impairment loss through a charge to operating results to the extent the present value of anticipated net cash flows attributable to the asset are less than the asset s carrying value. When it is determined that the useful life of assets are shorter than originally estimated, and there are sufficient cash flows to support the carrying value of the assets, the Company will accelerate the rate of amortization charges in order to fully amortize the assets over their new shorter useful lives.

During the quarter ended September 30, 2012, an intangible asset related to one of the Company s non-primary products was determined to be impaired based on the Company s analysis of the intangible asset s carrying value and projected future cash flows. As a result of the impairment analysis, the Company determined that the fair value of the intangible asset was less than its carrying value and recorded a write-down of approximately \$2.7 million related to this intangible asset. During the quarter ended September 30, 2012, the Company determined that the product, which was one of the products acquired as part of the Company s December 2011 acquisition of the assets of Graceway Pharmaceuticals, LLC ( Graceway ), would no longer be sold. The \$2.7 million impairment charge reduced the intangible asset s carrying value to \$0.

During the quarter ended September 30, 2011, an intangible asset related to an authorized generic product from which the Company receives contract revenue was determined to be impaired based on the Company s analysis of the intangible asset s carrying value and projected future cash flows. As a result of the impairment analysis, the Company recorded a write-down of \$2.3 million related to this intangible asset. Factors affecting the future cash flows of the contract revenue related to the authorized generic product included projected net revenues for the authorized generic product for which the Company receives contract revenue being less than originally anticipated.

**12. SEGMENT AND PRODUCT INFORMATION**

The Company operates in one business segment: pharmaceuticals. The Company s current pharmaceutical franchises are divided between the dermatological and non-dermatological fields. The dermatological field represents products for the treatment of acne and acne-related dermatological conditions and non-acne dermatological conditions. The non-dermatological field represents products for the treatment of urea cycle disorder, contract revenue, and beginning on December 2, 2011, upon the Company s acquisition of the assets of Graceway, products in the respiratory and women s health specialties. The acne and acne-related dermatological product lines include SOLODY<sup>®</sup> and ZIANA<sup>®</sup>. During early 2011, the Company discontinued its TRIAZ<sup>®</sup>

**Table of Contents**

branded products and decided to no longer promote its PLEXION® branded products. The non-acne dermatological product lines include DYSPORT®, LOPROX®, PERLANE®, RESTYLANE®, VANOS® and ZYCLARA®. ZYCLARA® was acquired by the Company as part of the acquisition of the assets of Graceway on December 2, 2011. The non-dermatological product lines include AMMONUL®, BUPHENYL® and the MAXAIR® AUTOHALER®. The MAXAIR® AUTOHALER® was acquired by the Company as part of the acquisition of the assets of Graceway on December 2, 2011. The non-dermatological field also includes contract revenues associated with licensing agreements and authorized generic agreements.

The Company's pharmaceutical products, with the exception of AMMONUL® and BUPHENYL®, are promoted to dermatologists and plastic surgeons. Such products are often prescribed by physicians outside these two specialties, including family practitioners, general practitioners, primary-care physicians and OB/GYNs, as well as hospitals, government agencies and others. Currently, the Company's products are sold primarily to wholesalers and retail chain drug stores.

Net revenues and the percentage of net revenues for each of the product categories are as follows (amounts in thousands):

	Three Months Ended		Nine Months Ended	
	September 30,	September 30,	September 30,	September 30,
	2012	2011	2012	2011
Acne and acne-related dermatological products	\$ 85,109	\$ 119,119	\$ 286,741	\$ 345,711
Non-acne dermatological products	80,773	55,659	235,885	165,599
Non-dermatological products	14,313	9,890	55,865	29,098
<b>Total net revenues</b>	<b>\$ 180,195</b>	<b>\$ 184,668</b>	<b>\$ 578,491</b>	<b>\$ 540,408</b>

	Three Months Ended		Nine Months Ended	
	September 30,	September 30,	September 30,	September 30,
	2012	2011	2012	2011
Acne and acne-related dermatological products	47 %	65 %	49 %	64 %
Non-acne dermatological products	45	30	41	31
Non-dermatological products	8	5	10	5
<b>Total net revenues</b>	<b>100 %</b>	<b>100 %</b>	<b>100 %</b>	<b>100 %</b>

During the three and nine months ended September 30, 2012, approximately 4.6% and 5.0% of the Company's net revenues were generated in Canada. No country or region outside of the U.S. and Canada generated more than 5%, individually or in the aggregate, of the Company's net revenues during the three or nine months ended September 30, 2012. During the three and nine months ended September 30, 2011, less than 5% of the Company's net revenues were generated outside of the U.S.

**13. INVENTORIES**

The Company utilizes third parties to manufacture and package inventories held for sale, takes title to certain inventories once manufactured, and warehouses such goods until packaged for final distribution and sale. Inventories consist of salable products held at the Company's warehouses, as well as raw materials and components at the manufacturers' facilities, and are valued at the lower of cost or market using the first-in, first-out method. The Company provides valuation reserves for estimated obsolescence or unmarketable inventory in an amount equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions.

Inventory costs associated with products that have not yet received regulatory approval are capitalized if, in the view of the Company's management, there is probable future commercial use and future economic benefit. If future commercial use and future economic benefit are not considered probable, then costs associated with pre-launch inventory that has not yet received regulatory approval are expensed as research and development expense during the period the costs are incurred. As of September 30, 2012 and December 31, 2011, there were no costs capitalized into inventory for products that had not yet received regulatory approval.

**Table of Contents**

Inventories as of September 30, 2012 and December 31, 2011 is comprised of the following (in thousands):

	<b>September 30, 2012</b>	<b>December 31, 2011</b>
Raw materials	\$ 11,678	\$ 9,100
Work-in-process	987	5,495
Finished goods	27,875	29,250
Valuation reserve	(5,659)	(9,326)
<b>Total inventories</b>	<b>\$ 34,881</b>	<b>\$ 34,519</b>

**14. OTHER CURRENT LIABILITIES**

Other current liabilities as of September 30, 2012 and December 31, 2011 is comprised of the following (in thousands):

	<b>September 30, 2012</b>	<b>December 31, 2011</b>
Accrued incentives, including SARs liability	\$ 44,199	\$ 41,516
Deferred revenue	11,351	13,703
Counterparty Settlement Agreement liability (see Note 15)	24,925	-
Other accrued expenses	33,962	23,566
	<b>\$ 114,437</b>	<b>\$ 78,785</b>

Deferred revenue as of September 30, 2012 and December 31, 2011 is comprised of the following (in thousands):

	<b>September 30, 2012</b>	<b>December 31, 2011</b>
Deferred revenue - aesthetics products, net of cost of revenue	\$ 7,694	\$ 13,349
Deferred revenue - sales into distribution channel in excess of eight weeks of projected demand	3,513	212
Other deferred revenue	144	142
	<b>\$ 11,351</b>	<b>\$ 13,703</b>

The Company defers revenue, and the related cost of revenue, of its aesthetics products, including DYSPORT®, PERLANE® and RESTYLANE®, until its exclusive U.S. distributor ships the product to physicians. The Company also defers the recognition of revenue for certain sales of inventory into the distribution channel that are in excess of eight (8) weeks of projected demand. The increase in deferred revenue for units in the distribution channel in excess of eight weeks of projected demand during the nine months ended September 30, 2012 was primarily associated with units of ZYCLARA®.

**Table of Contents****15. LONG-TERM DEBT**

Long-term debt as of September 30, 2012 and December 31, 2011 is comprised of the following (in thousands):

	September 30, 2012	December 31, 2011
1.375% Convertible Senior Notes	\$ 500,000	\$
Discount on 1.375% Convertible Senior Notes	(74,187)	
1.375% Convertible Senior Notes, net of discount	425,813	
2.5% Contingent Convertible Senior Notes	168,926	169,145
1.5% Contingent Convertible Senior Notes	181	181
	594,920	169,326
Less current portion	(181)	(169,145)
Total long-term debt	\$ 594,739	\$ 181

*1.375% Convertible Senior Notes Due 2017*

On May 16, 2012, the Company issued and sold \$500.0 million of its 1.375% Convertible Senior Notes due 2017 (the "1.375% Notes") in a public offering. The 1.375% Notes will mature on June 1, 2017 and pay 1.375% annual cash interest, payable semi-annually in arrears on June 1 and December 1 of each year, beginning on December 1, 2012.

On or after March 1, 2017, until the close of business on the second scheduled trading day immediately preceding the stated maturity date, or prior to then but only under certain circumstances, the 1.375% Notes will be convertible into cash up to the principal amount, with the remaining amount, if any, to be satisfied, at the Company's option, in shares of the Company's Class A common stock, cash or a combination thereof. The 1.375% Notes will be convertible at an initial conversion rate of 21.2427 shares of the Company's Class A common stock per \$1,000 principal amount of the 1.375% Notes, subject to adjustment upon certain events, which is equivalent to an initial conversion price of approximately \$47.07 per share of the Company's Class A common stock.

The 1.375% Notes are convertible, at the holders' option, prior to the close of business on the business day immediately preceding March 1, 2017, into shares of the Company's Class A common stock in the following circumstances:

during any calendar quarter commencing after the calendar quarter ending on September 30, 2012, if the closing price of the Company's Class A common stock over a specified number of trading days during the previous quarter, including the last trading day of such quarter, is more than 130% of the conversion price of the 1.375% Notes in effect on each applicable trading day;

during the five consecutive trading day period immediately following any ten consecutive trading day period in which the trading price of the 1.375% Notes per \$1,000 principal amount for each such trading day was less than 98% of the product of the closing sale price of the Company's Class A common stock on such days and the then-current conversion rate of \$1,000 principal amount of the 1.375% Notes; or

upon the occurrence of specified corporate transactions.

The 1.375% Notes are senior unsecured obligations of the Company and are not guaranteed by any of the Company's subsidiaries. The 1.375% Notes rank senior in right of payment to the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 1.375% Notes; equal in right of payment to the Company's existing and future unsecured indebtedness that is not so subordinated; effectively junior in right of payment to any of the Company's secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries.



**Table of Contents**

The 1.375% Notes do not contain any restrictions on the payment of dividends, the incurrence of additional indebtedness or the repurchase of the Company's securities and do not contain any financial covenants. The 1.375% Notes require an anti-dilution adjustment to the conversion rate upon certain specified corporate dividend or common stock events or transactions, and if such event or transaction would result in at least a one percent (1%) change in the conversion rate. If the one percent (1%) threshold is not met on a particular qualifying event or transaction, the adjustment is carried forward and taken into account when a subsequent qualifying event or transaction is assessed for potential conversion rate adjustment. The Company may not redeem the 1.375% Notes prior to maturity and no sinking fund will be provided for the 1.375% Notes. If the Company undergoes a fundamental change, subject to certain conditions, holders of the 1.375% Notes may require the Company to purchase 1.375% Notes in whole or in part for cash at a fundamental change purchase price equal to 100% of the principal amount of the 1.375% Notes to be purchased, plus accrued and unpaid interest, if any, to, but excluding the fundamental change purchase date. In certain events of default, as defined in the 1.375% Notes indenture, the trustee by notice to the Company, or the holders of at least 25% in principal amount of the then outstanding 1.375% Notes by notice to the Company and trustee, may declare 100% of the principal of, and accrued and unpaid interest, if any, on, all outstanding 1.375% Notes to be due and payable. Upon such a declaration, such principal and accrued and unpaid interest, if any, will be due and payable immediately.

As of September 30, 2012, the 1.375% Notes were not convertible.

The conversion feature embedded within the 1.375% Notes is considered a derivative; however, it has not been bifurcated and accounted for separately because it is considered to be indexed to the Company's Class A common stock and meets the criteria for equity classification. Because the 1.375% Notes are considered to be cash convertible debt, the Company has separately accounted for the liability and equity components of the 1.375% Notes by allocating the \$500.0 million in proceeds from the issuance between the liability component and the embedded conversion option, or the equity component. The allocation was conducted by estimating an interest rate at the time of issuance of the 1.375% Notes for similar debt instruments that do not include the embedded conversion feature. A straight-debt interest rate of 5.0% was used to compute the initial fair value of the liability component of \$420.5 million. For purposes of the fair value measurement, the Company determined that the valuation of the 1.375% Notes falls under Level 2 of the fair value hierarchy. The excess of the \$500.0 million of proceeds from the issuance of the 1.375% Notes over the \$420.5 million initial amount allocated to the liability component, or \$79.5 million, was allocated to the embedded conversion option, or equity component. This excess was treated as a debt discount and is being amortized through interest expense, using the effective interest method, over the five-year term of the 1.375% Notes, which runs through June 1, 2017.

In connection with the offering of the 1.375% Notes, on May 10, 2012 and May 11, 2012, the Company entered into privately negotiated convertible note hedge transactions (the Convertible Note Hedge Transactions) with affiliates of the underwriters of the 1.375% Notes (the Option Counterparties). The Convertible Note Hedge Transactions cover, collectively, the number of shares of the Company's Class A common stock underlying the 1.375% Notes, subject to anti-dilution adjustments substantially similar to those applicable to the 1.375% Notes. The Company purchased these hedges for \$80.0 million, in aggregate, which was recorded as a reduction in additional paid-in capital during the three months ended June 30, 2012. The Company also entered into separate, privately-negotiated warrant transactions with the Option Counterparties on May 10, 2012 and into additional warrant transactions with the Option Counterparties on May 11, 2012 (collectively, the Warrant Transactions) and together with the Convertible Note Hedge Transactions, the Convertible Note Hedge and Warrant Transactions), initially covering a number of shares of the Company's Class A common stock underlying the 1.375% Notes, subject to customary anti-dilution adjustments. Subject to certain conditions, the Company may settle the warrants in cash or on a net-share basis. The warrants were issued and sold for proceeds of approximately \$35.2 million, which was recorded as an increase in additional paid-in capital during the three months ended June 30, 2012.

The Convertible Note Hedge Transactions are expected to reduce the potential economic dilution with respect to the Company's Class A common stock and/or reduce the Company's exposure to potential cash payments that may be required upon conversion of the 1.375% Notes. The strike price of the Warrant Transactions will initially be approximately \$60.26 per share, which represents a premium of approximately 60% over the last reported sale price of \$37.66 per share of the Company's Class A common stock on The New York Stock Exchange on May 10, 2012.

The Convertible Note Hedge and Warrant Transactions are considered derivative instruments; however, they have been classified within stockholders' equity because both financial instruments are considered to be indexed to the Company's Class A common stock and meet the criteria for equity classification.



---

**Table of Contents**

The Convertible Note Hedge and Warrant Transactions have been accounted for as separate financial instruments, in each case, entered into by the Company with the Option Counterparties, and are not part of the terms of the 1.375% Notes and will not affect any holder's rights under the 1.375% Notes. Holders of the 1.375% Notes will not have any rights with respect to the Convertible Note Hedge and Warrant Transactions.

On September 2, 2012, the Company entered into a settlement agreement (the "Counterparty Settlement Agreement") with one of the Option Counterparties to provide for settlement of the Convertible Note Hedge Transactions that the Company entered into with one of the Option Counterparties on May 10, 2012 and May 11, 2012, upon the occurrence of certain events in connection with the Merger Agreement with Valeant (see Note 2). Upon the public announcement, if any, that the merger with Valeant has closed, or upon the occurrence of certain other specified events, one of the Option Counterparties will be obligated to pay to the Company, in lieu of any payment or delivery otherwise due under the Convertible Note Hedge Transactions, a specified settlement amount per Relevant Note Hedging Unit (as defined in the Counterparty Settlement Agreement) on the Payment Date (as defined in the Counterparty Settlement Agreement), in full satisfaction of the respective rights and obligations of the parties under the Convertible Note Hedge Transactions in respect of such Relevant Note Hedging Units.

In addition, the Counterparty Settlement Agreement provides for settlement of the Warrant Transactions that the Company entered into with one of the Option Counterparties on May 10, 2012 and May 11, 2012, upon the occurrence of certain events in connection with the Merger Agreement with Valeant. Upon the public announcement, if any, that the Merger with Valeant has closed, or upon the occurrence of certain other specified events, the Company will be obligated to pay one of the Option Counterparties, in lieu of any payment or delivery otherwise due under the Warrant Transactions, a specified settlement amount per Relevant Warrant (as defined in the Counterparty Settlement Agreement) on the Payment Date, in full satisfaction of the respective rights and obligations of the parties under the Warrant Transactions in respect of such Relevant Warrants.

Notwithstanding the foregoing description, the Counterparty Settlement Agreement provides that the aggregate settlement amounts payable by one of the Option Counterparties to the Company is \$3.0 million after deducting any aggregate settlement amounts payable by the Company to one of the Option Counterparties under the Counterparty Settlement Agreement on the Payment Date. The Counterparty Settlement Agreement is also subject to termination or renegotiation upon the occurrence of certain events.

The Option Counterparty that entered into the Counterparty Settlement Agreement had also previously entered into an advisory and consulting agreement with the Company in December 2011 to advise the Company in a potential sale of the Company to a third party. That agreement (the "Consulting Agreement") provides that in the event the Option Counterparty assists with the sale of the Company, the Option Counterparty would be entitled to a fee as a percentage of the sale purchase price. Based on the actual purchase price proposed by Valeant for the Company on September 3, 2012, the amount of this fee will be approximately \$28.1 million upon the closing of the transaction.

Because the Counterparty Settlement Agreement added a settlement condition based on a fixed monetary payoff which is contingent upon an event not based on the Company's share price, the Note Hedge and Warrant Transactions entered into with one of the Option Counterparties no longer meet the criteria for equity classification.

Accordingly, the Company estimated and recorded the fair value of the Note Hedge and Warrant Transactions with this Counterparty immediately before the execution of the Counterparty Settlement Agreement which resulted in a \$17.2 million charge to additional paid-in capital and a corresponding increase to other current liabilities. Because the execution of the Counterparty Settlement Agreement was made in contemplation and consideration of the Consulting Agreement, the Company determined that the Counterparty Settlement Agreement, Note Hedge and Warrant Transactions with this Counterparty and Consulting Agreement should be subsequently accounted for and measured as one unit of account. Therefore, the Company subsequently determined the post execution Counterparty Settlement Agreement fair value of this equity derivative to be \$24.9 million, resulting in a \$7.7 million charge to other expense (income) and an increase to other current liabilities for the three months ended September 30, 2012.

The resulting liability will continue to be recorded at fair value with changes in fair value reflected through the income statement through the closing of the merger transaction.

The impact of the Counterparty Settlement Agreement has not been included in the Company's computation of dilutive earnings per share because such impact would be anti-dilutive.

**Table of Contents**

The Company incurred \$14.2 million of fees and other origination costs related to the issuance of the 1.375% Notes. These fees and other origination costs have been allocated to the liability and equity components of the 1.375% Notes in proportion to their allocated values. Approximately \$2.3 million of these fees and other origination costs were recorded as a reduction in additional paid-in capital. The remaining \$11.9 million of fees and other origination costs are included in other assets in the Company's condensed consolidated balance sheets and are being amortized through interest expense over the five-year term of the 1.375% Notes, which runs through June 1, 2017.

*2.5% Contingent Convertible Senior Notes Due 2032*

In June 2002, the Company sold \$400.0 million aggregate principal amount of its 2.5% Contingent Convertible Senior Notes Due 2032 (the 2.5% Notes) in private transactions. As discussed below, approximately \$230.8 million in principal amount of the 2.5% Notes was exchanged for 1.5% Notes on August 14, 2003. The 2.5% Notes bear interest at a rate of 2.5% per annum, which is payable on June 4 and December 4 of each year, beginning on December 4, 2002. The Company also agreed to pay contingent interest at a rate equal to 0.5% per annum during any six-month period, with the initial six-month period commencing June 4, 2007, if the average trading price of the 2.5% Notes reaches certain thresholds. Contingent interest of approximately \$0.3 million related to the 2.5% Notes was payable at September 30, 2012. No contingent interest related to the 2.5% Notes was payable at December 31, 2011. The 2.5% Notes will mature on June 4, 2032.

The Company may redeem some or all of the 2.5% Notes at any time on or after June 11, 2007, at a redemption price, payable in cash, of 100% of the principal amount of the 2.5% Notes, plus accrued and unpaid interest, including contingent interest, if any. Holders of the 2.5% Notes may require the Company to repurchase all or a portion of their 2.5% Notes on June 4, 2017, or upon a change in control, as defined in the indenture governing the 2.5% Notes, at 100% of the principal amount of the 2.5% Notes, plus accrued and unpaid interest to the date of the repurchase, payable in cash. Holders of the 2.5% Notes also had this option on June 4, 2012. Under GAAP, if an obligation is due on demand or will be due on demand within one year from the balance sheet date, even though liquidation may not be expected within that period, it should be classified as a current liability. Accordingly, the outstanding balance of 2.5% Notes along with the deferred tax liability associated with accelerated interest deductions on the 2.5% Notes are classified as a current liability during the respective twelve month periods prior to June 4, 2012 and June 4, 2017. As of December 31, 2011, \$169.1 million of the 2.5% Notes and \$62.5 million of deferred tax liabilities were classified as current liabilities in the Company's condensed consolidated balance sheets. The \$62.5 million of deferred tax liabilities were included within current deferred tax assets, net.

On May 3, 2012, the Company filed with the Securities and Exchange Commission (the SEC) a Tender Offer Statement on Schedule TO and a notice (the Company Notice) to the holders of the 2.5% Notes related to the option of the holders to require the Company to repurchase all or a portion of their 2.5% Notes on June 4, 2012. In addition, such Company Notice was made available through The Depository Trust Company and Deutsche Bank Trust Company Americas, the paying agent.

The Company Notice specified the terms, conditions and procedures for surrendering and withdrawing the 2.5% Notes for purchase. The Company Notice also stated that holders that did not surrender their 2.5% Notes for purchase would maintain the right to convert their 2.5% Notes into shares of the Company's Class A common stock, as further described below. Holders of \$3,000 in principal amount of the 2.5% Notes requested to have their 2.5% Notes repurchased by the Company.

The 2.5% Notes are convertible, at the holders' option, prior to the maturity date into shares of the Company's Class A common stock in the following circumstances:

during any quarter commencing after June 30, 2002, if the closing price of the Company's Class A common stock over a specified number of trading days during the previous quarter, including the last trading day of such quarter, is more than 110% of the conversion price of the 2.5% Notes, or \$31.96. The 2.5% Notes are initially convertible at a conversion price of \$29.05 per share, which is equal to a conversion rate of approximately 34.4234 shares per \$1,000 principal amount of 2.5% Notes, subject to adjustment;

if the Company has called the 2.5% Notes for redemption;

---

**Table of Contents**

during the five trading day period immediately following any nine consecutive day trading period in which the trading price of the 2.5% Notes per \$1,000 principal amount for each day of such period was less than 95% of the product of the closing sale price of the Company's Class A common stock on such days multiplied by the number of shares of the Company's Class A common stock issuable upon conversion of \$1,000 principal amount of the 2.5% Notes; or

upon the occurrence of specified corporate transactions.

The 2.5% Notes, which are unsecured, do not contain any restrictions on the payment of dividends, the incurrence of additional indebtedness or the repurchase of the Company's securities and do not contain any financial covenants.

The Company incurred \$12.6 million of fees and other origination costs related to the issuance of the 2.5% Notes. The Company amortized these costs over the first five-year Put period, which ran through June 4, 2007.

During the quarters ended December 31, 2011, March 31, 2012, June 30, 2012 and September 30, 2012, the 2.5% Notes met the criteria for the right of conversion into shares of the Company's Class A common stock. This right of conversion of the holders of 2.5% Notes was triggered by the stock closing above \$31.96 on 20 of the last 30 trading days and the last trading day of the quarters ended December 31, 2011, March 31, 2012, June 30, 2012 and September 30, 2012. During the quarter ended June 30, 2012, outstanding principal amounts of \$216,000 of 2.5% Notes were converted into shares of the Company's Class A common stock. The holders of the remaining \$168.9 million of 2.5% Notes have this conversion right only until December 31, 2012. At the end of each future quarter, the conversion rights will be reassessed in accordance with the bond indenture agreement to determine if the conversion trigger rights have been achieved.

*1.5% Contingent Convertible Senior Notes Due 2033*

On August 14, 2003, the Company exchanged approximately \$230.8 million in principal amount of its 2.5% Notes for approximately \$283.9 million in principal amount of its 1.5% Contingent Convertible Senior Notes Due 2033 (the "1.5% Notes"). Holders of 2.5% Notes that accepted the Company's exchange offer received \$1,230 in principal amount of 1.5% Notes for each \$1,000 in principal amount of 2.5% Notes. The terms of the 1.5% Notes are similar to the terms of the 2.5% Notes, but have a different interest rate, conversion rate and maturity date. Holders of 2.5% Notes that chose not to exchange continue to be subject to the terms of the 2.5% Notes.

The 1.5% Notes bear interest at a rate of 1.5% per annum, which is payable on June 4 and December 4 of each year, beginning December 4, 2003. The Company will also pay contingent interest at a rate of 0.5% per annum during any six-month period, with the initial six-month period commencing June 4, 2008, if the average trading price of the 1.5% Notes reaches certain thresholds. No contingent interest related to the 1.5% Notes was payable at September 30, 2012 or December 31, 2011. The 1.5% Notes will mature on June 4, 2033.

As a result of the exchange, the outstanding principal amounts of the 2.5% Notes and the 1.5% Notes were \$169.2 million and \$283.9 million, respectively. The Company incurred approximately \$5.1 million of fees and other origination costs related to the issuance of the 1.5% Notes. The Company amortized these costs over the first five-year Put period, which ran through June 4, 2008.

Holders of the 1.5% Notes were able to require the Company to repurchase all or a portion of their 1.5% Notes on June 4, 2008, at 100% of the principal amount of the 1.5% Notes, plus accrued and unpaid interest, including contingent interest, if any, to the date of the repurchase, payable in cash. Holders of approximately \$283.7 million of 1.5% Notes elected to require the Company to repurchase their 1.5% Notes on June 4, 2008. The Company paid \$283.7 million, plus accrued and unpaid interest of approximately \$2.2 million, to the holders of 1.5% Notes that elected to require the Company to repurchase their 1.5% Notes. The Company was also required to pay an accumulated deferred tax liability of approximately \$34.9 million related to the repurchased 1.5% Notes. This \$34.9 million deferred tax liability was paid during the second half of 2008. Following the repurchase of these 1.5% Notes, \$181,000 of principal amount of 1.5% Notes remained outstanding as of September 30, 2012 and December 31, 2011.

Remaining holders of the 1.5% Notes may require the Company to repurchase all or a portion of their 1.5% Notes on June 4, 2013 and June 4, 2018, or upon a change in control, as defined in the indenture governing the 1.5%

---

**Table of Contents**

Notes, at 100% of the principal amount of the 1.5% Notes, plus accrued and unpaid interest to the date of the repurchase, payable in cash. Under GAAP, if an obligation is due on demand or will be due on demand within one year from the balance sheet date, even though liquidation may not be expected within that period, it should be classified as a current liability. Accordingly, the outstanding balance of 1.5% Notes along with the deferred tax liability associated with accelerated interest deductions on the 1.5% Notes will be classified as a current liability during the respective twelve month periods prior to June 4, 2013 and June 4, 2018. As of September 30, 2012, \$181,000 of the 1.5% Notes and \$58,000 of deferred tax liabilities were classified as current liabilities in the Company's condensed consolidated balance sheets. The \$58,000 of deferred tax liabilities were included within current deferred tax assets, net.

The remaining 1.5% Notes are convertible, at the holders' option, prior to the maturity date into shares of the Company's Class A common stock in the following circumstances:

during any quarter commencing after September 30, 2003, if the closing price of the Company's Class A common stock over a specified number of trading days during the previous quarter, including the last trading day of such quarter, is more than 120% of the conversion price of the 1.5% Notes, or \$46.51. The 1.5% Notes are initially convertible at a conversion price of \$38.76 per share, which is equal to a conversion rate of approximately 25.7998 shares per \$1,000 principal amount of 1.5% Notes, subject to adjustment;

if the Company has called the 1.5% Notes for redemption;

during the five trading day period immediately following any nine consecutive day trading period in which the trading price of the 1.5% Notes per \$1,000 principal amount for each day of such period was less than 95% of the product of the closing sale price of the Company's Class A common stock on such days multiplied by the number of shares of the Company's Class A common stock issuable upon conversion of \$1,000 principal amount of the 1.5% Notes; or

upon the occurrence of specified corporate transactions.

The remaining 1.5% Notes, which are unsecured, do not contain any restrictions on the incurrence of additional indebtedness or the repurchase of the Company's securities and do not contain any financial covenants. The 1.5% Notes require an adjustment to the conversion price if the cumulative aggregate of all current and prior dividend increases, through June 11, 2008, above \$0.025 per share would result in at least a one percent (1%) increase in the conversion price. This threshold was not reached and no adjustment to the conversion price has been made.

During the quarter ended September 30, 2012, the 1.5% Notes did not meet the criteria for the right of conversion.

**Table of Contents***Interest expense*

Interest expense recognized related to the Company's long-term debt during the three and nine months ended September 30, 2012 and 2011 was as follows (in thousands):

	Three Months Ended		Nine Months Ended	
	September 30, 2012	September 30, 2011	September 30, 2012	September 30, 2011
<b>1.375% Notes:</b>				
Coupon rate interest	\$ 1,718	\$ -	\$ 2,569	\$ -
Amortization of discount	3,577	-	5,327	-
Amortization of issuance costs	595	-	891	-
<b>Total 1.375% Notes</b>	<b>5,890</b>	<b>-</b>	<b>8,787</b>	<b>-</b>
<b>2.5% Notes:</b>				
Coupon rate interest	1,056	1,057	3,170	3,171
Contingent interest	211	209	281	280
<b>Total 2.5% Notes</b>	<b>1,267</b>	<b>1,266</b>	<b>3,451</b>	<b>3,451</b>
<b>1.5% Notes:</b>				
Coupon rate interest	1	1	2	2
<b>Total 1.5% Notes</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>2</b>
<b>Total interest expense related to long-term debt</b>	<b>\$ 7,158</b>	<b>\$ 1,267</b>	<b>\$ 12,240</b>	<b>\$ 3,453</b>

*Fair value of long-term debt*

The fair value of the Company's long-term debt, based on market quotations, was approximately \$789.7 million and \$202.5 million at September 30, 2012 and December 31, 2011, respectively. The fair value of the long-term debt held as of September 30, 2012 and December 31, 2011 were valued using Level 2 pricing inputs based on quoted prices for similar instruments in markets that are not active, and through model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

**16. INCOME TAXES**

Income taxes are determined using an annual effective tax rate, which generally differs from the U.S. Federal statutory rate, primarily because of state and local income taxes, enhanced charitable contribution deductions for inventory, tax credits available in the U.S., the treatment of certain share-based payments that are not designed to normally result in tax deductions, various expenses that are not deductible for tax purposes, changes in the reserve for uncertain tax positions, changes in valuation allowances against deferred tax assets and differences in tax rates in certain non-U.S. jurisdictions. The Company's effective tax rate may be subject to fluctuations during the year as new information is obtained which may affect the assumptions it uses to estimate its annual effective tax rate, including factors such as its mix of pre-tax earnings in the various tax jurisdictions in which it operates, changes in valuation allowances against deferred tax assets, reserves for tax audit issues and settlements, utilization of tax credits and changes in tax laws in jurisdictions where the Company conducts operations. The Company recognizes tax benefits only if the tax position is more likely than not of being sustained. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities, along with net operating losses and credit carryforwards. The Company records valuation allowances against its deferred tax assets to reduce the net carrying value to amounts that management believes is more likely than not to be realized.

## Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 10-Q

On November 1, 2011, the Company closed its sale of all issued and outstanding shares of common stock of LipoSonix to Solta. The transaction resulted in a \$30.5 million capital loss for income tax purposes, of which \$26.2 million can be carried back and used to offset capital gains generated in prior tax years. Accordingly, an

---

**Table of Contents**

income tax benefit of \$9.4 million was recognized and is included in the gain from discontinued operations for the year ended December 31, 2011. A deferred tax asset was recorded on the portion of the capital loss (\$4.3 million) that could not be carried back to prior years. As a capital loss can only be utilized to offset capital gains, the Company recorded at December 31, 2011 a valuation allowance of \$1.5 million against the deferred tax asset in order to reduce the carrying value of the deferred tax asset to \$0, which was the amount that management believed was more likely than not to be realized. During the nine months ended September 30, 2012, the Company recognized a \$6.0 million capital gain (see Note 10), and accordingly, the reversal of this \$1.5 million valuation allowance has been reflected in the Company's estimate of its annual effective tax rate for 2012.

The sales price used to calculate the above capital loss consisted of \$15.5 million of cash received at closing, \$20.0 million of cash received on November 18, 2011 and \$29.3 million of value from future additional contingent cash and milestone payments. A deferred tax asset was recorded on the \$29.3 million as it was not recognized as additional selling price for financial reporting purposes. The Company has recorded a valuation allowance of \$10.5 million against this deferred tax asset in order to reduce the carrying value of this deferred tax asset to \$0, which is the amount that management believes is more likely than not to be realized.

At December 31, 2011, the Company had an unrealized tax loss of \$21.0 million related to the Company's option to acquire Revance or license Revance's topical product that is under development. The Company will not be able to determine the character of the loss until the Company exercises or fails to exercise its option. A realized loss characterized as a capital loss can only be utilized to offset capital gains. At December 31, 2011, the Company had recorded a valuation allowance of \$7.6 million against the deferred tax asset associated with this unrealized tax loss in order to reduce the carrying value of the deferred tax asset to \$0, which is the amount that management believes is more likely than not to be realized. As a result of the Settlement and Termination Agreement with Revance (see Note 22), the Company has reflected a \$1.7 million reduction of this valuation allowance in the Company's estimate of its annual effective tax rate for 2012.

At September 30, 2012, the Company has an unrealized tax loss of \$21.9 million related to the Company's option to acquire a privately-held U.S. biotechnology company. If the Company fails to exercise its option, a capital loss will be recognized. A loss characterized as a capital loss can only be used to offset capital gains. At September 30, 2012, the Company has recorded a valuation allowance of \$7.9 million against the deferred tax asset associated with this unrealized tax loss in order to reduce the carrying value of the deferred tax asset to \$0, which is the amount that management believes is more likely than not to be realized.

During the three months ended September 30, 2012 and September 30, 2011, the Company made net tax payments of \$1.4 million and \$13.0 million, respectively. During the nine months ended September 30, 2012 and September 30, 2011, the Company made net tax payments of \$43.8 million and \$51.0 million, respectively.

The Company operates in multiple tax jurisdictions and is periodically subject to audit in these jurisdictions. These audits can involve complex issues that may require an extended period of time to resolve and may cover multiple years. The Company and its domestic subsidiaries file a consolidated U.S. federal income tax return. Such returns have either been audited or settled through statute expiration through 2007. The state of California is currently conducting an examination of the Company's tax returns for the periods ending December 31, 2008 and December 31, 2009.

The Company owns two subsidiaries that file corporate tax returns in Sweden. The Swedish tax authorities examined the tax return of one of the subsidiaries for fiscal 2004. The examiners issued a no change letter, and the examination is complete. The Company's other subsidiary in Sweden has not been examined by the Swedish tax authorities. The Swedish statute of limitations may be open for up to five years from the date the tax return was filed. Thus, all returns filed for periods ending December 31, 2007 forward are open under the statute of limitations.

At September 30, 2012 and December 31, 2011, the Company had unrecognized tax benefits of \$9.1 million and \$8.6 million, respectively. The amount of unrecognized tax benefits which, if ultimately recognized, could favorably affect the Company's effective tax rate in a future period is \$6.3 million and \$5.6 million as of September 30, 2012 and December 31, 2011, respectively. The Company estimates that it is reasonably possible that the amount of unrecognized tax benefits will decrease by \$0.3 million in the next twelve months due to audit settlements.

## **Table of Contents**

The Company recognizes accrued interest and penalties, if applicable, related to unrecognized tax benefits in income tax expense. The Company had approximately \$0.6 million and \$0.3 million for the payment of interest and penalties accrued (net of tax benefit) at September 30, 2012 and December 31, 2011, respectively.

### **17. DIVIDENDS DECLARED ON COMMON STOCK**

On September 21, 2012, the Company announced that its Board of Directors had declared a cash dividend of \$0.10 per issued and outstanding share of the Company's Class A common stock, which was paid on October 31, 2012, to stockholders of record at the close of business on October 1, 2012. The \$5.8 million dividend was recorded as a reduction of accumulated earnings and is included in other current liabilities in the accompanying condensed consolidated balance sheets as of September 30, 2012. The Company has not adopted a dividend policy.

### **18. STOCK REPURCHASE**

On August 8, 2011, the Company announced that its Board of Directors approved a Stock Repurchase Plan to purchase up to \$200 million in aggregate value of shares of Medicis Class A common stock (common stock). The plan was set to expire on August 7, 2012; however, on August 7, 2012, the Company's Board of Directors approved a six-month extension of the plan to February 7, 2013. The plan may also terminate at the time at which the purchase limit is reached, and may be suspended or terminated at any time at the Company's discretion without prior notice.

Any repurchases will be made in compliance with the SEC's Rule 10b-18 if applicable, and may be made in the open market or in privately negotiated transactions, including the entry into derivatives transactions.

The number of shares to be repurchased and the timing of repurchases will depend on a variety of factors, including, but not limited to, stock price, economic and market conditions and corporate and regulatory requirements. It is intended that any repurchases will be funded by existing general corporate funds. The plan does not obligate the Company to repurchase any common stock.

As part of its stock repurchase program, the Company may from time to time enter into structured share repurchase agreements with financial institutions. These agreements generally require the Company to make one or more cash payments in exchange for the right to receive shares of its common stock and/or cash at the expiration of the agreement and/or at various times during the term of the agreement, generally based on the market price of the Company's common stock during the relevant valuation period or periods, but the Company may enter into structured share repurchase agreements with different features.

During the three and nine months ended September 30, 2012, 1,533,619 shares were repurchased in the open market at a weighted average cost of \$32.55 per share. Total shares repurchased from the inception of the plan through September 30, 2012 in the open market and through structured share repurchase arrangements was 5,971,852 shares at a weighted average cost of \$33.49 per share.

As of September 30, 2012, the plan has terminated as the purchased limit has been reached.



**Table of Contents****19. NET INCOME PER COMMON SHARE**

The following table sets forth the computation of basic and diluted net income per common share (in thousands, except per share amounts):

	Three Months Ended					
	September 30, 2012			September 30, 2011		
	Continuing Operations	Discontinued Operations	Net Income	Continuing Operations	Discontinued Operations	Net Income
<b>BASIC</b>						
Net income (loss)	\$ 937	\$ -	\$ 937	\$ 22,950	\$ (3,498)	\$ 19,452
Less: income (loss) allocated to participating securities	-	-	-	702	-	583
Net income (loss) available to common stockholders	937	-	937	22,248	(3,498)	18,869
Weighted average number of common shares outstanding	57,222	-	57,222	61,336	61,336	61,336
Basic net income (loss) per common share	\$ 0.02	\$ -	\$ 0.02	\$ 0.36	\$ (0.06)	\$ 0.31
<b>DILUTED</b>						
Net income (loss)	\$ 937	\$ -	\$ 937	\$ 22,950	\$ (3,498)	\$ 19,452
Less: income (loss) allocated to participating securities	-	-	-	702	-	583
Net income (loss) available to common stockholders	937	-	937	22,248	(3,498)	18,869
Less:						
Undistributed earnings allocated to unvested stockholders	-	-	-	(579)	-	(466)
Add:						
Undistributed earnings re-allocated to unvested stockholders	-	-	-	572	-	460
Add:						
Tax-effected interest expense related to 2.5% Notes	-	-	-	799	-	799
Net income (loss) assuming dilution	\$ 937	\$ -	\$ 937	\$ 23,040	\$ (3,498)	\$ 19,662
Weighted average number of common shares outstanding	57,222	-	57,222	61,336	61,336	61,336
Effect of dilutive securities:						
2.5% Notes	-	-	-	5,823	-	5,823
1.5% Notes	-	-	-	4	-	4
Stock options	1,104	-	1,104	751	-	751
Weighted average number of common shares assuming dilution	58,326	-	58,326	67,914	61,336	67,914
Diluted net income (loss) per common share	\$ 0.02	\$ -	\$ 0.02	\$ 0.34	\$ (0.06)	\$ 0.29

**Table of Contents**

	Nine Months Ended					
	September 30, 2012			September 30, 2011		
	Continuing Operations	Discontinued Operations	Net Income	Continuing Operations	Discontinued Operations	Net Income
<b>BASIC</b>						
Net income (loss)	\$ 21,213	\$ -	\$ 21,213	\$ 84,146	\$ (16,551)	\$ 67,595
Less: income (loss) allocated to participating securities	551	-	551	2,645	-	2,097
Net income (loss) available to common stockholders	20,662	-	20,662	81,501	(16,551)	65,498
Weighted average number of common shares outstanding	57,296	-	57,296	60,264	60,264	60,264
Basic net income (loss) per common share	\$ 0.36	\$ -	\$ 0.36	\$ 1.35	\$ (0.27)	\$ 1.09
<b>DILUTED</b>						
Net income (loss)	\$ 21,213	\$ -	\$ 21,213	\$ 84,146	\$ (16,551)	\$ 67,595
Less: income (loss) allocated to participating securities	551	-	551	2,645	-	2,097
Net income (loss) available to common stockholders	20,662	-	20,662	81,501	(16,551)	65,498
Less:						
Undistributed earnings allocated to unvested stockholders	(124)	-	(124)	(2,244)	-	(1,709)
Add:						
Undistributed earnings re-allocated to unvested stockholders	123	-	123	2,213	-	1,685
Add:						
Tax-effected interest expense related to 2.5% Notes	2,175	-	2,175	2,175	-	2,175
Tax-effected interest expense related to 1.5% Notes	1	-	1	1	-	1
Net income (loss) assuming dilution	\$ 22,837	\$ -	\$ 22,837	\$ 83,646	\$ (16,551)	\$ 67,650
Weighted average number of common shares outstanding	57,296	-	57,296	60,264	60,264	60,264
Effect of dilutive securities:						
2.5% Notes	5,821	-	5,821	5,823	-	5,823
1.5% Notes	4	-	4	4	-	4
Stock options	551	-	551	869	-	869
Weighted average number of common shares assuming dilution	63,672	-	63,672	66,960	60,264	66,960
Diluted net income (loss) per common share	\$ 0.36	\$ -	\$ 0.36	\$ 1.25	\$ (0.27)	\$ 1.01

Diluted net income per common share must be calculated using the if-converted method. Diluted net income per share using the if-converted method is calculated by adjusting net income for tax-effected net interest on the 2.5% Notes and 1.5% Notes, divided by the weighted average number of common shares outstanding assuming conversion.

---

**Table of Contents**

Unvested share-based payment awards that contain rights to receive nonforfeitable dividends or dividend equivalents (whether paid or unpaid) are participating securities, and thus, are included in the two-class method of computing earnings per share. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that would otherwise have been available to common stockholders. Restricted stock granted to certain employees by the Company (see Note 5) participate in dividends on the same basis as common shares, and these dividends are not forfeitable by the holders of the restricted stock. As a result, the restricted stock grants meet the definition of a participating security.

The diluted net income per common share computation for the three months ended September 30, 2012 and 2011 excludes 1,629,144 and 1,695,545 shares of stock, respectively, that represented outstanding stock options whose impact would be anti-dilutive. The diluted net income per common share computation for the three months ended September 30, 2012, also excludes 5,815,016 and 4,685 shares of common stock, issuable upon conversion of the 2.5% Notes and 1.5% Notes, respectively, as the effect of applying the if-converted method in calculating diluted net income per common share would be anti-dilutive. For the three months ended September 30, 2012, the calculation of basic and diluted earnings per share under the two-class method is also anti-dilutive.

The diluted net income per common share computation for the nine months ended September 30, 2012 and 2011 excludes 2,541,543 and 2,581,316 shares of stock, respectively, that represented outstanding stock options whose impact would be anti-dilutive.

Due to the net loss from discontinued operations during the three and nine months ended September 30, 2011, diluted earnings per share and basic earnings per share from discontinued operations are the same, as the effect of potentially dilutive securities would be anti-dilutive.

## **20. COMMITMENTS AND CONTINGENCIES**

### **Legal Matters**

The Company is currently party to various legal proceedings, including those noted in this section. Unless specifically noted below, any possible range of loss associated with the legal proceedings described below is not reasonably estimable at this time. The Company is engaged in numerous other legal actions not described below arising in the ordinary course of its business and, while there can be no assurance, the Company believes that the ultimate outcome of these actions will not have a material adverse effect on its operating results, liquidity or financial position.

From time to time the Company may conclude it is in the best interests of its stockholders, employees and customers to settle one or more litigation matters, and any such settlement could include substantial payments; however, other than as noted below, the Company has not reached this conclusion with respect to any particular matter at this time. There are a variety of factors that influence the Company's decisions to settle and the amount the Company may choose to pay, including the strength of its case, developments in the litigation, the behavior of other interested parties, the demand on management time and the possible distraction of the Company's employees associated with the case and/or the possibility that the Company may be subject to an injunction or other equitable remedy. It is difficult to predict whether a settlement is possible, the amount of an appropriate settlement or when is the opportune time to settle a matter in light of the numerous factors that go into the settlement decision. Unless otherwise specified below, any settlement payment made pursuant to any of the completed settlement agreements described below is immaterial to the Company for financial reporting purposes.

#### *Revance Litigation*

On May 18, 2012, the Company received notice that Revance Therapeutics, Inc. ( Revance ) filed a lawsuit against the Company in the Court of Chancery of the State of Delaware. As previously disclosed, the Company is a minority owner of Revance and had an option to acquire Revance or license Revance's topical product that is under development. Revance alleged that the option period had commenced and sought specific performance and an injunction against the Company. The Company believed that the option period had not commenced. Revance amended its complaint on June 8, 2012. The Company filed an answer to Revance's

**Table of Contents**

amended complaint on June 25, 2012 and, on the same day, filed counterclaims against Revance seeking declaratory relief, injunctive relief and specific performance from Revance. Trial began on September 12, 2012 and lasted through September 14, 2012. On October 8, 2012, the parties entered into a Settlement and Termination Agreement (the "Revance Settlement Agreement"). The terms of the settlement provide for the upfront payment by Revance to the Company of \$7.0 million to be made within 30 days of the Revance Settlement Agreement, payments to the Company of up to \$14.0 million to be made upon certain Revance capital raising achievements and a payment to the Company of \$4.0 million to be made upon the achievement of certain regulatory milestones. The Revance Settlement Agreement also terminated (i) the option to acquire Revance or to exclusively license certain of Revance's topical botulinum toxin products purchased by the Company on December 11, 2007 and (ii) the License Agreement dated July 28, 2009 between the Company and Revance. Pursuant to the Revance Settlement Agreement, the litigation filed by Revance against the Company and the Company's counterclaims were dismissed with prejudice on October 8, 2012 and all claims under the terminated agreements, whether known or unknown, were released.

*Stockholder Litigation Related to the Merger with Valeant*

On September 11, 2012, October 1, 2012, and October 25, 2012, putative class action lawsuits were filed in the Court of Chancery of the State of Delaware by Susan Omohundro Wood (Wood v. Shacknai, C.A. No. 7857-CS), Leslie Russell (Russell v. Shacknai, C.A. No. 7916-CS) and Maureen Collier (Collier v. Shacknai, C.A. No. 7984-CS), and on September 11, 2012 in the Superior Court of Arizona in Maricopa County by Kimberly Swint (Swint v. Medicis Pharmaceutical Corporation, CV2012-055635), alleged stockholders of the Company. Plaintiffs Swint and Wood subsequently amended their lawsuits on September 26, 2012 and September 28, 2012, respectively. The Delaware lawsuits have been consolidated under the name In re Medicis Pharmaceutical Corporation Shareholder Litigation, Consolidated C.A. No-7857-CS (the "Delaware Actions").

The lawsuits allege that the members of the Company's board of directors breached their fiduciary duties in negotiating and approving the Merger Agreement, that the Merger consideration negotiated in the Merger Agreement undervalues the Company, that the Company's stockholders will not receive adequate or fair value for their Company common stock in the Merger, that the terms of the Merger Agreement impose improper deal protection devices that preclude competing offers, and that the Preliminary Proxy Statement filed in connection with the Merger contains material misstatements and/or omissions. They further allege that the Company, Valeant Pharmaceuticals International, Inc., and in the case of the Delaware Action, Valeant Pharmaceuticals International and its wholly-owned subsidiary Merlin Merger Sub, Inc., aided and abetted the purported breaches of fiduciary duty. The lawsuits seek, among other things, an injunction against the completion of the Merger and rescission in the event that the Merger has already been consummated prior to the entry of the Court's final judgment, and an award of damages and costs and expenses, including attorneys' and experts' fees and expenses. The Company believes the lawsuits are meritless and intends to defend against them vigorously.

*Q-Med AB Complaint Related to the Merger with Valeant*

On November 7, 2012, Q-Med AB ("Q-Med") filed a complaint (the "Complaint") against the Company, HA North American Sales AB, a wholly-owned subsidiary of the Company ("HANA") and Medicis Aesthetics Holdings Inc., in the United States District Court for the Southern District of New York.

The Company and HANA hold exclusive U.S. and Canadian rights to market certain dermal filler products, including RESTYLANE®, RESTYLANE-L®, PERLANE®, PERLANE-L® and RESTYLANE FINE LINES, through certain license and supply agreements with Q-Med (the "Agreements"). The Complaint alleges that Q-Med has the right under the Agreements to withhold consent to a change of control of the Company that would result in a transfer to Valeant of the exclusive rights to market and sell the dermal filler products under the Agreements, and that the Company has breached or anticipatorily breached the Agreements. Q-Med alleges that the action is in aid of arbitration to prevent the Company from transferring such rights to Valeant as a result of the Merger.

The Complaint seeks (1) a declaration that Q-Med has the right to withhold consent in accordance with the terms of the Agreements; (2) a finding that the Company has materially breached its obligations under the Agreements, entitling Q-Med to contractual remedies, including termination or rescission of the Agreements; (3) a preliminary injunction prohibiting the Company from transferring its rights under the Agreements to Valeant during the pendency of the arbitration proceedings that Q-Med will bring; and (4) other relief as the court deems just and proper.

The Company believes that Q-Med's action is without merit and intends to vigorously defend itself. The Merger Agreement does not require the consent of Q-Med as a condition to consummating the Merger.

In addition to the matters discussed above, in the ordinary course of business, the Company is involved in a number of legal actions, both as plaintiff and defendant, and could incur uninsured liability in any one or more of them. Although the outcome of these actions is not presently

determinable, it is the opinion of the Company's management, based upon the information available at this time, that the expected outcome of these matters, individually or in the aggregate, will not have a material adverse effect on the results of operations, financial condition or cash flows of the Company.

**21. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS**

In May 2011, the FASB issued Accounting Standards Update (ASU) No. 2011-04, *Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and International Financial Reporting Standards (Topic 820) – Fair Value Measurement*, to provide a consistent definition of fair value and ensure that the fair value measurement and disclosure requirements are similar between U.S. GAAP and International Financial Reporting Standards. ASU No. 2011-04 changes certain fair value measurement principles and enhances the disclosure requirements, particularly for level 3 fair value measurements. ASU No. 2011-04 is effective for interim and annual reporting periods beginning after December 15, 2011 and must be applied prospectively. The Company adopted ASU No. 2011-04 as of January 1, 2012 and the revised guidance, which relates to disclosure, did not impact its results of operations and financial condition.

**Table of Contents**

In June 2011, the FASB issued ASU No. 2011-05, *Comprehensive Income (Topic 220): Presentation of Comprehensive Income*. The updated guidance amends the FASB Accounting Standards Codification ( Codification ) to allow an entity the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In both alternatives, an entity is required to present each component of net income along with total net income, each component of other comprehensive income along with a total for other comprehensive income, and a total amount for comprehensive income. ASU No. 2011-05 eliminates the option to present the components of other comprehensive income as part of the statement of changes in stockholders' equity. The amendments to the Codification in the ASU do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. ASU No. 2011-05 will be applied retrospectively. ASU No. 2011-05 is effective for annual reporting periods beginning after December 15, 2011, with early adoption permitted, and will be applied retrospectively. The Company adopted ASU No. 2011-05 as of January 1, 2012, and the adoption of this amendment only impacted the presentation of comprehensive income within the Company's condensed consolidated financial statements. Comprehensive income is now presented in the condensed consolidated statements of comprehensive income that are now included as part of the Company's condensed consolidated financial statements.

In September 2011, the FASB issued ASU 2011-08, *Intangibles - Goodwill and Other (Topic 350): Testing Goodwill for Impairment*. The updated guidance permits an entity to make a qualitative assessment of whether it is more likely than not that a reporting unit's fair value is less than its carrying value before applying the two-step goodwill impairment model that is currently in place. If it is determined through the qualitative assessment that a reporting unit's fair value is more likely than not greater than its carrying value, the remaining impairment steps would be unnecessary. The qualitative assessment is optional, allowing companies to go directly to the quantitative assessment. ASU 2011-08 is effective for annual and interim goodwill impairment tests performed in annual reporting periods beginning after December 15, 2011, with early adoption permitted. The Company adopted ASU 2011-08 as of January 1, 2012, and the revised guidance did not impact its results of operations and financial condition.

In July 2012, the FASB issued ASU 2012-02, *Intangibles - Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment*. The updated guidance allows an entity to first assess qualitative factors to determine whether it is necessary to perform a quantitative impairment test. Under the updated guidance, an entity would not be required to calculate the fair value of an indefinite-lived intangible asset unless the entity determines, based on qualitative assessment, that it is not more likely than not, the indefinite-lived intangible asset is impaired. The updated guidance also includes a number of events and circumstances for an entity to consider in conducting the qualitative assessment. ASU 2012-02 is effective for annual and interim indefinite-lived intangible asset impairment tests performed in annual reporting periods beginning after September 15, 2012, with early adoption permitted. The Company is currently assessing what impact, if any, the revised guidance will have on its results of operations and financial condition.

**22. SUBSEQUENT EVENTS**

The Company has evaluated subsequent events through the date of issuance of its condensed consolidated financial statements.

On October 8, 2012, the Company entered into a Settlement and Termination Agreement (the Agreement) with Revance to settle litigation and terminate certain contractual relationships between the Company and Revance. Pursuant to the terms of the Agreement, (i) the option to acquire Revance or to exclusively license certain of Revance's topical botulinum toxin products purchased by the Company on December 11, 2007 and (ii) the License Agreement dated July 28, 2009 between the Company and Revance have been terminated. In accordance with the Agreement, the previously disclosed litigation filed by Revance against the Company in the Court of Chancery of the State Delaware and the Company's counterclaims were dismissed with prejudice and all claims under the terminated agreements, whether known or unknown, were released. The Agreement also provides for an upfront payment to the Company of \$7.0 million to be made within 30 days of the Agreement, payments to the Company of up to \$14.0 million to be made upon certain Revance capital raising achievements and a payment to the Company of \$4.0 million to be made upon the achievement of certain regulatory milestones.

---

**Table of Contents**

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

*Executive Summary*

We are a leading independent specialty pharmaceutical company focused primarily on helping patients attain a healthy and youthful appearance and self-image through the development and marketing in the U.S. and Canada of products for the treatment of dermatological and aesthetic conditions. We offer a broad range of products addressing various conditions or aesthetics improvements, including facial wrinkles, glabellar lines, acne, fungal infections, hyperpigmentation, photoaging, psoriasis, actinic keratosis, bronchospasms, external genital and perianal warts/condyloma acuminata, seborrheic dermatitis and cosmesis (improvement in the texture and appearance of skin).

During the fourth quarter of 2011, we acquired substantially all of the assets of Graceway Pharmaceuticals, LLC ( Graceway ) for approximately \$455.9 million in cash, after our successful bid at a bankruptcy auction. Graceway's commercial pharmaceutical product portfolio includes on-market prescription products and important development projects primarily in dermatology and women's health specialties.

Our current product lines are divided between the dermatological and non-dermatological fields. The dermatological field represents products for the treatment of acne and acne-related dermatological conditions and non-acne dermatological conditions. The non-dermatological field represents products in the respiratory and women's health specialties and products for the treatment of urea cycle disorder. Our non-dermatological field also includes contract revenues associated with licensing agreements and authorized generic agreements. Our acne and acne-related dermatological product lines include SOLODYN<sup>®</sup> and ZIANA<sup>®</sup>. Our non-acne dermatological product lines include DYSPORT<sup>®</sup>, LOPROX<sup>®</sup>, PERLANE<sup>®</sup>, RESTYLANE<sup>®</sup>, VANOS<sup>®</sup> and ZYCLARA<sup>®</sup>. Our non-dermatological product lines include AMMONUL<sup>®</sup>, BUPHENYL<sup>®</sup> and the MAXAIR<sup>®</sup> AUTOHALER<sup>®</sup>.

*Agreement and Plan of Merger with Valeant*

On September 2, 2012, we, Valeant Pharmaceuticals International ( Valeant ), Valeant Pharmaceuticals International, Inc., and Merlin Merger Sub, Inc., a wholly-owned subsidiary of Valeant ( Merger Sub ), entered into an Agreement and Plan of Merger (the Merger Agreement ). Pursuant to the terms of the Merger Agreement, upon consummation of the Merger (as defined below) each share of our Class A common stock, par value \$0.014 per share (the Shares ), issued and outstanding immediately prior to the Merger will convert into a right to receive \$44.00 per Share (the Per Share Merger Consideration ), without interest, and Merger Sub will merge with and into us (the Merger ) with us continuing as the surviving corporation and a wholly owned subsidiary of Valeant.

Upon consummation of the Merger, each option to acquire Shares (whether vested or unvested) that is outstanding immediately prior to the Merger will be cancelled in exchange for the right to receive the Per Share Merger Consideration less the exercise price per Share of each respective award. Each stock appreciation right relating to Shares (whether vested or unvested) that is outstanding immediately prior to the Merger will be canceled in exchange for the right to receive the Per Share Merger Consideration less the exercise price per share of the stock appreciation right. Each Share that is subject to vesting restrictions will also convert into a right to receive the Per Share Merger Consideration.

The completion of the Merger is subject to customary conditions, including the approval of our stockholders, the absence of any material adverse effect on our business and receiving antitrust approvals (including under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended). Therefore, no assurance can be given that the Merger will be completed.

The Merger Agreement contains customary representations, warranties and covenants by us and Valeant. We have agreed, among other things, not to solicit alternative transactions. We have also agreed, subject to certain exceptions, not to enter into discussions concerning, or provide confidential information in connection with, any alternative transaction. In addition, each of the parties has agreed to use their reasonable best efforts to cause the Merger to be consummated. Subject to certain exceptions, the Merger Agreement also requires us to call and hold a stockholders' meeting and for our board of directors (the Board ) to recommend that our stockholders adopt the Merger Agreement.

## **Table of Contents**

The Merger Agreement may be terminated under certain circumstances, including by Valeant if the Board (i) makes a change to its recommendation in support of the Merger, (ii) fails to reaffirm its recommendation in support of the Merger within specified periods of time, or (iii) fails to recommend against a competing tender offer or exchange offer for outstanding Shares within certain periods of time. We may terminate the Merger Agreement prior to its adoption by our stockholders in the event that we receive an unsolicited proposal that the Board concludes, after following certain procedures, is a Superior Proposal (as defined in the Merger Agreement). In each of these cases, we may be required to pay Valeant a fee of \$85 million and reimburse Valeant for up to \$7.5 million in expenses (the Termination Fee). In addition, if either party terminates the Merger Agreement (i) under certain circumstances specified in the Merger Agreement and we have received an Acquisition Proposal (as defined in the Merger Agreement) or an Acquisition Proposal has been publicly announced and has not been publicly withdrawn prior to a specified time and (ii) we enter into an agreement to consummate, or actually consummates, certain alternative transactions within twelve (12) months after such termination, we may be required to pay Valeant the Termination Fee.

The Merger Agreement has been approved by the boards of directors of both Valeant and us. Our Board has also determined that the Merger is fair to, and in the best interests of, us and our stockholders, approved and declared advisable the Merger Agreement and the Merger and the other transactions contemplated by the Merger Agreement and recommended that our stockholders adopt the Merger Agreement.

On September 18, 2012, we filed a Preliminary Proxy Statement with the SEC indicating our intention to call a special meeting of our stockholders at a still-to-be-specified date to vote on the Merger Agreement.

On October 17, 2012, we announced that our stockholders of record at the close of business on October 29, 2012, will be entitled to notice of, and vote at a special meeting of stockholders upon, among other things, the proposal to adopt the Merger Agreement. The meeting will be held on December 7, 2012, at 9:00 a.m. local time, at the Scottsdale Resort and Conference Center, 7700 East McCormick Parkway, Scottsdale, Arizona 85258.

On November 5, 2012, we filed a Definitive Proxy Statement with the SEC.

### *Financial Information About Segments*

We operate in one business segment: pharmaceuticals. Our current pharmaceutical franchises are divided between the dermatological and non-dermatological fields. Information on revenues, operating income, identifiable assets and supplemental revenue of our business franchises appears in the condensed consolidated financial statements included in Item 1 hereof.

### *Key Aspects of Our Business*

We derive a majority of our revenue from our primary products: DYSPO<sup>®</sup>, PERLANE<sup>®</sup>, RESTYLANE<sup>®</sup>, SOLODYN<sup>®</sup>, VANOS<sup>®</sup>, ZIANA<sup>®</sup> and ZYCLARA<sup>®</sup>. We believe that sales of our primary products will constitute a significant portion of our revenue for 2012.

We have built our business by executing a four-part growth strategy: promoting existing brands, developing new products and important product line extensions, entering into and utilizing strategic collaborations and acquiring complementary products, technologies and businesses. Our core philosophy is to cultivate high integrity relationships of trust and confidence with the foremost physicians in the U.S. and Canada. We rely on third parties to manufacture our products.

We estimate customer demand for our prescription products primarily through use of third party syndicated data sources which track prescriptions written by health care providers and dispensed by licensed pharmacies. The data represents extrapolations from information provided only by certain pharmacies and are estimates of historical demand levels. We estimate customer demand for our non-prescription products primarily through internal data that we compile. We observe trends from these data and, coupled with certain proprietary information, prepare demand forecasts that are the basis for purchase orders for finished and component inventory from our third party manufacturers and suppliers. Our forecasts may fail to accurately anticipate ultimate customer demand for our products. Overestimates of demand and sudden changes in market conditions may result in excessive inventory production and underestimates may result in inadequate supply of our products in channels of distribution.

We schedule our inventory purchases to meet anticipated customer demand. As a result, miscalculation of customer demand or relatively small delays in our receipt of manufactured products could result in revenues being deferred or lost. Our operating expenses are based upon anticipated sales levels, and a high percentage of our operating expenses are relatively fixed in the short term.





## **Table of Contents**

We sell our products primarily to major wholesalers and retail pharmacy chains. Approximately 70%-80% of our gross revenues are typically derived from two major drug wholesale concerns. Depending on the customer, we recognize revenue at the time of shipment to the customer, or at the time of receipt by the customer, net of estimated provisions. We recognize revenue on our aesthetics products DYSPO<sup>®</sup>, PERLANE<sup>®</sup> and RESTYLANE<sup>®</sup> upon shipment from McKesson, our exclusive U.S. distributor of these products, to physicians. Consequently, variations in the timing of revenue recognition could cause significant fluctuations in operating results from period to period and may result in unanticipated periodic earnings shortfalls or losses. We have distribution services agreements with our two largest wholesale customers. We review the supply levels of our significant products sold to major wholesalers by reviewing periodic inventory reports that are supplied to us by our major wholesalers in accordance with the distribution services agreements. We rely wholly upon our wholesale and retail chain drugstore customers to effect the distribution allocation of substantially all of our prescription products. We believe our estimates of trade inventory levels of our products, based on our review of the periodic inventory reports supplied by our major wholesalers and the estimated demand for our products based on prescription and other data, are reasonable. We further believe that inventories of our products among wholesale customers, taken as a whole, are similar to those of other specialty pharmaceutical companies, and that our trade practices, which periodically involve volume discounts and early payment discounts, are typical of the industry.

We periodically offer promotions to wholesale and retail chain drugstore customers to encourage dispensing of our prescription products, consistent with prescriptions written by licensed health care providers. Because many of our prescription products compete in multi-source markets, it is important that licensed health care providers' dispensing instructions are fulfilled with our branded products and are not improperly substituted with a generic product or another therapeutic alternative product which may be contrary to the licensed health care providers' recommended and prescribed Medicis brand. We believe that a critical component of our brand protection program is maintenance of full product availability at wholesale and retail chain drugstore customers. We believe such availability reduces the probability of local and regional product substitutions, shortages and backorders, which could result in lost sales. We expect to continue providing favorable terms to wholesale and retail chain drugstore customers as may be necessary to ensure the fullest possible distribution of our branded products within the pharmaceutical chain of commerce. From time to time we may enter into business arrangements (e.g., loans or investments) involving our customers and those arrangements may be reviewed by federal and state regulators.

Purchases by any given customer, during any given period, may be above or below actual prescription volumes of any of our products during the same period, resulting in fluctuations of product inventory in the distribution channel. In addition, we consistently assess our product mix and portfolio to promote a high level of profitability and revenues and to ensure that our products are responsive to consumer tastes and changes to regulatory classifications. During early 2011, we discontinued our TRIAZ<sup>®</sup> branded products and decided to no longer promote our PLEXION<sup>®</sup> branded products. During the fourth quarter of 2011, we acquired substantially all of the assets of Graceway for approximately \$455.9 million in cash, after our successful bid at a bankruptcy auction. Graceway's commercial pharmaceutical product portfolio includes on-market prescription products and development projects primarily in dermatology and women's health specialties. Also during the fourth quarter of 2011, we closed the sale of our LipoSonix business to Solta Medical, Inc. for aggregate cash consideration of approximately \$35.5 million and continuing milestone payments based upon the commercial success of the LipoSonix products.

In March 2012, we launched our alternate fulfillment initiatives. Currently, our SOLODYN<sup>®</sup> and ZIANA<sup>®</sup> branded products are participating in the initiatives. The alternate fulfillment initiatives are designed to transfer unprofitable prescriptions from the traditional wholesale and retail chain drugstore channel and improve the profitability of the brands. During the second quarter of 2012, as a result of our alternate fulfillment initiatives and the accompanying decrease in the number of prescriptions flowing through the traditional wholesale and retail chain drugstore channel, wholesale customers reduced their inventory purchases to better correspond to the reduced demand through their channels. This trend continued during the third quarter of 2012 as our wholesale and retail chain drugstore customers continue to adjust their inventory levels to better correspond to reduced demand.

**Table of Contents**

*Recent Developments*

As described in more detail below, the following significant events and transactions occurred during the nine months ended September 30, 2012 (in chronological order) and affected our results of operations, our cash flows and our financial condition:

- License agreement with 3M;
- Increase of our quarterly dividend from \$0.08 per share to \$0.10 per share;
- Amended and restated collaboration agreement and asset purchase agreement with Hyperion;
- Development and license agreement with a specialty pharmaceutical company;
- Amended and restated joint development agreement with Lupin;
- Issuance of 1.375% Convertible Senior Notes due 2017; and
- Extension of Stock Repurchase Plan and repurchase of approximately \$50 million of our stock.

*License agreement with 3M*

On February 24, 2012, we entered into a License Agreement with 3M Company and 3M Innovative Properties Company (collectively, 3M ) for worldwide rights to a number of leading molecules in 3M s platform of immune response modifiers, for all topical dermatology indications and options for all human uses associated with the licensed molecules, excluding vaccine adjuvant. Under the terms of the agreement, we made an up-front payment of \$7.5 million to 3M in connection with the execution of the agreement, and will pay up to an additional \$25.6 million of contingent license and option fees. We may also pay up to an additional \$25.0 million upon the achievement of certain research, development and regulatory milestones, as well as royalties on future sales. The initial \$7.5 million payment was recognized as research and development expense during the three months ended March 31, 2012.

*Increase of our quarterly dividend from \$0.08 per share to \$0.10 per share*

On February 27, 2012, we announced that our Board of Directors had declared a cash dividend of \$0.10 per issued and outstanding share of our Class A common stock, which was paid on April 30, 2012, to stockholders of record at the close of business on April 2, 2012. This represented a 25% increase compared to our previous \$0.08 dividend. Subsequent cash dividends announced in June and September 2012 were also at the rate of \$0.10 per issued and outstanding share of our Class A common stock. The dividend declared in June 2012 was paid on July 31, 2012 to stockholders of record at the close of business on July 2, 2012. The dividend declared in September 2012 was paid on October 31, 2012 to stockholders of record at the close of business on October 1, 2012.

*Amended and restated collaboration agreement and asset purchase agreement with Hyperion*

On March 22, 2012, Ucyclid Pharma, Inc. ( Ucyclid ), our wholly-owned subsidiary, and Hyperion Therapeutics, Inc. ( Hyperion ) entered into an Amended and Restated Collaboration Agreement (the Amended Collaboration Agreement ), which amended and restated our existing Collaboration Agreement, dated August 23, 2007, as previously amended on or about November 24, 2008, June 29, 2009 and October 12, 2009 (the Prior Collaboration Agreement ).

Pursuant to the terms of the Prior Collaboration Agreement, Ucyclid granted rights to Hyperion, exercisable in the future, to purchase certain worldwide rights to Ucyclid s existing on-market products AMMONUL<sup>®</sup> and BUPHENYL<sup>®</sup> under certain conditions, as well as to develop and commercialize Ravicti , a compound referred to as HPN-100 (and also previously referred to as GT4P in the Prior Collaboration Agreement), for the treatment of urea cycle disorder, hepatic encephalopathies and other indications. The parties agreed to supersede the Prior Collaboration Agreement with the Amended Collaboration Agreement, under which Hyperion will continue to have the right, exercisable no earlier than January 1, 2013, to purchase certain worldwide rights to AMMONUL<sup>®</sup> and BUPHENYL<sup>®</sup>, subject to Ucyclid s right to elect to retain such rights to AMMONUL<sup>®</sup>, and an Asset Purchase Agreement of even date with the Amended Collaboration Agreement (the APA ), under which Hyperion agreed to purchase Ucyclid s rights to Ravicti on the terms set forth therein. The parties completed the sale of Ravicti under the APA on March 22, 2012, for which Hyperion paid Ucyclid \$6.0 million. If Ravicti is not approved by the FDA by January 1, 2013, Ucyclid will pay Hyperion \$0.5 million per month until June 30, 2013, or until Ravicti is approved, whichever comes first, subject to a maximum of \$3.0 million in aggregate payments. Pursuant to the APA, Hyperion will pay Ucyclid certain royalties and regulatory and sales

**Table of Contents**

relating to Ravicti and, pursuant to the terms of the Amended Collaboration Agreement, following exercise of its purchase rights, Hyperion will pay Ucyclid certain royalties and regulatory and sales milestones relating to AMMONUL<sup>®</sup> and BUPHENYL<sup>®</sup>. Ucyclid will continue to be entitled to all revenue from the sales of AMMONUL<sup>®</sup> and BUPHENYL<sup>®</sup> until the exercise of the purchase rights by Hyperion. If Hyperion elects to purchase AMMONUL<sup>®</sup> and BUPHENYL<sup>®</sup>, but Ucyclid elects to retain AMMONUL<sup>®</sup>, then AMMONUL<sup>®</sup> will remain an asset of Ucyclid and Ucyclid will continue to be entitled to all revenue from the sales of AMMONUL<sup>®</sup>. A net gain of \$3.0 million on the sale of Ravicti to Hyperion was recognized in other income during the three months ended March 31, 2012. This consisted of the \$6.0 million payment Ucyclid received from Hyperion, partially offset by the \$3.0 million in potential contingent payments that Ucyclid could pay to Hyperion during the first six months of 2013, based upon the timing of the approval of Ravicti by the FDA.

*Development and license agreement with a specialty pharmaceutical company*

On March 30, 2012, we entered into a Development and License Agreement with a specialty pharmaceutical company pursuant to which we obtained exclusive worldwide rights for the development and commercialization of an investigational drug targeted at certain topical skin applications. Under the terms of the agreement, we agreed to pay an up-front payment of \$25.0 million in connection with the execution of the agreement, and will pay up to an additional \$80.0 million upon the achievement of certain research, development and regulatory milestones and up to an additional \$120.0 million upon the achievement of certain commercial milestones, as well as royalties on future sales. The initial \$25.0 million up-front payment, paid in April 2012, was recognized as research and development expense during the three months ended March 31, 2012.

*Amended and restated joint development agreement with Lupin*

On July 21, 2011, we entered into a Joint Development Agreement (the Original Agreement) with Lupin Limited, on behalf of itself and its affiliates (hereinafter collectively referred to as Lupin), whereby we and Lupin will collaborate to develop multiple novel proprietary therapeutic products. Pursuant to the Original Agreement, subject to the terms and conditions contained therein, we made an up-front \$20.0 million payment to Lupin and were to make additional payments to Lupin upon the achievement of certain research, development, regulatory and other milestones, as well as royalty payments on sales of the products covered under the Original Agreement. In addition, we were to receive an exclusive, worldwide (excluding India) license on the sale of the products covered under the Original Agreement.

On March 30, 2012, we entered into an Amended and Restated Joint Development Agreement with Lupin (the Amended and Restated Joint Development Agreement), which modified the list of products being developed. We made a \$2.5 million payment to Lupin in April 2012 in connection with the execution of the Amended and Restated Joint Development Agreement, and will make additional payments to Lupin of up to \$35.5 million upon the achievement of certain research, development, regulatory and other milestones, as well as royalty payments on sales of the products covered under the Amended and Restated Joint Development Agreement, which supersedes the additional payments we would have made under the Original Agreement. In addition, we will receive an exclusive, worldwide (excluding India) license on the sale of the products covered under the Amended and Restated Joint Development Agreement.

The \$20.0 million up-front payment related to the Original Agreement was recognized as research and development expense during the three months ended September 30, 2011. The \$2.5 million payment related to the Amended and Restated Joint Development Agreement was recognized as research and development expense during the three months ended March 31, 2012.

*Issuance of 1.375% Convertible Senior Notes Due 2017*

On May 16, 2012, we issued and sold \$500.0 million of our 1.375% Convertible Senior Notes due 2017 (the 1.375% Notes) in a public offering. The 1.375% Notes will mature on June 1, 2017 and pay 1.375% annual cash interest, payable semi-annually in arrears on June 1 and December 1 of each year, beginning on December 1, 2012.

On or after March 1, 2017, until the close of business on the second scheduled trading day immediately preceding the stated maturity date, or prior to then but only under certain circumstances, the 1.375% Notes will be convertible into cash up to the principal amount, with the remaining amount, if any, to be satisfied, at our option, in shares of our Class A common stock, cash or a

---

**Table of Contents**

combination thereof. The 1.375% Notes will be convertible at an initial conversion rate of 21.2427 shares of our Class A common stock per \$1,000 principal amount of the 1.375% Notes, subject to adjustment upon certain events, which is equivalent to an initial conversion price of approximately \$47.07 per share of our Class A common stock.

The 1.375% Notes are convertible, at the holders' option, prior to the close of business on the business day immediately preceding March 1, 2017, into shares of our Class A common stock in the following circumstances:

during any calendar quarter commencing after the calendar quarter ending on September 30, 2012, if the closing price of our Class A common stock over a specified number of trading days during the previous quarter, including the last trading day of such quarter, is more than 130% of the conversion price of the 1.375% Notes in effect on each applicable trading day.

during the five consecutive trading day period immediately following any ten consecutive trading day period in which the trading price of the 1.375% Notes per \$1,000 principal amount for each such trading day was less than 98% of the product of the closing sale price of our Class A common stock on such days and the then-current conversion rate of \$1,000 principal amount of the 1.375% Notes; or

upon the occurrence of specified corporate transactions.

The 1.375% Notes are our senior unsecured obligations and are not guaranteed by any of our subsidiaries. The 1.375% Notes rank senior in right of payment to our existing and future indebtedness that is expressly subordinated in right of payment to the 1.375% Notes; equal in right of payment to our existing and future unsecured indebtedness that is not so subordinated; effectively junior in right of payment to any of our secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all existing and future indebtedness (including trade payables) incurred by our subsidiaries.

The 1.375% Notes do not contain any restrictions on the payment of dividends, the incurrence of additional indebtedness or the repurchase of our securities and do not contain any financial covenants. The 1.375% Notes require an anti-dilution adjustment to the conversion rate upon certain specified corporate dividend or common stock events or transactions, and if such event or transaction would result in at least a one percent (1%) change in the conversion rate. If the one percent (1%) threshold is not met on a particular qualifying event or transaction, the adjustment is carried forward and taken into account when a subsequent qualifying event or transaction is assessed for potential conversion rate adjustment. We may not redeem the 1.375% Notes prior to maturity and no sinking fund will be provided for the 1.375% Notes. If we undergo a fundamental change, subject to certain conditions, holders of the 1.375% Notes may require us to purchase 1.375% Notes in whole or in part for cash at a fundamental change purchase price equal to 100% of the principal amount of the 1.375% Notes to be purchased, plus accrued and unpaid interest, if any, to, but excluding the fundamental change purchase date. In certain events of default, as defined in the 1.375% Notes indenture, the trustee by notice to us, or the holders of at least 25% in principal amount of the then outstanding 1.375% Notes by notice to us and trustee, may declare 100% of the principal of, and accrued and unpaid interest, if any, on, all outstanding 1.375% Notes to be due and payable. Upon such a declaration, such principal and accrued and unpaid interest, if any, will be due and payable immediately.

As of September 30, 2012, the 1.375% Notes were not convertible.

The conversion feature embedded within the 1.375% Notes is considered a derivative; however, it has not been bifurcated and accounted for separately because it is considered to be indexed to our Class A common stock and meets the criteria for equity classification. Because the 1.375% Notes are considered to be cash convertible debt, we have separately accounted for the liability and equity components of the 1.375% Notes by allocating the \$500.0 million in proceeds from the issuance between the liability component and the embedded conversion option, or the equity component. The allocation was conducted by estimating an interest rate at the time of issuance of the 1.375% Notes for similar debt instruments that do not include the embedded conversion feature. A straight-debt interest rate of 5.0% was used to compute the initial fair value of the liability component of \$420.5 million. For purposes of the fair value measurement, we determined that the valuation of the 1.375% Notes falls under Level 2 of the fair value hierarchy. The excess of the \$500.0 million of proceeds from the issuance of the 1.375% Notes over the \$420.5 million initial amount allocated to the liability component, or \$79.5 million, was allocated to the embedded conversion option, or equity component. This excess was treated as a debt discount and is being amortized through interest expense, using the effective interest method, over the five-year term of the 1.375% Notes, which runs through June 1, 2017.



**Table of Contents**

In connection with the offering of the 1.375% Notes, on May 10, 2012 and May 11, 2012, we entered into privately negotiated convertible note hedge transactions (the Convertible Note Hedge Transactions ) with affiliates of the underwriters of the 1.375% Notes (the Option Counterparties ). The Convertible Note Hedge Transactions cover, collectively, the number of shares of our Class A common stock underlying the 1.375% Notes, subject to anti-dilution adjustments substantially similar to those applicable to the 1.375% Notes. We purchased these hedges for \$80.0 million, in aggregate, which was recorded as a reduction in additional paid-in capital during the three months ended June 30, 2012. We also entered into separate, privately-negotiated warrant transactions with the Option Counterparties on May 10, 2012 and into additional warrant transactions with the Option Counterparties on May 11, 2012 (collectively, the Warrant Transactions and together with the Convertible Note Hedge Transactions, the Convertible Note Hedge and Warrant Transactions ), initially covering a number of shares of our Class A common stock underlying the 1.375% Notes, subject to customary anti-dilution adjustments. Subject to certain conditions, we may settle the warrants in cash or on a net-share basis. The warrants were issued and sold for proceeds of approximately \$35.2 million, which was recorded as an increase in additional paid-in capital during the three months ended June 30, 2012.

The Convertible Note Hedge Transactions are expected to reduce the potential dilution with respect to our Class A common stock and/or reduce our exposure to potential cash payments that may be required upon conversion of the 1.375% Notes. The strike price of the Warrant Transactions will initially be approximately \$60.26 per share, which represents a premium of approximately 60% over the last reported sale price of \$37.66 per share of our Class A common stock on The New York Stock Exchange on May 10, 2012.

The Convertible Note Hedge and Warrant Transactions are considered derivative instruments; however, they have been classified within stockholders' equity because both financial instruments are considered to be indexed to the Company's Class A common stock and meet the criteria for equity classification.

The Convertible Note Hedge and Warrant Transactions have been accounted for as separate financial instruments, in each case, we entered into with the Option Counterparties, and are not part of the terms of the 1.375% Notes and will not affect any holder's rights under the 1.375% Notes. Holders of the 1.375% Notes will not have any rights with respect to the Convertible Note Hedge and Warrant Transactions.

On September 2, 2012, we entered into a settlement agreement (the Counterparty Settlement Agreement ) with one of the Option Counterparties to provide for settlement of the Convertible Note Hedge Transactions we entered into with one of the Option Counterparties on May 10, 2012 and May 11, 2012, upon the occurrence of certain events in connection with the Merger Agreement with Valeant. Upon the public announcement, if any, that the merger with Valeant has closed, or upon the occurrence of certain other specified events, one of the Option Counterparties will be obligated to pay to us, in lieu of any payment or delivery otherwise due under the Convertible Note Hedge Transactions, a specified settlement amount per Relevant Note Hedging Unit (as defined in the Counterparty Settlement Agreement) on the Payment Date (as defined in the Counterparty Settlement Agreement), in full satisfaction of the respective rights and obligations of the parties under the Convertible Note Hedge Transactions in respect of such Relevant Note Hedging Units.

In addition, the Counterparty Settlement Agreement provides for settlement of the Warrant Transactions that we entered into with one of the Option Counterparties on May 10, 2012 and May 11, 2012, upon the occurrence of certain events in connection with the Merger Agreement with Valeant. Upon the public announcement, if any, that the Merger with Valeant has closed, or upon the occurrence of certain other specified events, we will be obligated to pay one of the Option Counterparties, in lieu of any payment or delivery otherwise due under the Warrant Transactions, a specified settlement amount per Relevant Warrant (as defined in the Counterparty Settlement Agreement) on the Payment Date, in full satisfaction of the respective rights and obligations of the parties under the Warrant Transactions in respect of such Relevant Warrants.

Notwithstanding the foregoing description, the Counterparty Settlement Agreement provides that the aggregate settlement amounts payable by one of the Option Counterparties to us is \$3.0 million after deducting any aggregate settlement amounts payable by us to one of the Option Counterparties under the Counterparty Settlement Agreement on the Payment Date. The Counterparty Settlement Agreement is also subject to termination or renegotiation upon the occurrence of certain events.

---

**Table of Contents**

The Option Counterparty that entered into the Counterparty Settlement Agreement had also previously entered into an advisory and consulting agreement with us in December 2011 to advise us in a potential sale of the Company to a third party. That agreement (the Consulting Agreement) provides that in the event the Option Counterparty assists with the sale of the Company, the Option Counterparty would be entitled to a fee as a percentage of the sale purchase price. Based on the actual purchase price proposed by Valeant for the Company on September 3, 2012, the amount of this fee will be approximately \$28.1 million upon the closing of the transaction.

Because the Counterparty Settlement Agreement added a settlement condition based on a fixed monetary payoff which is contingent upon an event not based on our share price, the Note Hedge and Warrant Transactions entered into with one of the Option Counterparties no longer meet the criteria for equity classification.

Accordingly, we estimated and recorded the fair value of the Note Hedge and Warrant Transactions with this Counterparty immediately before the execution of the Counterparty Settlement Agreement which resulted in a \$17.2 million charge to additional paid-in capital and a corresponding increase to other current liabilities. Because the execution of the Counterparty Settlement Agreement was made in contemplation and consideration of the Consulting Agreement, we determined that the Counterparty Settlement Agreement, Note Hedge and Warrant Transactions with this Counterparty and Consulting Agreement should be subsequently accounted for and measured as one unit of account. Therefore, we subsequently determined the post execution Counterparty Settlement Agreement fair value of this equity derivative to be \$24.9 million, resulting in a \$7.7 million charge to other expense (income) and an increase to other current liabilities for the three months ended September 30, 2012.

The resulting liability will continue to be recorded at fair value with changes in fair value reflected through the income statement through the closing of the merger transaction.

The impact of the Counterparty Settlement Agreement has not been included in our computation of dilutive earnings per share because such impact would be anti-dilutive.

We incurred \$14.2 million of fees and other origination costs related to the issuance of the 1.375% Notes. These fees and other origination costs have been allocated to the liability and equity components of the 1.375% Notes in proportion to their allocated values. Approximately \$2.3 million of these fees and other origination costs were recorded as a reduction in additional paid-in capital. The remaining \$11.9 million of fees and other origination costs were recorded in other assets in our condensed consolidated balance sheets and are being amortized through interest expense over the five-year term of the 1.375% Notes, which runs through June 1, 2017.

Interest expense recognized during the three months ended September 30, 2012 related to the 1.375% Notes was approximately \$5.9 million, including \$3.6 million from the amortization of the discount and \$0.6 million from the amortization of debt issuance costs. Interest expense recognized during the nine months ended September 30, 2012 related to the 1.375% Notes was approximately \$8.8 million, including \$5.3 million from the amortization of the discount and \$0.9 million from the amortization of debt issuance costs.

*Extension of Stock Repurchase Plan and repurchase of approximately \$50 million of our stock*

On August 8, 2011, we announced that our Board of Directors approved a Stock Repurchase Plan to purchase up to \$200 million in aggregate value of shares of Medicis Class A common stock. The plan was set to expire on the first anniversary of the plan, August 7, 2012; however, on August 7, 2012, our Board of Directors approved a six-month extension of the expiration date of the plan to February 7, 2013. The plan may also terminate at the time at which the purchase limit is reached, and may be suspended or terminated at any time at our discretion without prior notice.

Any repurchases will be made in compliance with the SEC's Rule 10b-18, if applicable, and may be made in the open market or in privately negotiated transactions, including the entry into derivatives transactions. The number of shares to be repurchased and the timing of repurchases will depend on a variety of factors, including, but not limited to, stock price, economic and market conditions and corporate and regulatory requirements. It is intended that any repurchases will be funded by existing general corporate funds. The plan does not obligate us to repurchase any common stock.

During the three months ended September 30, 2012, we repurchased 1,533,619 shares in the open market at a weighted average cost of \$32.55 per share, or approximately \$49.9 million in the aggregate. From the inception of the plan through September 30, 2012, we repurchased a total of 5,971,852 shares in the open market and through structured share repurchase arrangements, at a weighted average cost of \$33.49 per share, or approximately \$200.0 million in the aggregate.





**Table of Contents**

As of September 30, 2012, the plan has terminated as the purchased limit has been reached.

*Subsequent Events*

On October 8, 2012, we entered into a Settlement and Termination Agreement (the Agreement ) with Revance to settle litigation and terminate certain contractual relationships between us and Revance. Pursuant to the terms of the Agreement, (i) the option to acquire Revance or to exclusively license certain of Revance's topical botulinum toxin products purchased by us on December 11, 2007 and (ii) the License Agreement dated July 28, 2009 between us and Revance have been terminated. In accordance with the Agreement, the previously disclosed litigation filed by Revance against us in the Court of Chancery of the State Delaware and our counterclaims were dismissed with prejudice and all claims under the terminated agreements, whether known or unknown, were released. The Agreement also provides for an upfront payment to us of \$7.0 million to be made within 30 days of the Agreement, payments to us of up to \$14.0 million to be made upon certain Revance capital raising achievements and a payment to us of \$4.0 million to be made upon the achievement of certain regulatory milestones.

**Table of Contents**

## Results of Operations

The following table sets forth certain data as a percentage of net revenues for the periods indicated.

	Three Months Ended		Nine Months Ended	
	September 30, 2012 (a)	September 30, 2011 (b)	September 30, 2012 (c)	September 30, 2011 (d)
Net revenues	100.0%	100.0%	100.0%	100.0%
Gross profit (e)	89.1	90.7	89.2	90.8
Operating expenses	80.4	71.2	79.8	64.8
Operating income	8.7	19.5	9.4	26.0
Other (expense) income, net	(4.3)	-	(1.3)	-
Interest and investment (expense) income, net	(3.4)	-	(1.7)	0.1
Income from continuing operations before income tax expense	1.0	19.5	6.4	26.1
Income tax expense	(0.5)	(7.1)	(2.7)	(10.4)
Net income from continuing operations	0.5	12.4	3.7	15.7
Loss from discontinued operations, net of income tax benefit	-	(1.9)	-	(3.1)
Net income	0.5%	10.5%	3.7%	12.6%

- (a) Included in operating expenses is \$6.4 million (3.5% of net revenues) of costs associated with the pending Merger with Valeant, \$3.5 million (1.9% of net revenues) of professional fees related to the Federal Trade Commission ( FTC ) investigation, \$2.7 million (1.5% of net revenues) related to the write-down of an intangible asset related to a non-primary product and \$13.6 million (7.5% of net revenues) of compensation expense related to stock options, restricted stock and stock appreciation rights.
- (b) Included in operating expenses is \$20.0 million (10.8% of net revenues) paid to Lupin related to a product development agreement, \$2.5 million (1.4% of net revenues) of legal settlements paid related to intellectual property disputes, \$2.3 million (1.2% of net revenues) related to the write-down of an intangible asset related to an authorized generic product for which we receive contract revenue and \$4.4 million (2.4% of net revenues) of compensation expense related to stock options, restricted stock and stock appreciation rights.
- (c) Included in operating expenses is \$25.0 million (4.3% of net revenues) related to a development and license agreement with a specialty pharmaceutical company, \$7.5 million (1.3% of net revenues) paid to 3M related to a license agreement, \$11.5 million (2.0% of net revenues) of charges related to product development agreements with Medicis partners, \$2.5 million (0.4% of net revenues) related to a product development agreement with Lupin, \$6.4 million (1.1% of net revenues) of costs associated with the pending Merger with Valeant, \$4.7 million (0.8% of net revenues) of professional fees related to the FTC investigation, \$2.7 million (0.5% of net revenues) related to the write-down of an intangible asset related to a non-primary product and \$25.7 million (4.5% of net revenues) of compensation expense related to stock options, restricted stock and stock appreciation rights.
- (d) Included in operating expenses is \$20.0 million (3.7% of net revenues) paid to Lupin related to a product development agreement, \$7.0 million (1.3% of net revenues) paid to Anacor related to a product development agreement, \$5.5 million (1.0% of net revenues) paid related to a product development agreement with a privately-held U.S. biotechnology company, \$2.0 million (0.4% of net revenues) paid to a Medicis partner related to a product development agreement, \$2.5 million (0.5% of net revenues) of legal settlements paid related to intellectual property disputes, \$2.3 million (0.4% of net revenues) related to the write-down of an intangible asset related to an authorized generic product for which we receive contract revenue and \$20.4 million (3.8% of net revenues) of compensation expense related to stock options, restricted stock and stock appreciation rights.
- (e) Gross profit does not include amortization of the related intangibles as such expense is included in operating expenses.

**Table of Contents**

Three Months Ended September 30, 2012 Compared to the Three Months Ended September 30, 2011

*Net Revenues*

The following tables set forth our net revenues for the three months ended September 30, 2012 (the third quarter of 2012) and September 30, 2011 (the third quarter of 2011), along with the percentage of net revenues and percentage point change for each of our product categories (dollar amounts in millions):

	Third Quarter 2012	Third Quarter 2011	\$ Change	% Change
Net product revenues	\$ 179.1	\$ 183.5	\$ (4.4)	(2.4) %
Net contract revenues	1.1	1.2	(0.1)	(8.3) %
<b>Total net revenues</b>	<b>\$ 180.2</b>	<b>\$ 184.7</b>	<b>\$ (4.5)</b>	<b>(2.4) %</b>

	Third Quarter 2012	Third Quarter 2011	\$ Change	% Change
Acne and acne-related dermatological products	\$ 85.1	\$ 119.1	\$ (34.0)	(28.5) %
Non-acne dermatological products	80.8	55.7	25.1	45.1 %
Non-dermatological products (including contract revenues)	14.3	9.9	4.4	44.4 %
<b>Total net revenues</b>	<b>\$ 180.2</b>	<b>\$ 184.7</b>	<b>\$ (4.5)</b>	<b>(2.4) %</b>

	Third Quarter 2012	Third Quarter 2011	Change
Acne and acne-related dermatological products	47.2 %	64.5 %	(17.3) %
Non-acne dermatological products	44.8 %	30.1 %	14.7 %
Non-dermatological products (including contract revenues)	8.0 %	5.4 %	2.6 %
<b>Total net revenues</b>	<b>100.0 %</b>	<b>100.0 %</b>	

Net revenues associated with our acne and acne-related dermatological products decreased by \$34.0 million, or 28.5%, during the third quarter of 2012 as compared to the third quarter of 2011, primarily due to a reduction in SOLODYN<sup>®</sup> and ZIANA<sup>®</sup> inventory purchases by our wholesale and retail customers to better correspond to the reduced demand through their channels due to the impact of our alternate fulfillment program. Net revenues of SOLODYN<sup>®</sup> during the third quarter of 2012 as compared to the third quarter of 2011 were also impacted by a reduction in consumer rebates due to the launch of our alternate fulfillment initiatives during the first quarter of 2012, and an increase in managed care rebates as a result of new managed care contracts that were entered into during December 2011. See Critical Accounting Policies and Estimates Items Deducted from Gross Revenue for a discussion of our managed care rebates.

Net revenues associated with our non-acne dermatological products increased by \$25.1 million, or 45.1%, during the third quarter of 2012 as compared to the third quarter of 2011 primarily due to sales of ZYCLARA<sup>®</sup> and ALDARA<sup>®</sup>. ZYCLARA<sup>®</sup> and ALDARA<sup>®</sup> were acquired during December 2011 as part of our acquisition of the assets of Graceway. Our net revenues of our non-acne dermatological products also increased because of increases in net revenues of DYSPORT<sup>®</sup>, PERLANE<sup>®</sup> and VANOS<sup>®</sup>.

**Table of Contents**

Net revenues associated with our non-dermatological products increased by \$4.4 million, or 44.4%, during the third quarter of 2012 as compared to the third quarter of 2011 primarily due to sales of various products that were acquired as part of the acquisition of the assets of Graceway during December 2011, partially offset by decreases in net revenues of BUPHENYL<sup>®</sup> and AMMONUL<sup>®</sup>.

*Gross Profit*

Gross profit represents our net revenues less our cost of product revenue. Our cost of product revenue includes our acquisition cost for the products we purchase from our third party manufacturers and royalty payments made to third parties. Amortization of intangible assets related to products sold is not included in gross profit. Amortization expense related to these intangibles for the third quarter of 2012 and 2011 was approximately \$15.6 million and \$5.3 million, respectively. Product mix plays a significant role in our quarterly and annual gross profit as a percentage of net revenues. Different products generate different gross profit margins, and the relative sales mix of higher gross profit products and lower gross profit products can affect our total gross profit.

The following table sets forth our gross profit for the third quarter of 2012 and 2011, along with the percentage of net revenues represented by such gross profit (dollar amounts in millions):

	<b>Third Quarter 2012</b>	<b>Third Quarter 2011</b>	<b>\$ Change</b>	<b>% Change</b>
Gross profit	\$ 160.6	\$ 167.5	\$ (6.9)	(4.1)%
% of net revenues	89.1 %	90.7 %		

The decrease in gross profit during the third quarter of 2012 as compared to the third quarter of 2011 is primarily due to the \$4.5 million decrease in net revenues.

*Selling, General and Administrative Expenses*

The following table sets forth our selling, general and administrative expenses for the third quarter of 2012 and 2011, along with the percentage of net revenues represented by selling, general and administrative expenses (dollar amounts in millions):

	<b>Third Quarter 2012</b>	<b>Third Quarter 2011</b>	<b>\$ Change</b>	<b>% Change</b>
Selling, general and administrative	\$ 111.5	\$ 93.2	\$ 18.3	19.6%
% of net revenues	61.9%	50.5%		
Share-based compensation expense included in selling, general and administrative	\$ 12.6	\$ 4.3	\$ 8.3	193.0%

Selling, general and administrative expenses increased \$18.3 million, or 19.6%, during the third quarter of 2012 as compared to the third quarter of 2011, and increased as a percentage of net revenues from 50.5% during the third quarter of 2011 to 61.9% during the third quarter of 2012. Included in this increase was an \$8.3 million increase in personnel costs, an \$8.9 million increase in professional fees and costs and an increase of \$1.1 million of other selling, general and administrative costs. Included in the increase in personnel costs was an \$8.3 million increase in stock compensation expense, primarily related to the revaluation of stock appreciation rights ( SARs ) awards based on changes in the market price of our common stock at the end of each of the comparable periods. The increase in professional fees and costs included \$4.6 million of professional fees related to the pending Merger with Valeant and \$3.5 million related to the FTC investigation. Other selling, general and administrative costs included an additional \$1.8 million of costs related to the pending Merger with Valeant.

**Table of Contents***Research and Development Expenses*

The following table sets forth our research and development expenses for the third quarter of 2012 and 2011 (dollar amounts in millions):

	Third Quarter 2012	Third Quarter 2011	\$ Change	% Change
Research and development	\$ 12.3	\$ 28.7	\$ (16.4)	(57.1)%
Charges included in research and development	\$ (0.5)	\$ 21.0	\$ (21.5)	(102.4)%
Share-based compensation expense included in research and development	\$ 0.9	\$ 0.1	\$ 0.8	800.0%

Included in research and development expense for the third quarter of 2011 was a \$20.0 million payment related to a product development agreement with Lupin. We expect research and development expenses to continue to fluctuate from quarter to quarter based on the timing of the achievement of development milestones under license and development agreements, as well as the timing of other development projects and the funds available to support these projects.

*Depreciation and Amortization Expenses*

Depreciation and amortization expenses during the third quarter of 2012 increased \$11.0 million, or 152.6%, to \$18.3 million during the third quarter of 2012, as compared to \$7.3 million during the third quarter of 2011, primarily as a result of \$335.8 million of intangible assets acquired during December 2011 as part of the acquisition of the assets of Graceway. Amortization expense is expected to be significantly higher during 2012, and in subsequent years, as compared to 2011, as 2011 only included one month of amortization expense related to these acquired intangible assets.

*Impairment of Intangible Assets*

During the quarter ended September 30, 2012, an intangible asset related to one of our non-primary products was determined to be impaired based on our analysis of the intangible asset's carrying value and projected future cash flows. As a result of the impairment analysis, we determined that the fair value of the intangible asset was less than its carrying value and recorded a write-down of approximately \$2.7 million related to this intangible asset. During the quarter ended September 30, 2012, we determined that the product, which was one of the products acquired as part of our December 2011 acquisition of the assets of Graceway, would no longer be sold. The \$2.7 million impairment charge reduced the intangible asset's carrying value to \$0.

During the quarter ended September 30, 2011, an intangible asset related to an authorized generic product from which we receive contract revenue was determined to be impaired based on our analysis of the intangible asset's carrying value and projected future cash flows. As a result of the impairment analysis, we recorded a write-down of \$2.3 million related to this intangible asset. Factors affecting the future cash flows of the contract revenue related to the authorized generic product included projected net revenues for the authorized generic product for which we receive contract revenue being less than originally anticipated.

*Interest and Investment Income*

Interest and investment income during the third quarter of 2012 decreased \$0.3 million, or 25.9%, to \$1.0 million from \$1.3 million during the third quarter of 2011.

*Interest Expense*

Interest expense during the third quarter of 2012 increased \$5.9 million from \$1.3 million during the third quarter of 2011 to \$7.2 million during the third quarter of 2012. The increase was due to \$5.9 million of interest expense incurred during the third quarter of 2012 related to our 1.375% Notes that were issued during May 2012. Included in the \$5.9 million of interest expense related to the 1.375% Notes was \$3.6 million from the amortization of the debt discount and \$0.6 million from the amortization of debt issuance costs.

**Table of Contents**

*Other Expense*

Other expense of \$7.7 million during the third quarter of 2012 represented the net loss recognized related to the Counterparty Settlement Agreement we entered into on September 2, 2012 with one of the Option Counterparties of the hedge and warrant transactions related to our 1.375% Notes, in connection with our pending merger with Valeant. See Note 15 to our condensed consolidated financial statements.

*Income Tax Expense*

Our effective tax rate for continuing operations for the third quarter of 2012 was 48.6%, as compared to 36.3% for the third quarter of 2011.

*Loss from Discontinued Operations, Net of Income Tax Benefit*

Loss from discontinued operations, net of income tax benefit, was \$3.5 million during the third quarter of 2011. See Note 3 in our accompanying condensed consolidated financial statements for further discussion.

**Table of Contents**

*Nine Months Ended September 30, 2012 Compared to the Nine Months Ended September 30, 2011*

*Net Revenues*

The following table sets forth our net revenues for the nine months ended September 30, 2012 (the 2012 nine months ) and September 30, 2011 (the 2011 nine months ), along with the percentage of net revenues and percentage point change for each of our product categories (dollar amounts in millions):

	<b>2012 Nine Months</b>	<b>2011 Nine Months</b>	<b>\$ Change</b>	<b>% Change</b>
Net product revenues	\$ 574.3	\$ 537.2	\$ 37.1	6.9%
Net contract revenues	4.2	3.2	1.0	31.3%
<b>Total net revenues</b>	<b>\$ 578.5</b>	<b>\$ 540.4</b>	<b>\$ 38.1</b>	<b>7.1%</b>

	<b>2012 Nine Months</b>	<b>2011 Nine Months</b>	<b>\$ Change</b>	<b>% Change</b>
Acne and acne-related dermatological products	\$ 286.7	\$ 345.7	\$ (59.0)	(17.1)%
Non-acne dermatological products	235.9	165.6	70.3	42.5%
Non-dermatological products (including contract revenues)	55.9	29.1	26.8	92.1%
<b>Total net revenues</b>	<b>\$ 578.5</b>	<b>\$ 540.4</b>	<b>\$ 38.1</b>	<b>7.1%</b>

	<b>2012 Nine Months</b>	<b>2011 Nine Months</b>	<b>Change</b>
Acne and acne-related dermatological products	49.6%	64.0%	(14.4)%
Non-acne dermatological products	40.8%	30.6%	10.2%
Non-dermatological products (including contract revenues)	9.6%	5.4%	4.2%
<b>Total net revenues</b>	<b>100.0%</b>	<b>100.0%</b>	<b>-%</b>

Net revenues associated with our acne and acne-related dermatological products decreased by \$59.0 million, or 17.1%, during the 2012 nine months as compared to the 2011 nine months, primarily due to a reduction in SOLODYN<sup>®</sup> inventory purchases by our wholesale and retail customers during the second and third quarters of 2012 to better correspond to the reduced demand through their channels due to the impact of our alternate fulfillment program. Net revenues of SOLODYN<sup>®</sup> during the 2012 nine months as compared to the 2011 nine months were also impacted by a reduction in consumer rebates due to the launch of our alternate fulfillment initiatives during the first quarter of 2012, and an increase in managed care rebates as a result of new managed care contracts that were entered into during December 2011.

Net revenues associated with our non-acne dermatological products increased by \$70.3 million, or 42.5%, during the 2012 nine months as compared to the 2011 nine months primarily due to sales of ZYCLARA<sup>®</sup> and ALDARA<sup>®</sup>. ZYCLARA<sup>®</sup> and ALDARA<sup>®</sup> were acquired during December 2011 as part of our acquisition of the assets of Graceway. Our net revenues of our non-acne dermatological products also increased because of increases in net revenues of RESTYLANE<sup>®</sup>, PERLANE<sup>®</sup>, DYSPORT<sup>®</sup> and VANOS<sup>®</sup>.



**Table of Contents**

Net revenues associated with our non-dermatological products increased by \$26.8 million, or 92.1%, during the 2012 nine months as compared to the 2011 nine months primarily due to sales of various products that were acquired as part of the acquisition of the assets of Graceway during December 2011.

*Gross Profit*

Gross profit represents our net revenues less our cost of product revenue. Our cost of product revenue includes our acquisition cost for the products we purchase from our third party manufacturers and royalty payments made to third parties. Amortization of intangible assets related to products sold is not included in gross profit. Amortization expense related to these intangibles for the 2012 nine months and 2011 nine months was approximately \$47.0 million and \$16.0 million, respectively. Product mix plays a significant role in our quarterly and annual gross profit as a percentage of net revenues. Different products generate different gross profit margins, and the relative sales mix of higher gross profit products and lower gross profit products can affect our total gross profit.

The following table sets forth our gross profit for the 2012 nine months and 2011 nine months, along with the percentage of net revenues represented by such gross profit (dollar amounts in millions):

	2012 Nine Months	2011 Nine Months	\$ Change	% Change
Gross profit	\$ 516.2	\$ 490.7	\$ 25.5	5.2%
% of net revenues	89.2%	90.8%		

The increase in gross profit during the 2012 nine months as compared to the 2011 nine months is primarily due to the \$38.1 million increase in net revenues.

*Selling, General and Administrative Expenses*

The following table sets forth our selling, general and administrative expenses for the 2012 nine months and 2011 nine months, along with the percentage of net revenues represented by selling, general and administrative expenses (dollar amounts in millions):

	2012 Nine Months	2011 Nine Months	\$ Change	% Change
Selling, general and administrative	\$ 316.9	\$ 268.3	\$ 48.6	18.1%
% of net revenues	54.8%	49.6%		
Share-based compensation expense included in selling, general and administrative expense	\$ 24.2	\$ 19.3	\$ 4.9	25.4%

Selling, general and administrative expenses increased \$48.6 million, or 18.1%, during the 2012 nine months as compared to the 2011 nine months, and increased as a percentage of net revenues from 49.6% during the 2011 nine months to 54.8% during the 2012 nine months. Included in this increase was a \$27.0 million increase in professional fees and costs, a \$14.7 million increase in personnel costs and an increase of \$6.9 million of other selling, general and administrative costs. The increase in professional fees and costs was primarily due to increased legal fees related to intellectual property and other disputes, and included \$4.6 million of professional fees related to the pending Merger with Valeant incurred during the third quarter of 2012 and \$4.7 million related to the FTC investigation. The increase in personnel costs was primarily due to an increase in headcount (excluding research and development personnel) from 601 as of September 30, 2011 to 770 as of September 30, 2012. The increase in personnel costs also included a \$4.9 million increase in stock compensation expense, primarily related to the revaluation of SARs awards based on changes in the market price of our common stock at the end of each of the comparable periods. Other selling, general and administrative costs included an additional \$1.8 million of costs related to the pending Merger with Valeant incurred during the third quarter of 2012.

**Table of Contents***Research and Development Expenses*

The following table sets forth our research and development expenses for the 2012 nine months and 2011 nine months (dollar amounts in millions):

	2012 Nine Months	2011 Nine Months	\$ Change	% Change
Research and development	\$ 87.4	\$ 58.2	\$ 29.2	50.2 %
Charges included in research and development	\$ 46.5	\$ 35.5	\$ 11.0	31.0 %
Share-based compensation expense included in research and development	\$ 1.6	\$ 1.1	\$ 0.5	45.5 %

Included in research and development expenses for the 2012 nine months was a \$25.0 million payment to a specialty pharmaceutical company related to a development and license agreement, a \$7.5 million payment to 3M related to a license agreement, \$4.0 million paid to a Medicis partner related to a product development agreement, \$2.5 million paid to Lupin related to a product development agreement and \$7.5 million in aggregate charges related to development and license agreements with certain Medicis partners. Included in research and development expense for the 2011 nine months was a \$20.0 million payment related to a product development agreement with Lupin, a \$7.0 million payment to Anacor related to a product development agreement, a \$5.5 million payment related to a product development agreement with a privately-held U.S. biotechnology company and \$2.0 million paid to a Medicis partner related to a product development agreement. We expect research and development expenses to continue to fluctuate from quarter to quarter based on the timing of the achievement of development milestones under license and development agreements, as well as the timing of other development projects and the funds available to support these projects.

*Depreciation and Amortization Expenses*

Depreciation and amortization expenses during the 2012 nine months increased \$32.8 million, or 151.2%, to \$54.5 million during the 2012 nine months, as compared to \$21.7 million during the 2011 nine months, primarily as a result of \$335.8 million of intangible assets acquired during December 2011 as part of the acquisition of the assets of Graceway. Amortization expense is expected to be significantly higher during 2012, and in subsequent years, as compared to 2011, as 2011 only included one month of amortization expense related to these acquired intangible assets.

*Impairment of Intangible Assets*

During the quarter ended September 30, 2012, an intangible asset related to one of our non-primary products was determined to be impaired based on our analysis of the intangible asset's carrying value and projected future cash flows. As a result of the impairment analysis, we determined that the fair value of the intangible asset was less than its carrying value and recorded a write-down of approximately \$2.7 million related to this intangible asset. During the quarter ended September 30, 2012, we determined that the product, which was one of the products acquired as part of our December 2011 acquisition of the assets of Graceway, would no longer be sold. The \$2.7 million impairment charge reduced the intangible asset's carrying value to \$0.

During the quarter ended September 30, 2011, an intangible asset related to an authorized generic product from which we receive contract revenue was determined to be impaired based on our analysis of the intangible asset's carrying value and projected future cash flows. As a result of the impairment analysis, we recorded a write-down of \$2.3 million related to this intangible asset. Factors affecting the future cash flows of the contract revenue related to the authorized generic product included projected net revenues for the authorized generic product for which we receive contract revenue being less than originally anticipated.

*Interest and Investment Income*

Interest and investment income during the 2012 nine months decreased \$1.7 million, or 44.1%, to \$2.1 million from \$3.8 million during the 2011 nine months, due to a decrease in the amount of funds available for investment during the 2012 nine months. The decrease in the amount of funds available for investment was primarily impacted by the

## **Table of Contents**

\$455.9 million used to acquire the assets of Graceway during the fourth quarter of 2011 and the \$150.1 million used to repurchase shares of our common stock during the second half of 2011. The net proceeds from the issuance of our 1.375% Notes during May 2012 was only available for investment for a portion of the 2012 nine months and therefore did not generate significant comparable incremental interest and investment income during the period.

### *Interest Expense*

Interest expense during the 2012 nine months increased \$8.7 million from \$3.5 million during the 2011 nine months to \$12.2 million during the 2012 nine months. The increase was due to \$8.8 million of interest expense incurred during the 2012 nine months related to our 1.375% Notes that were issued in May 2012. Included in the \$8.8 million of interest expense related to the 1.375% Notes was \$5.3 million from the amortization of the debt discount and \$0.9 million from the amortization of debt issuance costs.

### *Other Expense, net*

Other expense of \$7.6 million during the 2012 nine months primarily consisted of the \$7.7 million net loss recognized related to the Counterparty Settlement Agreement we entered into on September 2, 2012 with one of the Option Counterparties of the hedge and warrant transactions related to our 1.375% Notes, in connection with our pending merger with Valeant. See Note 15 to our condensed consolidated financial statements. Other expense, net, during the 2012 nine months also included a \$3.0 million gain on the sale of the product rights for Ravicti™ to Hyperion, and a \$2.9 million other-than-temporary impairment recorded against an investment in a third party entity.

### *Income Tax Expense*

Our effective tax rate for the 2012 nine months was 42.6%, as compared to 40.2% for the 2011 nine months.

### *Loss from Discontinued Operations, Net of Income Tax Benefit*

Loss from discontinued operations, net of income tax benefit, was \$16.6 million during the 2011 nine months. See Note 3 in our accompanying condensed consolidated financial statements for further discussion.

**Table of Contents**

## Liquidity and Capital Resources

*Overview*

The following table highlights selected cash flow components for the 2012 nine months and 2011 nine months, and selected balance sheet components as of September 30, 2012 and December 31, 2011 (dollar amounts in millions):

	2012 Nine Months	2011 Nine Months	\$ Change	% Change
Cash provided by (used in):				
Operating activities	\$ 76.9	\$ 136.7	\$ (59.8)	(43.7)%
Investing activities	(372.9)	(160.3)	(212.6)	(132.6)%
Financing activities	382.9	(10.4)	393.3	(3,781.7)%

	Sept. 30, 2012	Dec. 31, 2011	\$ Change	% Change
Cash, cash equivalents, and short-term investments	\$ 759.9	\$ 288.3	\$ 471.6	163.6%
Working capital	677.6	(23.6)	701.2	2,971.2%
Long-term investments	12.8	40.3	(27.5)	(68.2)%
1.375% convertible senior notes due 2017, net of discount	425.8	-	425.8	100.0%
2.5% contingent convertible senior notes due 2032	168.9	169.1	(0.2)	(0.1)%
1.5% contingent convertible senior notes due 2033	0.2	0.2	-	-%

**Table of Contents***Working Capital*

Working capital as of September 30, 2012 and December 31, 2011 consisted of the following (dollar amounts in millions):

	Sept. 30, 2012	Dec. 31, 2011	\$ Change	% Change
Cash, cash equivalents, and short-term investments	\$ 759.9	\$ 288.3	\$ 471.6	163.6%
Accounts receivable, net	145.8	193.0	(47.2)	(24.5)%
Inventories, net	34.9	34.5	0.4	1.2%
Deferred tax assets, net	73.5	12.7	60.8	478.7%
Prepaid income taxes	31.6	1.3	30.3	2,330.8%
Other current assets	22.9	21.3	1.6	7.5%
<b>Total current assets</b>	<b>1,068.6</b>	<b>551.1</b>	<b>517.5</b>	<b>93.9%</b>
Accounts payable	77.4	54.1	23.3	43.1%
Current portion of long-term debt	0.2	169.1	(168.9)	(99.9)%
Reserve for sales returns	52.3	60.0	(7.7)	(12.8)%
Accrued consumer rebate and loyalty programs	63.6	139.9	(76.3)	(54.5)%
Managed care and Medicaid reserves	83.1	72.8	10.3	14.1%
Other current liabilities	114.4	78.8	35.6	45.2%
<b>Total current liabilities</b>	<b>391.0</b>	<b>574.7</b>	<b>(183.7)</b>	<b>(32.0)%</b>
<b>Working capital</b>	<b>\$ 677.6</b>	<b>\$ (23.6)</b>	<b>\$ 701.2</b>	<b>2,971.2%</b>

We had cash, cash equivalents and short-term investments of \$759.9 million and working capital of \$677.6 million at September 30, 2012, as compared to \$288.3 million of cash, cash equivalents and short-term investments and negative working capital of \$23.6 million at December 31, 2011. The increase in cash, cash equivalents and short-term investments was primarily due to the proceeds received from the issuance of our 1.375% Notes in May 2012, net of a purchase of a related hedge and the proceeds from the issue of related warrants, of approximately \$455 million and the generation of \$76.9 million of operating cash flow during the first nine months of 2012, partially offset by \$49.9 million of cash used to repurchase shares of our Class A common stock. In addition to the impact of these events, the increase in working capital was also impacted by the reclassification of our 2.5% Notes to long-term liabilities subsequent to the June 4, 2012 option the holders of the 2.5% Notes had to require us to offer to repurchase their 2.5% Notes for cash. Only holders of \$3,000 in principal amount requested their 2.5% Notes be repurchased. During the twelve month period prior to June 4, 2012, the 2.5% Notes were classified as a current liability.

Accounts receivable, net, was \$145.8 million and \$193.0 million at September 30, 2012 and December 31, 2011, respectively. The decrease was primarily due to a \$45.4 million decrease in gross sales during the month of September 2012 as compared to the month of December 2011. As our standard payment terms are 30 days, orders that occur during the last month of a quarter are typically not due for payment until after the end of the quarter. Gross sales during the month of September 2012 were \$156.4 million, or 54.8% of the total gross sales for the third quarter of 2012, as compared to gross sales during the month of December 2011 of \$201.8 million, or 54.8% of total gross sales for the fourth quarter of 2011. Days sales outstanding, calculated as accounts receivable, net, as of the end of the reporting period, divided by total gross sales for the quarter, multiplied by the number of days in the quarter, was 47 days as of September 30, 2012 as compared to 48 days as of December 31, 2011. The calculated days sales outstanding is impacted by the amount and timing of orders placed within their inventory management agreement terms by customers during the third quarter of 2012 and the fourth quarter of 2011. Total purchases by customers, excluding the impact of the sales of Graceway products, decreased during the third quarter of 2012 as compared to prior quarters primarily due to a reduction in SOLODYN® and ZIANA® inventory purchases by our wholesale and retail customers to better correspond to the reduced demand through their channels due to the impact

**Table of Contents**

of our alternate fulfillment program. Gross sales during the first nine months of 2012 and during the month of December 2011 included sales of Graceway products, which were acquired as part of our acquisition of the assets of Graceway in December 2011. We sell our products primarily to major wholesalers and retail chain drugstores. We have distribution services agreements with our two largest wholesale customers. We review the supply levels of our significant products sold to major wholesalers by reviewing periodic inventory reports that are supplied to us by our major wholesalers in accordance with the distribution services agreements. Other than our alternate fulfillment program for SOLODYN<sup>®</sup> and ZIANA<sup>®</sup>, which began in 2012, we rely wholly upon our wholesale and retail chain drugstore customers to effect the distribution allocation of substantially all of our prescription products. We also defer the recognition of revenue for certain sales of inventory into the distribution channel that are in excess of eight (8) weeks of projected demand, and we defer the recognition of revenue of our aesthetics products DYSPORT<sup>®</sup>, PERLANE<sup>®</sup> and RESTYLANE<sup>®</sup>, until our exclusive U.S. distributor, McKesson, ships these products to physicians.

Management believes existing cash and short-term investments, together with funds generated from operations, should be sufficient to meet operating requirements for the foreseeable future. Our cash and short-term investments are available for dividends, milestone payments related to our product development collaborations, strategic investments, acquisitions of companies or products complementary to our business, the repayment of outstanding indebtedness, repurchases of our outstanding securities and other potential large-scale needs. In addition, we may consider incurring additional indebtedness and issuing additional debt or equity securities in the future to fund potential acquisitions or investments, to refinance existing debt or for general corporate purposes. If a material acquisition or investment is completed, our operating results and financial condition could change materially in future periods. However, no assurance can be given that additional funds will be available on satisfactory terms, or at all, to fund such activities.

As of September 30, 2012, our long-term investments included \$12.8 million of auction rate floating securities. Our auction rate floating securities are debt instruments with a long-term maturity and with an interest rate that is reset in short intervals through auctions. During the three months ended March 31, 2008, we were informed that there was insufficient demand at auction for the auction rate floating securities, and since that time we have been unable to liquidate our holdings in such securities. As a result, these affected auction rate floating securities are now considered illiquid, and we could be required to hold them until they are redeemed by the holder at maturity or until a future auction on these investments is successful. During the 2012 nine months, we liquidated approximately \$0.1 million of our auction rate floating securities at par.

**Table of Contents***Operating Activities*

Net cash provided by operating activities during the 2012 nine months was approximately \$76.9 million, compared to cash provided by operating activities of approximately \$136.7 million during the 2011 nine months. The following is a summary of the primary components of cash provided by operating activities during the 2012 nine months and 2011 nine months (in millions):

	<b>2012 Nine Months</b>	<b>2011 Nine Months</b>
Income taxes paid	\$ (43.8)	\$ (51.0)
Payment made to a specialty pharmaceutical company related to a development agreement	(25.0)	-
Payment made to 3M related to a license agreement	(7.5)	-
Payment made to Lupin partner related to a development agreement	(2.5)	(20.0)
Payment made to Anacor related to development agreement	-	(7.0)
Payment made to a privately-held U.S. biotechnology company related to a development agreement	-	(5.5)
Payments made to other Medicis partners related to development agreements	(7.0)	(2.0)
Decrease (increase) in accounts receivable	47.6	(23.4)
Increase in accounts payable	21.3	6.3
(Decrease ) increase in reserve for returns	(7.7)	12.0
(Decrease) increase in accrued consumer rebates and loyalty programs	(76.3)	30.8
Increase in Managed care and Medicaid reserves	10.2	10.0
Decrease in other current liabilities	(7.8)	(13.9)
Cash used in operating activities from discontinued operations	-	(12.3)
Other cash provided by operating activities	175.4	212.7
Cash provided by operating activities	\$ 76.9	\$ 136.7

*Investing Activities*

Net cash used in investing activities during the 2012 nine months was approximately \$372.9 million, compared to net cash used in investing activities during the 2011 nine months of \$160.3 million. The change was primarily due to the net purchases and sales of our short-term and long-term investments during the respective periods.

*Financing Activities*

Net cash provided by financing activities during the 2012 nine months was \$382.9 million, compared to net cash used in financing activities of \$10.4 million during the 2011 nine months. Included in the net cash provided by financing activities during the 2012 nine months was \$500.0 million of proceeds received from the issuance of our 1.375% Notes, \$80.0 million used to purchase a hedge related to the 1.375% Notes, \$35.2 million of proceeds received from the sale of warrants related to the 1.375% Notes and \$14.2 million used for costs associated with the issuance of the 1.375% Notes. Proceeds from the exercise of stock options were \$18.9 million during the 2012 nine months compared to \$58.1 million during the 2011 nine months. Cash used for the repurchase of our common stock was \$49.9 million during the 2012 nine months. During the 2011 nine months we paid \$50.0 million as an up-front payment under a structured share repurchase arrangement. Dividends paid during the 2012 nine months were \$16.6 million and dividends paid during the 2011 nine months were \$13.6 million.

*Long-Term Debt and Other Long-Term Commitments*

On May 16, 2012, we issued and sold \$500.0 million of our 1.375% Notes in a public offering. The 1.375% Notes will mature on June 1, 2017 and will pay 1.375% annual cash interest, payable semi-annually in arrears on June 1 and December 1 of each year, beginning on December 1, 2012. On or after March 1, 2017, until the close of business on the second scheduled trading day immediately preceding the stated maturity date, or prior to then but only under certain circumstances, the 1.375% Notes will be convertible into cash up to the principal

**Table of Contents**

amount, with the remaining amount, if any, to be satisfied, at our option, in shares of our Class A common stock, cash or a combination thereof. The 1.375% Notes are unsecured and do not contain any restrictions on the payment of dividends, the incurrence of additional indebtedness or the repurchase of our securities, and do not contain any financial covenants.

We also have two outstanding series of Contingent Convertible Senior Notes, consisting of \$168.9 million principal amount of 2.5% Contingent Convertible Senior Notes due 2032 (the 2.5% Notes ) and \$0.2 million principal amount of 1.5% Contingent Convertible Senior Notes due 2033 (the 1.5% Notes ). The 1.5% Notes and the 2.5% Notes are unsecured and do not contain any restrictions on the incurrence of additional indebtedness or the repurchase of our securities, and do not contain any financial covenants. The 2.5% Notes do not contain any restrictions on the payment of dividends. The 1.5% Notes require an adjustment to the conversion price if the cumulative aggregate of all current and prior dividend increases, through June 11, 2008, above \$0.025 per share would result in at least a one percent (1%) increase in the conversion price. This threshold was not reached and no adjustment to the conversion price has been made.

On June 4, 2017, or upon the occurrence of a change in control, holders of the 2.5% Notes may require us to offer to repurchase their 2.5% Notes for cash. On June 4, 2013 and 2018, or upon the occurrence of a change in control, holders of the 1.5% Notes may require us to offer to repurchase their 1.5% Notes for cash. Holders of the 2.5% Notes also had this option on June 4, 2012. Under GAAP, if an obligation is due on demand or will be due on demand within one year from the balance sheet date, even though liquidation may not be expected within that period, it should be classified as a current liability. Accordingly, the outstanding balance of 2.5% Notes along with the deferred tax liability associated with accelerated interest deductions on the 2.5% Notes are classified as a current liability during the respective twelve month periods prior to June 4, 2012 and June 4, 2017, and the outstanding balance of 1.5% Notes along with the deferred tax liability associated with accelerated interest deductions on the 1.5% Notes are classified as a current liability during the respective twelve month periods prior to June 4, 2013 and June 4, 2018. As of December 31, 2011, \$169.1 million of the 2.5% Notes and \$62.5 million of deferred tax liabilities were classified as current liabilities in our condensed consolidated balance sheets. The \$62.5 million of deferred tax liabilities were included within current deferred tax assets, net. Holders of \$3,000 of principal amount of the 2.5% Notes requested to have their 2.5% Notes repurchased by us on June 4, 2012. As of September 30, 2012, \$181,000 of the 1.5% Notes and \$58,000 of deferred tax liabilities were classified as current liabilities in our condensed consolidated balance sheets. The \$58,000 of deferred tax liabilities were included within current deferred tax assets, net.

If all of the 1.5% Notes are put back to us on June 4, 2013, we would be required to pay \$181,000 to purchase the 1.5% Notes. We would also be required to pay the accumulated deferred tax liability related to the 1.5% Notes.

During the quarters ended December 31, 2011, March 31, 2012, June 30, 2012 and September 30, 2012, the 2.5% Notes met the criteria for the right of conversion into shares of our Class A common stock. This right of conversion of the holders of 2.5% Notes was triggered by the stock closing above \$31.96 on 20 of the last 30 trading days and the last trading day of the quarters ended December 31, 2011, March 31, 2012, June 30, 2012 and September 30, 2012. During the quarter ended June 30, 2012, outstanding principal amounts of \$216,000 of 2.5% Notes were converted into shares of our Class A common stock. The holders of the remaining \$168.9 million of 2.5% Notes have this conversion right only until December 31, 2012. At the end of each future quarter, the conversion rights will be reassessed in accordance with the bond indenture agreement to determine if the conversion trigger rights have been achieved. During the quarter ended September 30, 2012, the 1.5% Notes did not meet the criteria for the right of conversion.

Except for the 1.375% Notes and 2.5% Notes, we had only \$50.2 million of long-term liabilities at September 30, 2012, and, except for the 1.5% Notes, we had \$390.8 million of current liabilities at September 30, 2012. Our other commitments and planned expenditures consist principally of payments we will make in connection with strategic collaborations and research and development expenditures, and we will continue to invest in sales and marketing infrastructure.

*Dividends*

We do not have a dividend policy. Prior to July 2003, we had not paid a cash dividend on our common stock. From July 2003 through September 30, 2012, we have paid quarterly cash dividends aggregating



## **Table of Contents**

approximately \$95.2 million on our common stock. In addition, on September 21, 2012, we announced that our Board of Directors had declared a cash dividend of \$0.10 per issued and outstanding share of common stock, which was paid on October 31, 2012, to our stockholders of record at the close of business on October 1, 2012. Any future determinations to pay cash dividends will be at the discretion of our Board of Directors and will be dependent upon our financial condition, operating results, capital requirements and other factors that our Board of Directors deems relevant.

### *Fair Value Measurements*

We utilize unobservable (Level 3) inputs in determining the fair value of our auction rate floating security investments, which totaled \$12.8 million at September 30, 2012. These securities were included in long-term investments at September 30, 2012. We also utilize unobservable (Level 3) inputs in determining the fair value of the liability associated with the Counterparty Settlement Agreement, which is included in other current liabilities at September 30, 2012.

Our auction rate floating securities are classified as available-for-sale securities and are reflected at fair value. In prior periods, due to the auction process which took place every 30-35 days for most securities, quoted market prices were readily available, which would qualify as Level 1 within the fair value hierarchy. However, due to events in credit markets that began during the first quarter of 2008, the auction events for most of these instruments failed, and, therefore, we determined the estimated fair values of these securities, beginning in the first quarter of 2008, utilizing a discounted cash flow analysis. These analyses consider, among other items, the collateralization underlying the security investments, the expected future cash flows, including the final maturity, associated with the securities, and the expectation of the next time the security is expected to have a successful auction. These securities were also compared, when possible, to other observable market data with similar characteristics to the securities held by us. Due to these events, we reclassified these instruments as Level 3 during the first quarter of 2008.

### *Off-Balance Sheet Arrangements*

As of September 30, 2012, we are not involved in any off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of SEC Regulation S-K.

### *Non-GAAP Financial Information*

In addition to our GAAP results, we use non-GAAP financial information as a supplemental measure of our operating performance. Our management measures our performance using non-GAAP financial measures to provide meaningful supplemental information regarding our operational performance and to enhance our investors' overall understanding of our core financial performance. This information facilitates our management's internal comparisons to our historical core operating results and competitors' core operating results, and is a basis for financial decision making. Our management believes that our investors benefit from seeing our results on the same basis as management, in addition to the GAAP presentation, where applicable. In our view, non-GAAP financial measures, such as non-GAAP net income and non-GAAP diluted cash earnings per share, are informative to investors, allowing them to focus on the ongoing operations and core results of our business. This information is not in accordance with, or an alternative for, information prepared using GAAP. Non-GAAP net income excludes certain items, such as amortization of intangible assets, non-cash interest expense, impairment of intangible assets, special charges associated with research and development milestone or contract payments, fluctuations in our stock price and the resulting effect on our SARs, legal settlements and costs related to significant legal matters, costs related to business combinations and other items we believe are not part of our ongoing operations and core operating results of our business. These items may have a material effect on our net income and diluted earnings per common share calculated in accordance with GAAP. We exclude such items and the related tax benefits or expenses when analyzing our financial results, as the items are distinguishable events or large non-cash expenses. Our management believes that, by viewing our results of operations excluding these items, investors are given an indication of the ongoing results of our operations.

**Table of Contents**

The following table presents data related to non-GAAP net income and non-GAAP cash earnings per share, for the periods indicated (in thousands, except per share data):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2012	2011	2012	2011
GAAP net income	\$ 937	\$ 19,452	\$ 21,213	\$ 67,595
Amortization of intangible assets	15,670	5,330	47,148	16,177
Non-cash interest expense related to our 1.375% convertible notes	4,172	-	6,218	-
Impact of stock price fluctuation on SARs	8,093	(103)	10,105	6,456
Loss related to Counterparty Settlement Agreement	7,743	-	7,743	-
Research and development expenses related to our collaborations	(500)	21,000	46,506	35,500
Impairment of intangible assets	2,745	2,259	2,745	2,259
Legal settlements	-	2,500	-	2,500
Professional fees related to FTC investigation	3,486	-	4,712	-
Costs related to pending merger with Valeant	6,378	-	6,378	-
Write-down of equity investment in third-party	-	-	2,900	-
Gain on sale of product rights to Hyperion	-	-	(3,000)	-
Loss from discontinued operations	-	5,196	-	25,538
Income tax effects related to the above transactions	(18,088)	(13,479)	(49,482)	(30,631)
<b>Non-GAAP net income</b>	<b>\$ 30,636</b>	<b>\$ 42,155</b>	<b>\$ 103,186</b>	<b>\$ 125,394</b>
<b>Non-GAAP diluted cash earnings per share</b>	<b>\$ 0.48</b>	<b>\$ 0.61</b>	<b>\$ 1.60</b>	<b>\$ 1.84</b>

**Critical Accounting Policies and Estimates**

The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in conformity with U.S. generally accepted accounting principles. The preparation of the condensed consolidated financial statements requires us to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates related to sales allowances, chargebacks, rebates, returns and other pricing adjustments, depreciation and amortization and other contingencies and litigation. We base our estimates on historical experience and various other factors related to each circumstance. Actual results could differ from those estimates based upon future events, which could include, among other risks, changes in the regulations governing the manner in which we sell our products, changes in the health care environment and managed care consumption patterns. Our significant accounting policies are described in Note 2 to the consolidated financial statements included in our Form 10-K for the year ended December 31, 2011. There were no new significant accounting estimates in the third quarter of 2012, nor were there any material changes to the critical accounting policies and estimates discussed in our Form 10-K for the year ended December 31, 2011.

*Items Deducted From Gross Revenue*

Our accounting policies for revenue recognition have a significant impact on our reported results and rely on certain estimates that require complex and subjective judgment on the part of our management. If the levels of product returns, inventory in the distribution channel, cash discounts, chargebacks, managed care and Medicaid rebates and consumer rebate and loyalty programs fluctuate significantly and/or if our estimates do not adequately reserve for these reductions of gross product revenues, our reported net product revenues could be negatively affected.

**Table of Contents**

The following table shows the activity of each reserve, associated with the various sales provisions that serve to reduce our accounts receivable balance or increase our accrued expenses or deferred revenue, for the three months ended September 30, 2012 and 2011 (in thousands):

	Reserve for Sales Returns	Deferred Revenue	Sales Discounts Reserve	Chargebacks Reserve	Managed Care & Medicaid Rebates Reserve	Consumer Rebate and Loyalty Programs	Total
Balance at June 30, 2012	\$ 63,920	\$ 8,070	\$ 2,153	\$ 2,169	\$ 96,252	\$ 81,240	\$ 253,804
Actual	(4,941)		(4,133)	(2,989)	(49,751)	(81,307)	(143,121)
Provision	(6,661)	(4,557)	4,918	3,663	36,542	63,688	97,593
Balance at Sept. 30, 2012	\$ 52,318	\$ 3,513	\$ 2,938	\$ 2,843	\$ 83,043	\$ 63,621	\$ 208,276

	Reserve for Sales Returns	Deferred Revenue	Sales Discounts Reserve	Chargebacks Reserve	Managed Care & Medicaid Rebates Reserve	Consumer Rebate and Loyalty Programs	Total
Balance at June 30, 2011	\$ 78,220	\$ 2,441	\$ 3,655	\$ 1,489	\$ 51,239	\$ 124,922	\$ 261,966
Actual	(11,656)		(7,045)	(1,693)	(22,462)	(100,935)	(143,791)
Provision	6,116	(2,243)	6,748	1,823	30,644	108,445	151,533
Balance at Sept. 30, 2011	\$ 72,680	\$ 198	\$ 3,358	\$ 1,619	\$ 59,421	\$ 132,432	\$ 269,708

The provision for product returns during the three months ended September 30, 2012 was a benefit to net revenues, or a reduction of the provision, of \$6.7 million, or 2.3% of gross product sales. The provision for product returns during the three months ended September 30, 2011 was \$6.1 million, or 1.8% of gross product sales. The reserve for product returns decreased \$11.6 million, from \$63.9 million as of June 30, 2012 to \$52.3 million as of September 30, 2012. The decrease in the provision during the comparable periods and in the reserve during the three months ended September 30, 2012 was primarily related to a decrease in the amount of expected future returns of SOLODYN®.

The provision for sales discounts (or cash discounts) was \$4.9 million, or 1.7% of gross product sales, and \$6.7 million, or 2.0% of gross product sales, for the three months ended September 30, 2012 and 2011, respectively. The reserve for cash discounts increased \$0.7 million, from \$2.2 million as of June 30, 2012 to \$2.9 million as of September 30, 2012. The decrease in the provision during the comparable periods was due to a decrease in gross product sales, primarily due to a reduction in SOLODYN® inventory purchases by our wholesale and retail customers to better correspond to the reduced demand through their channels due to the impact of our alternate fulfillment program. The balance in the reserve for sales discounts at the end of a quarterly period is related to the amount of accounts receivable that is outstanding at that date that is still eligible for the cash discounts to be taken by the customers. The fluctuation in the reserve for sales discounts between periods is normally reflective of increases or decreases in the related eligible outstanding accounts receivable amounts at the comparable dates.

**Table of Contents**

The provision for managed care and Medicaid rebates was \$36.5 million, or 12.9% of gross product sales, and \$30.6 million, or 8.9% of gross product sales, for the three months ended September 30, 2012 and 2011, respectively. The reserve for managed care and Medicaid rebates decreased \$13.3 million, from \$96.3 million as of June 30, 2012 to \$83.0 million as of September 30, 2012. The increase in the provision during the comparable periods was primarily due to new managed care contracts entered into during December 2011. The decrease in the reserve for managed care and Medicaid rebates from June 30, 2012 to September 30, 2012 is primarily due to decreased rebate volumes from the first two quarters of 2012 to the third quarter of 2012.

The provision for consumer rebates and loyalty programs was \$63.7 million, or 22.4% of gross product sales, and \$108.4 million, or 31.4% of gross product sales, for the three months ended September 30, 2012 and 2011, respectively. The reserve for consumer rebates and loyalty programs decreased \$17.6 million, from \$81.2 million as of June 30, 2012 to \$63.6 million as of September 30, 2012. The decrease in the provision during the comparable periods and the reserve during the third quarter of 2012 was due to the impact of our alternate fulfillment initiatives launched during the first quarter of 2012.

The following table shows the activity of each reserve, associated with the various sales provisions that serve to reduce our accounts receivable balance or increase our accrued expenses or deferred revenue, for the nine months ended September 30, 2012 and 2011 (in thousands):

	Reserve for Sales Returns	Deferred Revenue	Sales Discounts Reserve	Chargebacks Reserve	Managed Care & Medicaid Rebates Reserve	Consumer Rebate and Loyalty Programs	Total
Balance at Dec. 31, 2011	\$ 60,024	\$ 211	\$ 4,137	\$ 2,050	\$ 72,801	\$ 139,948	\$ 279,171
Actual	(16,157)		(19,875)	(7,374)	(135,661)	(335,849)	(514,916)
Provision	8,451	3,302	18,676	8,167	145,903	259,522	444,021
Balance at Sept. 30, 2012	\$ 52,318	\$ 3,513	\$ 2,938	\$ 2,843	\$ 83,043	\$ 63,621	\$ 208,276

	Reserve for Sales Returns	Deferred Revenue	Sales Discounts Reserve	Chargebacks Reserve	Managed Care & Medicaid Rebates Reserve	Consumer Rebate and Loyalty Programs	Total
Balance at Dec. 31, 2010	\$ 60,692	\$ 582	\$ 2,830	\$ 1,151	\$ 49,375	\$ 101,678	\$ 216,308
Actual	(36,753)		(19,769)	(4,527)	(69,901)	(290,117)	(421,067)
Provision	48,741	(384)	20,297	4,995	79,947	320,871	474,467
Balance at Sept. 30, 2011	\$ 72,680	\$ 198	\$ 3,358	\$ 1,619	\$ 59,421	\$ 132,432	\$ 269,708

**Table of Contents**

The provision for product returns was \$8.5 million, or 0.8% of gross product sales, and \$48.7 million, or 4.7% of gross product sales, for the nine months ended September 30, 2012 and 2011, respectively. The reserve for product returns decreased \$7.7 million, from \$60.0 million as of December 31, 2011 to \$52.3 million as of September 30, 2012. The decrease in the provision during the comparable periods was primarily related to additional estimated required reserves for newly-launched products recorded during the 2011 nine months, and due to the impact of a decrease in the amount of expected future returns of SOLODYN<sup>®</sup> recorded during the third quarter of 2012. The decrease in the reserve during the nine months ended September 30, 2012 was primarily related to a decrease in the amount of expected future returns of SOLODYN<sup>®</sup>.

Deferred revenue increased \$3.3 million, from \$0.2 million as of December 31, 2011 to \$3.5 million as of September 30, 2012. The increase in deferred revenue during the 2012 nine months was primarily due to the deferral of revenue related to units of ZYCLARA<sup>®</sup> in the distribution channel in excess of eight weeks of projected demand.

The provision for sales discounts (or cash discounts) was \$18.7 million, or 1.8% of gross product sales, and \$20.3 million, or 2.0% of gross product sales, for the nine months ended September 30, 2012 and 2011, respectively. The reserve for cash discounts decreased \$1.2 million, from \$4.1 million as of December 31, 2011 to \$2.9 million as of September 30, 2012. The balance in the reserve for sales discounts at the end of a quarterly period is related to the amount of accounts receivable that is outstanding at that date that is still eligible for the cash discounts to be taken by the customers. The fluctuation in the reserve for sales discounts between periods is normally reflective of increases or decreases in the related eligible outstanding accounts receivable amounts at the comparable dates.

The provision for managed care and Medicaid rebates was \$145.9 million, or 13.9% of gross product sales, and \$79.9 million, or 7.7% of gross product sales, for the nine months ended September 30, 2012 and 2011, respectively. The reserve for managed care and Medicaid rebates increased \$10.2 million, from \$72.8 million as of December 31, 2011 to \$83.0 million as of September 30, 2012. The increase in the provision during the comparable periods and in the reserve during the 2012 nine months was primarily due to new managed care contracts entered into during December 2011.

The provision for consumer rebates and loyalty programs was \$259.5 million, or 24.8% of gross product sales, and \$320.9 million, or 31.0% of gross product sales, for the nine months ended September 30, 2012 and 2011, respectively. The reserve for consumer rebates and loyalty programs decreased \$76.3 million, from \$139.9 million as of December 31, 2011 to \$63.6 million as of September 30, 2012. The decrease in the provision during the comparable periods and the reserve during the 2012 nine months was due to the impact of our alternate fulfillment initiatives launched during the first quarter of 2012.

*Recent Accounting Pronouncements*

In May 2011, the FASB issued Accounting Standards Update (ASU) No. 2011-04, *Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and International Financial Reporting Standards (Topic 820) – Fair Value Measurement*, to provide a consistent definition of fair value and ensure that the fair value measurement and disclosure requirements are similar between U.S. GAAP and International Financial Reporting Standards. ASU No. 2011-04 changes certain fair value measurement principles and enhances the disclosure requirements, particularly for level 3 fair value measurements. ASU No. 2011-04 is effective for interim and annual reporting periods beginning after December 15, 2011 and must be applied prospectively. We adopted ASU No. 2011-04 as of January 1, 2012 and the revised guidance, which relates to disclosure, did not impact our results of operations and financial condition.

In June 2011, the FASB issued ASU No. 2011-05, *Comprehensive Income (Topic 220): Presentation of Comprehensive Income*. The updated guidance amends the FASB Accounting Standards Codification (Codification) to allow an entity the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In both alternatives, an entity is required to present each component of net income along with total net income, each component of other comprehensive income along with a total for other comprehensive income, and a total amount for comprehensive income. ASU No. 2011-05 eliminates the option to present the components of other comprehensive income as part of the statement of changes in stockholders' equity. The amendments to the Codification in the ASU do not change the items that must be reported

**Table of Contents**

in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. ASU No. 2011-05 will be applied retrospectively. ASU No. 2011-05 is effective for annual reporting periods beginning after December 15, 2011, with early adoption permitted, and will be applied retrospectively. We adopted ASU No. 2011-05 as of January 1, 2012, and the adoption of this amendment only impacted the presentation of comprehensive income within our condensed consolidated financial statements. Comprehensive income is now presented in the condensed consolidated statements of comprehensive income that are now included as part of our condensed consolidated financial statements.

In September 2011, the FASB issued ASU 2011-08, *Intangibles – Goodwill and Other (Topic 350): Testing Goodwill for Impairment*. The updated guidance permits an entity to make a qualitative assessment of whether it is more likely than not that a reporting unit's fair value is less than its carrying value before applying the two-step goodwill impairment model that is currently in place. If it is determined through the qualitative assessment that a reporting unit's fair value is more likely than not greater than its carrying value, the remaining impairment steps would be unnecessary. The qualitative assessment is optional, allowing companies to go directly to the quantitative assessment. ASU 2011-08 is effective for annual and interim goodwill impairment tests performed in annual reporting periods beginning after December 15, 2011, with early adoption permitted. We adopted ASU 2011-08 as of January 1, 2012, and the revised guidance did not impact our results of operations and financial condition.

In July 2012, the FASB issued ASU 2012-02, *Intangibles – Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment*. The updated guidance allows an entity to first assess qualitative factors to determine whether it is necessary to perform a quantitative impairment test. Under the updated guidance, an entity would not be required to calculate the fair value of an indefinite-lived intangible asset unless the entity determines, based on qualitative assessment, that it is not more likely than not, the indefinite-lived intangible asset is impaired. The updated guidance also includes a number of events and circumstances for an entity to consider in conducting the qualitative assessment. ASU 2012-02 is effective for annual and interim indefinite-lived intangible asset impairment tests performed in annual reporting periods beginning after September 15, 2012, with early adoption permitted. We are currently assessing what impact, if any, the revised guidance will have on our results of operations and financial condition.

**Forward Looking Statements**

This Quarterly Report on Form 10-Q and other documents we file with the SEC include forward-looking statements. These include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales and marketing efforts, expenses, the outcome of contingencies, such as legal proceedings, and financial results. From time to time, we also may make forward-looking statements in press releases or written statements, or in our communications and discussions with investors and analysts in the normal course of business through meetings, webcasts, phone calls and conference calls. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements are based on certain assumptions made by us based on our experience and perception of historical trends, current conditions, expected future developments and other factors we believe are appropriate in the circumstances. We caution you that actual outcomes and results may differ materially from what is expressed, implied or forecast by our forward-looking statements. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond our control. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as anticipate, estimate, expect, project, intend, plan, believe, will, should, outlook, could, target, and other words having similar meaning in connection with any discussion of future operations or financial performance. Among the factors that could cause actual results to differ materially from our forward-looking statements are the following:

- development and launch of new competitive products, including over-the-counter or generic competitor products;
- the ability to compete against generic and other branded products;
- the ability to successfully execute our alternate fulfillment initiatives, and to grow the number of profitable prescriptions;
- increases or decreases in the expected costs to be incurred in connection with the research and development, clinical trials, regulatory approvals, commercialization and marketing of our products;

**Table of Contents**

the success of research and development activities, including the development of additional forms of SOLODYN<sup>®</sup>, and our ability to obtain regulatory approvals;

the speed with which regulatory authorizations and product launches may be achieved;

changes in the FDA's position on the safety or effectiveness of our products;

changes in our product mix;

the anticipated size of the markets and demand for our products;

changes in prescription levels;

the impact of acquisitions, divestitures and other significant corporate transactions;

manufacturing or supply interruptions;

importation of other dermal filler or botulinum toxin products, including the unauthorized distribution of products approved in countries neighboring the U.S.;

the impact, beginning in 2013, of potential excise taxes on medical devices;

changes in the prescribing or procedural practices of dermatologists and/or plastic surgeons, including prescription levels;

the ability to successfully market both existing products and new products, including products we acquired from Graceway in December 2011;

difficulties or delays in manufacturing and packaging of our products, including delays and quality control lapses of third party manufacturers and suppliers of our products;

the availability of product supply or changes in the cost of raw materials;

trends toward managed care and health care cost containment, including health care initiatives and other third-party cost-containment pressures that could impose financial burdens or cause us to sell our products at lower prices, resulting in decreased revenues;

our strategy to negotiate additional new, multi-year contracts with targeted managed care organizations and pharmacy benefit managers, which may result in increased managed care rebates and have a negative impact on sales, reserves, profitability and the average selling price for affected products, such as SOLODYN<sup>®</sup>;

our ability to continue offering patient discounts and rebates for our products;

our ability to successfully launch and execute new patient rebate and related programs;

inadequate protection of our intellectual property or challenges to the validity or enforceability of our proprietary rights and our ability to secure patent protection from filed patent applications for our primary products, including SOLODYN<sup>®</sup>;

possible introduction of generic versions of our products, including SOLODYN<sup>®</sup>;

possible federal and/or state legislation or regulatory action affecting, among other things, our ability to enter into agreements with companies introducing generic versions of our products as well as pharmaceutical pricing, federal pharmaceutical contracts, mandatory discounts, and reimbursement, including under Medicaid and Medicare and involuntary approval of prescription medicines for over-the-counter use;

legal defense costs, insurance expenses, settlement costs and the risk of an adverse decision or settlement related to product liability, patent protection, government investigations (including the civil investigative demand we recently received from the FTC relating to various settlement and other agreements we entered into with makers of generic SOLODYN<sup>®</sup> products and other efforts principally regarding SOLODYN<sup>®</sup>), and other legal proceedings (see Note 20 in our accompanying condensed consolidated financial statements and Part II, Item 1, Legal Proceedings);

changes in U.S. generally accepted accounting principles;

additional costs related to compliance with changing regulation of corporate governance and public financial disclosure;

any changes in business, political and economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world;

access to available and feasible financing on a timely basis;

the availability of product acquisition or in-licensing opportunities;

the risks and uncertainties normally incident to the pharmaceutical and medical device industries, including product liability claims;

the risks and uncertainties associated with obtaining necessary FDA approvals;

the inability to obtain required regulatory approvals for any of our pipeline products;

unexpected costs and expenses, or our ability to limit costs and expenses as our business continues to grow;

downturns in general economic conditions that negatively affect our dermal restorative and branded prescription products, and our ability to accurately forecast our financial performance as a result;

---

**Table of Contents**

failure to comply with our federal health care programs and FDA requirements, which could result in substantial civil or criminal penalties and our being excluded from government health care programs, which could materially reduce our sales and adversely affect our financial condition and results of operations;

the inability to successfully integrate newly-acquired entities; and

the actual results of the pending Merger with Valeant could vary materially as a result of a number of factors, including the possibility that various closing conditions for the transaction may not be satisfied or waived, the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement, the outcome of any legal proceedings related to the Merger, unexpected costs, liabilities or delays in connection with the pending Merger, and other risks to consummation of the Merger, including the risk that the transaction will not be consummated within the expected time period or at all.

We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to review any future disclosures contained in the reports that we file with the SEC. This Quarterly Report on Form 10-Q, our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2012 and our Annual Report on Form 10-K for the year ended December 31, 2011 contain discussions of various risks relating to our business that could cause actual results to differ materially from expected and historical results, which you should review. You should understand that it is not possible to predict or identify all such risks. Consequently, you should not consider any such list or discussion to be a complete set of all potential risks or uncertainties.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

As of September 30, 2012, there were no material changes to the information previously reported under Item 7A in our Annual Report on Form 10-K for the year ended December 31, 2011.

**Item 4. Controls and Procedures**

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) that are designed to ensure that information required to be disclosed in reports filed by us under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. Our Chief Executive Officer and Chief Financial Officer, with the participation of other members of management, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2012, and have concluded that, as of such date, our disclosure controls and procedures were effective to ensure that the information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms.

Although the management of the Company, including the Chief Executive Officer and the Chief Financial Officer, believes that our disclosure controls and internal controls currently provide reasonable assurance that our desired control objectives have been met, management does not expect that our disclosure controls or internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

During the three months ended September 30, 2012, there was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.



**Table of Contents****Part II. Other Information**

## Item 1. Legal Proceedings

*Stiefel VELTIN<sup>®</sup> Litigation*

On July 28, 2010, we filed suit against Stiefel Laboratories, Inc. ( Stiefel ), a subsidiary of GlaxoSmithKline plc ( GSK ), in the U.S. District Court for the Western District of Texas – San Antonio Division seeking a declaratory judgment that the manufacture and sale of Stiefel’s acne product VELTIN<sup>®</sup> Gel, which was approved by the FDA in 2010, will infringe one or more claims of our U.S. Patent No. RE41,134 (the 134 Patent ) covering our product ZIANA<sup>®</sup> Gel, a prescription topical gel indicated for the treatment of acne that was approved by the FDA in November 2006. The 134 Patent is listed in the FDA’s *Approved Drug Products with Therapeutic Equivalence Evaluations* (Orange Book) and expires in February 2015. We have rights to the 134 Patent pursuant to an exclusive license agreement with the owner of the patent. The relief we requested in the lawsuit includes a request for a permanent injunction preventing Stiefel from infringing the 134 Patent by engaging in the commercial manufacture, use, importation, offer to sell, or sale of any therapeutic composition or method of use covered by the 134 Patent, including such activities relating to VELTIN<sup>®</sup> Gel, and from inducing or contributing to any such activities. On October 8, 2010, we and the owner of the 134 Patent filed a motion for a Preliminary Injunction seeking to enjoin sales of VELTIN<sup>®</sup> Gel. We also requested a temporary restraining order, which application was heard and denied by the Court on October 15, 2010. On December 14, 2011, the case was reassigned to a new judge, who issued a new case scheduling order pursuant to which a Markman Hearing was held on March 20, 2012. At a Markman Hearing, a court determines the scope of the patent’s claims. The Markman Hearing will likely be reheard now that the case has been reassigned to a new judge and stayed, as described below.

On May 15, 2012, we filed an amended complaint converting the prior claim of declaratory relief into a claim of patent infringement. On June 15, 2012, Stiefel responded to the amended complaint and alleged a new declaratory relief counterclaim relating to U.S. Patent No. 6,387,383 (the 383 Patent ), which patent also covers our product ZIANA<sup>®</sup> Gel. Stiefel alleged that the counterclaim would obviate the need to proceed in the New Jersey case described below. On June 12, 2012, before the Court issued a Markman ruling, the judge recused himself from the case due to a conflict. The case has been transferred back to the original judge, who has stayed the entire case.

On March 20, 2012, we filed another suit against Stiefel, including naming Stiefel’s parent company, GSK. The suit was filed in the U.S. District Court for the District of New Jersey for patent infringement, and more specifically that Stiefel and GSK’s manufacture and sale of VELTIN<sup>™</sup> Gel infringes one or more claims of the 383 Patent covering our product ZIANA<sup>®</sup> Gel. The 383 Patent is also listed in the FDA’s *Approved Drug Products and Therapeutic Equivalence Evaluations* (Orange Book) and expires in August 2020. We have rights to the 383 Patent pursuant to an exclusive license agreement with the owner of the patent. In this action, we sought both monetary damages and a permanent injunction preventing Stiefel and/or GSK from engaging in infringing activities relating to the manufacture and sale of VELTIN<sup>™</sup> Gel. On June 18, 2012, Stiefel and GSK responded to the complaint and asserted declaratory relief counterclaims of noninfringement and patent invalidity. We responded to those counterclaims on July 9, 2012. We subsequently determined to file a motion to dismiss the case in New Jersey and continue to pursue the case filed against Stiefel in the U.S. District Court for the Western District of Texas – San Antonio Division described above. On October 26, 2012, the case in New Jersey was dismissed.

*Actavis ZIANA<sup>®</sup> Litigation*

On March 30, 2011, we received a Paragraph IV Patent Certification Notice from Actavis Mid Atlantic LLC ( Actavis ) advising that Actavis has filed an ANDA with the FDA for approval to market a generic version of ZIANA<sup>®</sup> (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel. Actavis has not advised us as to the expected timing of approval. Actavis’ Paragraph IV Patent Certification alleges that our 134 Patent and 383 Patent will not be infringed by Actavis’ manufacture, use and/or sale of the product for which the ANDA was submitted, and that the 134 Patent and the 383 Patent are otherwise invalid. The expiration date for the 134 Patent is in 2015, and the expiration date for the 383 Patent is in 2020. On May 11, 2011, we filed suit against Actavis in the U.S. District Court for the District of Delaware. Originally, the suit sought an adjudication that Actavis’ ANDA infringes one or more claims of the 134 Patent and the 383 Patent, and that if approved, Actavis’ product will infringe those patents. In February 2012, we withdrew the 134 Patent from the litigation and all claims concerning that patent were dismissed without prejudice. The relief we have requested includes a request for a permanent injunction preventing the FDA from approving Actavis’ ANDA. As a result of the filing of the suit, we believe that Actavis

**Table of Contents**

ANDA cannot be approved by the FDA until after the expiration of the 30-month stay period or a court decision that the patents-in-suit are invalid or not infringed. The Markman Hearing to construe the meaning of the claim terms in the '383 Patent was conducted on May 8, 2012, and on June 12, 2012, the judge issued his report regarding the claim terms at issue. Neither side objected to the report, and the judge's decision has become final. Fact discovery concluded in October 2012 and mediation is scheduled to take place in November 2012. A bench trial is set to commence on July 8, 2013.

In addition to seeking injunctive relief on the basis of patent infringement in the federal case described above, we are also seeking injunctive relief and monetary damages in a lawsuit filed by us against Actavis in the Superior Court of the State of Arizona, County of Maricopa. In the lawsuit, which we filed on March 21, 2011, we allege that Actavis has breached an applicable distribution and supply agreement with us by filing and pursuing its ZIANA® ANDA with the FDA without following certain requirements set forth in our agreement, including a requirement to provide advance notice to us. In our pleadings, we allege that we have suffered and will continue to suffer harms as a result of Actavis' breach, and that certain of those harms cannot readily be quantified or fully compensated by an award of money damages. Accordingly, we have sought both money damages and injunctive relief as remedies in the action. The injunctive relief sought in the lawsuit includes a request to enjoin Actavis from pursuing its generic version of ZIANA® for a period of time that could extend beyond the 30-month stay applicable in the federal case. No assurance can be given that we will ultimately be successful in enforcing our contractual rights against Actavis in this case, or secure injunctive or other relief.

*Actavis ZYCLARA® Litigation*

On August 8, 2012, we received a Paragraph IV Patent Certification from Actavis advising that Actavis has filed an ANDA with the FDA for a generic version of our product ZYCLARA® (Imiquimod) Cream, 3.75%. Actavis' Paragraph IV Certification alleges that our U.S. Patent No. 8,236,816 (the '816 Patent) is invalid, unenforceable and/or will not be infringed by Actavis' manufacture, use or sale of the product for which the ANDA was submitted. The expiration date for the '816 Patent is in 2029. On August 31, 2012, we filed suit against Actavis in the U.S. District Court for the District of Delaware alleging infringement by Actavis of one or more claims of the '816 Patent. On September 26, 2012, Actavis filed its Answer, Affirmative Defenses and Counterclaims. On October 17, 2012, we filed an Answer to Actavis' Counterclaims.

As previously reported, we received an Issue Notification for a second patent covering ZYCLARA® Cream, 3.75%, which patent was expected to issue on August 14, 2012 pursuant to U.S. Patent Application No. 13/182,433 (the '433 Application). As a result of receiving the Paragraph IV Certification for the '816 Patent prior to the issuance of the '433 Application as a patent, and in light of having already secured patent protection on ZYCLARA® Cream, 3.75% with the '816 Patent, we voluntarily elected to file a Request for Continued Examination (RCE) with the USPTO for the '433 Application. After subsequently receiving a Paragraph IV Certification with respect to the '433 Application, and still prior to its issuance as a patent, we supplemented our RCE with an Information Disclosure Statement (IDS) disclosing the '433 Application Paragraph IV Certification to the USPTO. The RCE then allowed the USPTO to consider both of the Paragraph IV Certifications. On October 30, 2012, after considering the Paragraph IV Certifications, the USPTO issued U.S. Patent No. 8,299,109 under the '433 Application (the '109 Patent). The expiration date for the '109 Patent is in 2029.

On November 2, 2012, we received a Paragraph IV Patent Certification from Actavis alleging that the '109 Patent is invalid, unenforceable and/or will not be infringed by Actavis' manufacture, use or sale of the product for which the ANDA was submitted. The Paragraph IV Certification is in substance the same as the previously received Paragraph IV Certifications.

*Acella TRIAZ® Litigation*

On August 19, 2010, we filed suit against Acella Pharmaceuticals, Inc. (Acella) in the U.S. District Court for the District of Arizona based on Acella's manufacture and offer for sale of benzoyl peroxide foaming cloths which we believe infringe one or more claims of our U.S. Patent No. 7,776,355 (the '355 Patent) covering certain of our products, including TRIAZ® benzoyl peroxide) 3%, 6% and 9% Foaming Cloths indicated for the topical treatment of acne vulgaris. The '355 Patent was issued to us by the U.S. Patent and Trademark Office (the USPTO) on August 17, 2010 and expires in June 2026. The relief we requested in the lawsuit includes a request for a Permanent Injunction preventing Acella from infringing the '355 Patent by engaging in the manufacture, use, importation, offer to sell, or sale of any products covered by the '355 Patent, including Acella's benzoyl peroxide

**Table of Contents**

foaming cloths, and from inducing or contributing to any such activities. Acella filed with the USPTO a request for ex parte reexamination of the 355 Patent, and filed with the Court a request that the litigation be stayed for the duration of the reexamination. Both the request for reexamination and the request for a stay were initially denied. Acella resubmitted its request for reexamination to the USPTO, which was granted on December 15, 2010. Acella again requested that the case be stayed pending reexamination, and the Court again denied Acella's request. On August 12, 2011, the USPTO issued an initial action in the reexamination, confirming that several of the claims of the 355 Patent are patentable, including several claims that we believe are infringed by Acella. We filed a motion for a Preliminary Injunction on December 10, 2010. The hearing on the Preliminary Injunction motion was to be combined with a Markman Hearing that was scheduled for February 23, 2011. The Court held only the Markman Hearing on February 23, 2011, and deferred the hearing on the Preliminary Injunction motion until March 29, 2011. At the Markman Hearing, the Court determined the scope of the patent's claims. Due to the need to postpone the March 29, 2011 hearing on the Preliminary Injunction due to scheduled conflicts, we withdrew our motion for a Preliminary Injunction in favor of a motion for an expedited trial. In the meantime, Acella moved for summary judgment that the claims of the 355 Patent are invalid, and that we are entitled only to a reasonable royalty, not lost profit damages. We opposed this motion. On November 3, 2011, the Court granted the motion with respect to validity, and dismissed the motion with respect to lost profits damages. The Court rejected a motion for fees made by Acella. Acella did not appeal the denial of its motion for fees. We filed an appeal from the Court's invalidity ruling on November 30, 2011. Briefing in the appeal was suspended during mediation ordered by the Court of Appeals. The mediation was unsuccessful. Briefing in the appeal was completed on October 9, 2012, and the case is now before the Court of Appeals for decision. The USPTO issued a reexamination certificate for the 355 Patent on August 21, 2012 confirming the patentability of all of the 355 Patent's claims, without amending or canceling any of the claims.

*LOPROX® Patent Litigation*

We filed lawsuits against each of Perrigo Company, Inc. (Perrigo), Nycomed U.S., Inc. (hereunder Nycomed), and Taro Pharmaceuticals U.S.A., Inc. and Taro Pharmaceutical Industries, Ltd. (together, Taro) on July 19, 2011, and against Watson Pharmaceuticals, Inc. (Watson, and collectively with Perrigo, Nycomed, and Taro, the Defendants) on October 21, 2011, in the U.S. District Court for the Southern District of New York. Each of the lawsuits seeks an adjudication that the respective Defendant is infringing one or more claims of our U.S. Patent No. 7,981,909 (the 909 Patent) by making, using, offering for sale, selling in the U.S. or importing, without authority, a generic version of LOPROX® Shampoo (ciclopirox) 1%. Perrigo, Nycomed and Taro received FDA approval for generic ciclopirox 1% shampoos on or about February 16, 2010, May 25, 2010 and February 23, 2011, respectively. Watson acquired rights to a generic ciclopirox 1% shampoo from Perrigo on or about July 26, 2011, which shampoo was approved by the FDA on November 24, 2009. The 909 Patent was issued to us by the USPTO on July 19, 2011 and expires in September 2017. The relief we requested in each of the lawsuits includes damages and a request for a permanent injunction preventing the respective Defendant from selling a generic version of LOPROX® prior to the expiration of the 909 Patent. We formally served each of defendants Perrigo, Nycomed, and Taro Pharmaceuticals U.S.A., Inc. with the complaints on October 13, 2011. Taro Pharmaceutical Industries, Ltd. was formally served on October 24, 2011. Watson was formally served on December 8, 2011. On February 6, 2012, February 21, 2012, March 1, 2012 and July 12, 2012, respectively, we entered into License and Settlement Agreements with Watson, Taro, Perrigo, and Fougera Pharmaceuticals Inc. (the successor to Nycomed, hereunder Fougera) (collectively, the Loprox Settlement Agreements). In connection with the Loprox Settlement Agreements, we and Watson, Taro, Perrigo and Fougera, respectively, agreed to settle all legal disputes between us relating to LOPROX® Shampoo and we agreed to withdraw our complaints against such parties pending in the U.S. District Court for the Southern District of New York. Subject to the terms and conditions contained in the Loprox Settlement Agreements, we granted each of Watson, Taro, Perrigo and Fougera a non-exclusive royalty-bearing license to make and sell limited quantities of a generic version of LOPROX® Shampoo. With the Loprox Settlement Agreements, and as of the date of the settlement agreement with Fougera, we no longer have any pending patent infringement litigation with respect to generic versions of LOPROX®.

*Zydus Pharmaceuticals USA, Inc. SOLODYN® Litigation*

On June 4, 2012, we filed suit against Zydus Pharmaceuticals USA, Inc. and Cadila Healthcare Ltd. d/b/a/ Zydus Cadila (together, Zydus) in the U.S. District Court for the District of Delaware. On June 5, 2012, we filed suit against Zydus in the U.S. District Court for the District of New Jersey. The suits seek an adjudication that Zydus has infringed one or more claims of our U.S. Patent Nos. 5,908,838, 7,790,705 and 7,919,483 (the Patents) by submitting to the FDA an ANDA for generic versions of SOLODYN® (minocycline HCl, USP) Extended

**Table of Contents**

Release Tablets in 45mg, 55mg, 65mg, 80mg, 90mg, 105mg and 135mg strengths. The relief requested by us includes a request for a permanent injunction preventing Zydus from infringing the asserted claims of the Patents by engaging in the manufacture, use, offer to sell, sale, importation or distribution of generic versions of SOLODYN® before the expiration of the Patents.

*Alkem Laboratories Limited Paragraph IV Patent Certification for Generic Versions of SOLODYN®*

On October 29, 2012, we received a Paragraph IV Patent Certification from Alkem Laboratories Limited ( Alkem ) advising that Alkem has filed an ANDA with the FDA for generic versions of SOLODYN® (minocycline HCl, USP) Extended Release Tablets in 45mg, 65mg, 90mg, 115mg and 135mg strengths. Alkem has not advised us as to the timing or status of the FDA’s review of its filing, or whether it has complied with FDA requirements for proving bioequivalence. Alkem’s Paragraph IV Patent Certification alleges that our U.S. Patent Nos. 5,908,838, 7,541,347, 7,544,373, 7,790,705, 7,919,483, 8,252,776 and 8,268,804 are invalid, unenforceable and/or will not be infringed by Alkem’s manufacture, use or sale of the products for which the ANDA was submitted. The expiration dates for the patents are in 2018, 2027, 2025, 2027, 2025 and 2025, respectively. We intend to continue to vigorously defend our intellectual property relating to SOLODYN®.

*Sidmak Laboratories (India) Pvt., Ltd. Paragraph IV Patent Certification for Generic Versions of SOLODYN®*

On November 2, 2012, we received a Paragraph IV Patent Certification from Sidmak Laboratories (India) Pvt., Ltd. ( Sidmak ) advising that Sidmak has filed an ANDA with the FDA for generic versions of SOLODYN® (minocycline HCl, USP) Extended Release Tablets in 45mg, 55mg, 65mg, 80mg, 110mg, 115mg and 135mg strengths. Sidmak has not advised us as to the timing or status of the FDA’s review of its filing, or whether it has complied with FDA requirements for proving bioequivalence. Sidmak’s Paragraph IV Patent Certification alleges that our U.S. Patent Nos. 5,908,838, 7,790,705, 7,919,483, 8,252,776 and 8,268,804 are invalid and/or will not be infringed by Sidmak’s manufacture, use or sale of the products for which the ANDA was submitted. The expiration dates for the patents are in 2018, 2025, 2027, 2025 and 2025, respectively. We intend to continue to vigorously defend our intellectual property relating to SOLODYN®.

*Civil Investigative Demand from the U.S. Federal Trade Commission*

As previously disclosed in our SEC filings, we entered into various settlement and other agreements with makers of generic SOLODYN® products following patent infringement claims and litigation. On May 2, 2012, we received a civil investigative demand from the U.S. Federal Trade Commission (the FTC ) requiring that we provide to the FTC information and documents relating to such agreements, each of which was previously filed with the FTC and the Antitrust Division of the Department of Justice in accordance with the requirements of the Medicare Modernization Act of 2003, and other efforts principally relating to SOLODYN®. We are cooperating with this investigative process and, in that regard, have produced numerous documents to the FTC, and continue to do so. On October 9, 2012, we provided the FTC with a written response to its investigative demand. If, at the conclusion of this process, the FTC believes that any of the agreements or efforts violates antitrust laws, it could challenge us through a civil administrative or judicial proceeding. It is not possible to predict the outcome of this process or any subsequent proceedings, which could result in the imposition of monetary and/or injunctive relief, including the invalidation of agreements. However, we believe that the subject agreements and efforts do not exceed the term or scope of its patents and are otherwise consistent with antitrust laws and applicable precedents. If the FTC ultimately challenges the agreements, we would expect to vigorously defend itself in any such action, which we would anticipate to be a multi-year, protracted process. However, no assurance can be given as to the timing or outcome of such process.

The information set forth under Legal Matters in Note 20 in the notes to the condensed consolidated financial statements, included in Part I, Item I of this Report, is incorporated herein by reference. The pending proceedings described in this section and in Legal Matters in Note 20 in the notes to the condensed consolidated financial statements included in Part I, Item I of this Report involve complex questions of fact and law and will require the expenditure of significant funds and the diversion of other resources to prosecute and defend. The results of legal proceedings are inherently uncertain, and material adverse outcomes are possible. The resolution of intellectual property litigation may require us to pay damages for past infringement or to obtain a license under the other party’s intellectual property rights that could require one-time license fees or ongoing royalties, which could adversely impact our product gross margins in future periods, or could prevent us from manufacturing or selling some of our products or limit or restrict the type of work that employees involved in such litigation may perform for

---

**Table of Contents**

us. From time to time we may enter into confidential discussions regarding the potential settlement of pending litigation or other proceedings; however, there can be no assurance that any such discussions will occur or will result in a settlement. The settlement of any pending litigation or other proceeding could require us to incur substantial settlement payments and costs. In addition, the settlement of any intellectual property proceeding may require us to grant a license to certain of our intellectual property rights to the other party under a cross-license agreement. If any of those events were to occur, our business, financial condition and results of operations could be materially and adversely affected.

Item 1A. Risk Factors

We operate in a rapidly changing environment that involves a number of risks that could materially and adversely affect our business, financial condition, prospects, operating results or cash flows. For a detailed discussion of the risk factors that should be understood by any investor contemplating investment in our stock, please refer to Part I, Item 1A Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2011 and Part II, Item 1A Risk Factors in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2012.

Other than the additional risks set forth below, there are no material changes from the risk factors previously disclosed in Part I, Item 1A Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2011 and in Part II, Item 1A Risk Factors in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2012.

*There are risks and uncertainties associated with our pending Merger with Valeant.*

As previously announced, on September 2, 2012, we entered into a Merger Agreement with Valeant, Valeant Pharmaceuticals International, Inc. and Merger Sub, providing for the merger of Merger Sub with and into us, with us surviving the merger as a wholly-owned subsidiary of Valeant.

There are a number of risks and uncertainties relating to the Merger. For example, the Merger may not be consummated or may not be consummated in the timeframe or manner currently anticipated, as a result of several factors, including, among other things, the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement, including a termination under circumstances that would require us to pay to Valeant the Termination Fee. In addition, there can be no assurance that approval of our stockholders will be obtained, that the other conditions to closing of the Merger will be satisfied or waived or that other events will not intervene to delay or result in the termination of the Merger. If the Merger is not completed, the price of our common stock may change to the extent that the current market price of our common stock may reflect an assumption that the Merger will be consummated.

Pending the closing of the Merger, the Merger Agreement also restricts us from engaging in certain actions without Valeant's consent, which could prevent us from pursuing opportunities that may arise prior to the closing of the Merger. Any delay in closing or a failure to close could have a negative impact on our business and stock price as well as our relationships with our customers, vendors or employees, as well as a negative impact on our ability to pursue alternative strategic transactions or our ability to implement alternative business plans.

*Our business could be adversely impacted as a result of uncertainty related to the pending Merger.*

The pending Merger could cause disruptions to our business or business relationships, which could have an adverse impact on our financial condition, results of operations and cash flows. For example:

the attention of our management may be directed to transaction-related considerations and may be diverted from the day-to-day operations of our business;

our employees may experience uncertainty about their future roles with us, which might adversely affect our ability to retain and hire key personnel and other employees; and

**Table of Contents**

customers, suppliers or other parties with which we maintain business relationships may experience uncertainty about our future and seek alternative relationships with third parties or seek to alter their business relationships with us.

In addition, we have incurred, and will continue to incur, significant costs, expenses and fees for professional services and other transaction costs in connection with the Merger, and many of these fees and costs are payable by us regardless of whether or not the Merger is consummated.

## Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table summarizes our repurchases of equity securities for the three-month period ended September 30, 2012:

<b>Period</b>	<b>Total Number of Shares Repurchased</b>	<b>Average Price Paid Per Share</b>	<b>Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</b>	<b>Maximum Number (or Approximate Dollar Value) of Shares That May Yet Be Repurchased Under the Plans or Programs (1)</b>
July 1, 2012 to July 31, 2012	-	\$ -	-	\$ 49,914,188
August 1, 2012 to August 31, 2012	1,533,619	\$ 32.55	1,533,619	\$ 20
September 1, 2012 to September 30, 2012	-	\$ -	-	\$ 20
Total	1,533,619	\$ 32.55	1,533,619	\$ 20

(1) On August 8, 2011, the Company announced that its Board of Directors approved a Stock Repurchase Plan to purchase up to \$200 million in aggregate value of shares of Medicis Class A common stock. The plan was set to expire on August 7, 2012; however, on August 7, 2012, the Company's Board of Directors approved a six-month extension of the plan to February 7, 2013. The plan may also terminate at the time at which the purchase limit is reached, and may be suspended or terminated at any time at the Company's discretion without prior notice. As of September 30, 2012, 5,971,852 shares at an average cost of \$33.49 per share, or approximately \$200 million in the aggregate, have been purchased as part of this plan. As of September 30, 2012, the plan has terminated as the purchased limit has been reached.

**Table of Contents**

Item 6. Exhibits

Exhibit 2.1	Agreement and Plan of Merger, dated as of September 2, 2012, among Medicis Pharmaceutical Corporation, Valeant Pharmaceuticals International, Valeant Pharmaceuticals International, Inc. and Merlin Merger Sub, Inc. (1)
Exhibit 10.1	Settlement Agreement, dated as of September 2, 2012, between Medicis Pharmaceutical Corporation and Deutsche Bank AG, London Branch (1)
Exhibit 10.2+	Amendment to Stock Purchase Agreement, dated August 21, 2012, by and between Medicis Pharmaceutical Corporation and Solta Medical, Inc.
Exhibit 31.1+	Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 31.2+	Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 32.1++	Certification by the Chief Executive Officer and the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Exhibit 101++*	The following financial information from Medicis Pharmaceutical Corporation's Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, formatted in XBRL (Extensible Business Reporting Language) includes: (i) the Condensed Consolidated Balance Sheets as of September 30, 2012 and December 31, 2011, (ii) the Condensed Consolidated Statements of Income for each of the three-month and nine-month periods ended September 30, 2012 and 2011, (iii) the Condensed Consolidated Statements of Comprehensive Income for each of the three-month and nine-month periods ended September 30, 2012 and 2011, (iv) the Condensed Consolidated Statements of Cash Flows for each of the nine-month periods ended September 30, 2012 and 2011, and (v) the Notes to the Condensed Consolidated Financial Statements.

+ Filed herewith

++ Furnished herewith

\* Pursuant to applicable securities laws and regulations, we are deemed to have complied with the reporting obligation relating to the submission of interactive data files in such exhibits and are not subject to liability under any anti-fraud provisions of the federal securities laws as long as we have made a good faith attempt to comply with the submission requirements and promptly amend the interactive data files after becoming aware that the interactive data files fail to comply with the submission requirements. Users of this data are advised that, pursuant to Rule 406T, these interactive data files are deemed not filed and otherwise are not subject to liability.

(1) Incorporated by reference to the Company's Current Report on Form 8-K filed with the SEC on September 5, 2012.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**MEDICIS PHARMACEUTICAL CORPORATION**

Date: November 8, 2012

By: /s/ Jonah Shacknai  
Jonah Shacknai  
Chairman of the Board and  
  
Chief Executive Officer  
  
(Principal Executive Officer)

Date: November 8, 2012

By: /s/ Richard D. Peterson  
Richard D. Peterson  
Executive Vice President,  
  
Chief Financial Officer and Treasurer  
  
(Principal Financial and Accounting  
  
Officer)